



US009206130B2

(12) **United States Patent**
Ullrich et al.

(10) **Patent No.:** **US 9,206,130 B2**
(45) **Date of Patent:** **Dec. 8, 2015**

(54) **QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS**

(75) Inventors: **Axel Ullrich**, München (DE); **Pjotr Knyazev**, Stockdorf (DE); **Yixiang Zhang**, Boston, MA (US); **Kéri György**, Budapest (HU); **László Örfi**, Budapest (HU); **István Szabadkai**, Budapest (HU)

(73) Assignee: **Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.**, München (DE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 659 days.

(21) Appl. No.: **12/933,070**

(22) PCT Filed: **Apr. 16, 2009**

(86) PCT No.: **PCT/EP2009/002798**

§ 371 (c)(1),
(2), (4) Date: **Dec. 13, 2010**

(87) PCT Pub. No.: **WO2009/127417**

PCT Pub. Date: **Oct. 22, 2009**

(65) **Prior Publication Data**

US 2011/0092503 A1 Apr. 21, 2011

Related U.S. Application Data

(60) Provisional application No. 61/045,398, filed on Apr. 16, 2008.

(51) **Int. Cl.**

C07D 413/12 (2006.01)
C07D 409/12 (2006.01)
C07D 405/12 (2006.01)
C07D 401/12 (2006.01)
C07D 215/20 (2006.01)

(52) **U.S. Cl.**

CPC **C07D 215/20** (2013.01); **C07D 401/12** (2013.01); **C07D 405/12** (2013.01); **C07D 409/12** (2013.01); **C07D 413/12** (2013.01)

(58) **Field of Classification Search**

CPC .. C07D 413/12; C07D 405/12; C07D 401/12; C07D 409/12; C07D 215/20
USPC 514/312; 546/135
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,797,823 B1 9/2004 Kubo et al.
7,041,691 B1* 5/2006 McGee et al. 514/367
2008/0166359 A1 7/2008 Lamb

FOREIGN PATENT DOCUMENTS

WO WO 2005/030140 * 4/2005
WO WO 2006/117552 * 11/2006

OTHER PUBLICATIONS

Voskoglou-Nomikos et al., *Clinical Cancer Research*, vol. 9, 4227-4239.*
ptcl.chem.ox.ac.uk/MSDS structure activity relationship; Jaworska, 1-8, 2004.*
Cancer and Metastasis Reviews (1998), 17(1), 91-106.*
Science (1999), vol. 286, 531-537.*
International Search Report for PCT Application No. PCT/EP2009/002798 issued Sep. 9, 2009.
Written Opinion for PCT Application No. PCT/EP2009/002798 issued Sep. 9, 2009.
International Preliminary Report on Patentability for PCT Application No. PCT/EP2009/002798 issued Oct. 19, 2010.
Weigelt et al. "Breast Cancer Metastasis: Markers and Models" *Nature Reviews: Cancer*, 2005 (5), 591-602.
Shawver et al. "Smart drugs: Tyrosine kinase inhibitors in cancer therapy" *Cancer Cell*, 2002(1), 117-123.
Sebolt-Leopold et al. "Mechanisms of drug inhibition of signalling molecules" *Nature* 2006, 441, 457-462.
Blume-Jensen "Oncogenic kinase signalling" *Nature* 2001, 411, 355-365.
Varnum et al. "Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6" *Nature*, 1995, 373, 623-626.
Slamon et al. "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" *Science*, 1987, 235, 177-182.
Hanahan et al. "Hallmarks of Cancer: The Next Generation" *Cell*, 2011, 144, 646-674.
Nagata et al. "Identification of the Product of Growth Arrest-specific Gene 6 as a Common Ligand for Axl, Sky, and Mer Receptor Tyrosine Kinases." *The Journal of Biological Chemistry*, 1996, 271(47), 30022-30027.
Slamon et al. "Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer That Overexpresses HER2" 2001, 344(11), 783-792.
Stitt et al. "The Anticoagulation Factor Protein S and Its Relative, Gas6, Are Ligands for the Tyro 3/Axl Family of Receptor Tyrosine Kinases" *Cell*, 1995, 80, 661-670.
Cobleigh et al. "Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease" *Journal of Clinical Oncology*, 1999, 17(9), 2639-2648.

(Continued)

Primary Examiner — Rebecca Anderson
(74) *Attorney, Agent, or Firm* — Meyertons, Hood, Kivlin, Kowert & Goetzl, P.C.; Eric B. Meyertons

(57) **ABSTRACT**

Novel compounds which are inhibitors of receptor tyrosine kinases of the AXL receptor family are described herein. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by hyperfunction of a receptor of the AXL family. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly cancer metastases.

(56)

References Cited

OTHER PUBLICATIONS

Hafizi et al. "Signalling and functional diversity within the Axl sub-family of receptor tyrosine kinases" *Cytokine & Growth Factor Reviews*, 2006, 17, 295-304.

Janssen "A novel putative tyrosine kinase receptor with oncogenic potential" *Oncogene*, 1991, 6, 2113-2120.

O'Bryan et al. "axl, a Transforming Gene Isolated from Primary Human Myeloid Leukemia Cells, Encodes a Novel Receptor Tyrosine Kinase" *Molecular and Cellular Biology*, 1991, 5016-5031.

Berclaz et al. "Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast" *Annals of Oncology* 2001, 12, 819-824.

Craven et al. "Receptor Tyrosine Kinases Expressed in Metastatic Colon Cancer" *Int. J. Cancer*, 1995, 60, 791-797.

Shieh et al. "Expression of Axl in Lung Adenocarcinoma and Correlation with Tumor Progression" *Neoplasia*, 2005, 7(12) 2005, pp. 1058-1064.

Sun et al. "Coexpression of Gas6/Axl in Human Ovarian Cancers" *Oncology*, 2004, 66, 450-457.

Green et al. "Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours" *British Journal of Cancer*, 2006, 94, 1446-1451.

Ito et al. "Expression of the Axl Receptor Tyrosine Kinase in Human Thyroid Carcinoma" *Thyroid*, 1999, 9(6), 563-567.

Holland et al. "Multiple Roles for the Receptor Tyrosine Kinase Axl in Tumor Formation" *Cancer Res*, 2005, 65 (20), 9294-9303.

Vajkoczy et al. "Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival" *PNAS*, 2006, 103(15), 5799-5804.

Price et al., *Organic Syntheses, Coll.*, 1955, 3, 272; *Organic Syntheses, Coll.*, 1948, 28, 38.

Zhang et al. "AXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression" *Cancer Res* 2008;68, 1905-1915.

Robinson et al. "The Protein Kinase Family of the Human Genome" *Oncogene* (2000) 19, 5548-5557.

Zhang et al. "AXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression" *Cancer Res* (2008) 68, 1905-1915.

* cited by examiner

1

QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS

PRIORITY CLAIM

This application is a 371 of PCT Application No. PCT/EP2009/002798, filed Apr. 16, 2009, which claims priority to U.S. Provisional Application Ser. No. 61/045,398, filed Apr. 16, 2008.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to novel compounds which are inhibitors of receptor tyrosine kinases of the AXL receptor family. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by hyperfunction of a receptor of the AXL family. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly cancer metastases.

2. Description of the Relevant Art

Breast cancer is the most common malignant disease in western women. In these patients, it is not the primary tumour, but its metastases at distant sites that are the main cause of death (1). Despite surgical removal of the primary tumour, relapse at local or distant sites may occur because of incomplete removal of primary tumour tissue or the presence of micrometastases undetectable at the time of diagnosis. The development of chemotherapy as well as endocrine- and radiation therapy, administered as adjuvant treatment after surgery, has led to a reduction in the risk of relapse to 20-40%. However, adjuvant treatment has a wide range of acute and long-term side effects. Over the past twenty years, with the advances in understanding the molecular basis of signalling pathway dysregulation in various cancers, a new era of cancer therapy has begun, which is characterized by the identification of critical regulators of malignant properties of cancer cells as molecular targets (2, 3).

Deregulated expression of protein kinases by gene deletion, -mutation or -amplification has been found to be important for tumour initiation and -progression, involving cancer cell proliferation, -survival, -motility and -invasivity as well as tumour angiogenesis and chemotherapy resistance (4, 5). Because of the advanced understanding of their critical functions in oncogenesis, protein kinases have been at the forefront of targeted cancer therapy development since the 1980s. Most of the novel targeted cancer therapeutics currently approved by the FDA in clinical use is interfering with the signalling action of protein kinases. More than 100 additional protein kinase inhibitors and antibodies are in clinical trials, making kinases after G protein-coupled receptors the second most popular drug target class in the pharmaceutical and biotech industries (3).

In breast cancer, the receptor tyrosine kinase HER2/neu is overexpressed due to gene amplification in tumours of about 25% of breast cancer patients, and enhanced expression correlates with lack of response to adjuvant therapy and poor prognosis (6). Based on this discovery, Herceptin, a monoclonal antibody against HER2/neu oncoprotein, has been developed and is in clinical use since 1998 both as a single agent and in combination with chemotherapies for HER2/neu overexpressing metastatic breast cancer, which has helped to significantly prolong survival of patients (7, 8). However, metastatic breast cancer patients showing no overexpression of HER2/neu do not benefit from this therapy. Therefore, novel therapeutic targets are still urgently needed for intervention in breast cancer metastatic progression.

2


To identify the genes that mediate progression of breast cancer, we have focused on key elements of the phosphoprotein-mediated signalling system because of its established role in human cancer. After systematically analyzing expression profiles of kinases of thirteen weakly invasive and eight highly invasive breast cancer cell lines and normal mammary epithelia cell lines by cDNA array hybridization analysis, we identified a cluster of genes characteristic for highly invasive cell types. The RTK AXL was part of the gene cluster predictive of the aggressiveness of breast cancer cells.

The mammalian AXL RTK subfamily includes three closely related members: AXL, SKY, and MER. The subfamily is characterised by an extracellular domain, consisting of two immunoglobulin-like domains followed by two fibronectin type 3-like domains. GAS6, originally isolated as a growth arrest-specific gene, is the common ligand for AXL subfamily receptors (9-11). GAS6 has the highest affinity for AXL, followed by SKY, and finally MER (11). GAS6-AXL signalling has been implicated in a host of discrete cellular responses including cell survival, proliferation, migration and adhesion (12).

AXL was originally isolated from patients with chronic myelogenous leukaemia and was shown to have transforming potential when overexpressed (13, 14). Subsequently, AXL expression has been reported in a wide variety of human cancers (15-20). Especially, in breast cancer patients a significant correlation was found between AXL and tumour stage (15). Moreover, some reports indicated that AXL might be involved in cancer progression (21, 22).

SUMMARY OF THE INVENTION

Compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof are provided:



wherein

R^1 , R^2 , R^3 and R^4 , which may be the same or different, represent hydrogen, hydroxyl, nitro, halogen, cyano, $NR^{12}R^{13}$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{1-6} alkoxy,

wherein the C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} alkoxy groups are optionally mono- or polysubstituted by hydroxyl; halogen, C_{1-6} alkoxy; C_{1-6} alkylcarbonyl; carboxyl; C_{1-6} alkoxy carbonyl; $-(C=O)-NR^{12}R^{13}$, and/or $-NR^{12}R^{13}$ wherein R^{12} and R^{13} , which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl optionally substituted by hydroxyl, or alternatively R^{12} and R^{13} may combine with the nitrogen atom attached thereto to form a saturated or unsaturated five- or six-membered heterocyclic group; which is optionally mono- or polysubstituted by hydroxyl, an oxygen atom, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alky-

3

nyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system; wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl groups are optionally substituted by hydroxyl, C₁₋₆ alkoxy, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system; wherein R² and/or R³ also may be —O—(CH₂)_n—R¹⁴ wherein n is an integer of 0 to 6, —(CH₂)_n— is optionally substituted by C₁₋₆ alkyl, hydroxyl, or a halogen atom, and R¹⁴ represents a hydrogen atom; hydroxyl; a halogen atom; C₁₋₆ alkoxy; C₁₋₆ alkylcarbonyl; carboxyl; C₁₋₆ alkoxycarbonyl; —(C=O)—NR¹²R¹³, —NR¹²R¹³ wherein R¹² or R¹³ which may be the same or different, represent a hydrogen atom or C₁₋₄ alkyl optionally substituted by hydroxyl, or alternatively R¹² and R¹³ may combine with the nitrogen atom attached thereto to form a saturated or unsaturated five- or six-membered heterocyclic group; in which the heterocyclic group is optionally substituted by hydroxyl, an oxygen atom, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system; wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl groups are optionally substituted by hydroxyl, C₁₋₆ alkoxy, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system; amino in which one or two hydrogen atoms on the amino group are optionally substituted by C₁₋₆ alkyl or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system, and the C₁₋₆ alkyl group is optionally substituted by hydroxyl, C₁₋₆ alkoxy, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system; or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system optionally substituted by hydroxyl, an oxygen atom, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl groups are optionally substituted by hydroxyl, C₁₋₆ alkoxy, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system; when the carbocyclic or heterocyclic group is substituted by two C₁₋₆ alkyl groups, the two alkyl groups may combine together to form an alkylene chain; and the carbocyclic or heterocyclic group may be condensed with another saturated or unsaturated five- to seven-membered carbocyclic or heterocyclic group to form a bicyclic group. When n=0, —(CH₂)_n— represents a bond,

R⁵ and R⁶, which may be the same or different, represent a hydrogen atom, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, halogen, cyano or nitro, wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, and C₁₋₆ alkoxy groups are optionally mono- or polysubstituted by hydroxyl; halogen, C₁₋₆ alkoxy; C₁₋₆ alkylcarbonyl; carboxyl; C₁₋₆ alkoxycarbonyl; —(C=O)—NR¹²R¹³, and/or —NR¹²R¹³; wherein R¹² and R¹³, which may be the same or different, represent a hydrogen atom or C₁₋₄ alkyl optionally substituted by hydroxyl, or alternatively R¹² and R¹³ may combine with the nitrogen atom attached thereto to form a saturated or unsaturated five- or six-membered heterocyclic group; in which the heterocyclic group is optionally substituted by hydroxyl, an oxygen atom, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system; wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl groups are optionally substituted by

4

hydroxyl, C₁₋₆ alkoxy, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system,

R⁷, R⁸, R⁹ and R¹⁰, which may be the same or different, represent a hydrogen atom, halogen, nitro, C₁₋₆ alkyl, C₁₋₆ alkoxy,

wherein the C₁₋₆ alkyl or C₁₋₆ alkoxy groups are optionally mono- or polysubstituted by hydroxyl and/or halogen, C₁₋₄ alkyl and/or C₁₋₄ alkoxy, wherein the C₁₋₆ alkyl, C₁₋₆ alkoxy, wherein the C₁₋₆ alkyl or C₁₋₆ alkoxy groups are optionally mono- or polysubstituted by hydroxyl and/or halogen,

R¹¹ represents

(i) a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system which is optionally mono- or polysubstituted by an oxygen atom, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, a halogen atom, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and the C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, and C₁₋₆ alkoxy groups are optionally substituted by a halogen atom or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group,

(ii) C₁₋₆ alkyl or C₁₋₆ alkoxy which is unsubstituted or substituted by a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system which is optionally mono- or polysubstituted by an oxygen atom, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, a halogen atom, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and the C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, and C₁₋₆ alkoxy groups are optionally substituted by a halogen atom or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, or (iii) a nitrogen atom substituted with a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system which is optionally mono- or polysubstituted by an oxygen atom, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, a halogen atom, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and the C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, and C₁₋₆ alkoxy groups are optionally substituted by a halogen atom or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and

R¹⁵ represents a hydrogen atom or C₁₋₆ alkyl.

In one embodiment, embodiments relate to compounds as described above, preferably with the proviso that the compound is not N-[4-[(6,7-dimethoxy-4-quinolinyloxy)-3-fluorophenyl]-benzenemethanesulfonamide, N44-[(6,7-dimethoxy-4-quinolinyloxy)-3-fluorophenyl]-benzeneethanesulfonamide, or N44-[(6,7-dimethoxy-4-quinolinyloxy)-3-fluorophenyl]-benzenepropanesulfonamide. Further embodiments refer to compounds as described above, preferably with the proviso that compounds wherein R¹ is F and R¹⁰ is H are excluded.

The compounds described herein are efficient inhibitors of AXL receptor tyrosine kinase autophosphorylation and, thus, are suitable for the treatment of hyperproliferative disorders associated with, accompanied by and/or caused by AXL hyperfunction, particularly AXL receptor tyrosine kinase induced hyperproliferative disorders.

DETAILED DESCRIPTION OF THE INVENTION

The compounds described herein are quinoline-substituted sulfonamide derivatives which are inhibitors of autophosphorylation of receptors of the AXL family, particularly of the human AXL receptor. The compounds are capable of inhibiting cell proliferation and, thus, are suitable for the treatment and/or prevention of AXL receptor tyrosine kinase induced

hyperproliferative disorders, particularly selected from the group consisting of cancer and primary tumor metastases. In a preferred embodiment, the AXL receptor tyrosine kinase induced disorders are associated with AXL receptor tyrosine kinase receptor overexpression and/or hyperactivity, e.g. an increased degree of autophosphorylation compared to normal tissues. The disorders may be selected from breast, colon, prostate, lung, gastric, ovarian, endometrial, renal, hepatocellular, thyroid, uterine, esophagus, squamous cell cancer, leukemia, osteosarcoma, melanoma, glioblastoma and neuroblastoma. In an especially preferred embodiment, the disorders are selected from breast cancer, glioblastoma, renal cancer, non-small cell lung cancer (NSCLC), and melanoma. Most preferably, the disorder is breast cancer. It should be noted, however, that the compounds are also suitable for the prevention and/or treatment for other hyperproliferative disorders, particularly benign hyperproliferative disorders such as benign prostate hyperplasia.

In a further especially preferred embodiment, the compounds as described above are used for the treatment of cancer metastases, particularly primary metastases, optionally in combination with surgery, irradiation and/or administration of further antitumor agents, such as chemotherapeutic agents and/or antitumor antibodies.

The compounds are characterized by their ability to inhibit AXL receptor tyrosine kinase autophosphorylation in a cellular system, e.g. in NIH3T3 cells. In a preferred embodiment, the compounds have an IC_{50} value of 10 μ M or less, more preferably of 5 μ M or less, even more preferably of 2.5 μ M or less, and most preferably of 1 μ M or less.

In the compounds of formula (I), the terms "alkyl," "alkoxy," "alkenyl," and "alkynyl" as used herein as a group or a part of a group respectively mean straight chain or branched chain alkyl, alkoxy, alkenyl, and alkynyl.

C_{1-6} alkyl is preferably C_{1-4} alkyl.

C_{1-6} alkoxy is preferably C_{1-4} alkoxy.

C_{2-6} alkenyl is preferably C_{2-4} alkenyl.

C_{2-6} alkynyl is preferably C_{2-4} alkynyl.

Examples of C_{1-6} alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, and n-hexyl.

Examples of C_{1-6} alkoxy include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy, and t-butoxy.

Examples of C_{2-6} alkenyl include allyl, butenyl, pentenyl, and hexenyl.

Examples of C_{2-6} alkynyl include 2-propynyl, butynyl, pentynyl, and hexynyl.

The expression "alkyl optionally substituted by" as used herein refers to alkyl, in which one or more hydrogen atoms on the alkyl group have been substituted by one or more substituents which may be the same or different, and unsubstituted alkyl. It will be apparent to a person having ordinary skill in the art that the maximum number of substituents may be determined depending upon the number of substitutable hydrogen atoms on the alkyl group. This is true of a group having a substituent other than the alkyl group.

The term "halogen" means a fluorine, chlorine, bromine, or iodine atom.

Preferably, the term halogen means a fluorine or chlorine atom.

The three- to twelve-membered ring system may include a saturated or unsaturated three- to eight-membered carbocyclic ring, preferably a four- to seven-membered, more preferably five- or six-membered, saturated or unsaturated carbocyclic ring. Examples of saturated or unsaturated three- to ten-membered carbocyclic rings include phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

Further, the three- to twelve-membered ring system may include a saturated or unsaturated three- to eight-membered heterocyclic group containing at least one hetero-atom selected from oxygen, nitrogen, and sulfur atoms. The heterocyclic group preferably contains one, two or three hetero-atoms with the remaining ring-constituting atoms being carbon atoms. The heterocyclic group preferably includes a saturated or unsaturated four- to seven-membered heterocyclic ring, more preferably a saturated or unsaturated five- or six-membered heterocyclic ring. Examples of saturated or unsaturated three- to eight-membered heterocyclic groups include thienyl, pyridyl, 1,2,3-triazolyl, thiazolyl, imidazolyl, isoxazolyl, pyrazolyl, piperazinyl, quinolinyl, piperidyl, morpholinyl, homopiperazinyl, thiomorpholinyl, tetrahydropyrrolyl, and azepanyl.

Further, the saturated or unsaturated carboxylic and heterocyclic ring systems include condensed ring systems wherein a cyclic group is condensed with another saturated or unsaturated five- to seven-membered carbocyclic or heterocyclic ring to form a bicyclic group, preferably a saturated or unsaturated nine- to twelve-membered bicyclic carbocyclic or heterocyclic group. Such bicyclic groups include naphthyl, quinolyl, 1,2,3,4-tetrahydroquinolyl, 1,4-benzoxanyl, indanyl, indolyl, 1,2,3,4-tetrahydronaphthyl, and phthalimidyl.

R^1 preferably represents a hydrogen atom or C_{1-4} alkyl, e.g. methyl. More preferably, R^1 represents a hydrogen atom.


R^2 and R^3 may be the same or different. Preferably, one of R^2 and R^3 represents a group other than a hydrogen atom. More preferably, R^2 and/or R^3 represent hydroxyl, optionally substituted C_{1-6} alkoxy, halogen, or cyano. In a preferred embodiment, C_{1-6} alkoxy is not substituted by amino. In an especially preferred embodiment, R^2 represents unsubstituted C_{1-6} alkoxy, still more preferably methoxy or fluorine. In a further preferred embodiment, R^2 represents unsubstituted C_{1-6} alkoxy, still more preferably, methoxy, and R^3 represents hydroxyl or optionally substituted C_{1-6} alkoxy, or alternatively R^2 represents hydroxyl or optionally substituted C_{1-6} alkoxy and R^3 represents unsubstituted C_{1-6} alkoxy, still more preferably unsubstituted methoxy. For example, R^2 and R^3 both represent methoxy. In a further preferred embodiment, R^2 is halogen, e.g. fluorine and R^3 is hydrogen. According to another preferred embodiment, R^3 is preferably selected from the group consisting of benzyloxy, 3-amino-propoxy, 2-morpholin-4-yl-ethoxy, 3-(4-methyl-piperidin-1-yl), 3-(3-methyl-piperidin-1-yl), 3-morpholin-4-yl-propoxy. In a particular preferred embodiment, R^2 is methoxy and R^3 is selected from said group.

In a still further preferred embodiment, R^2 and/or R^3 may represent $-O-(CH_2)_n-R^{14}$ wherein n is an integer of 0 to 6, $-(CH_2)_n-$ is optionally substituted by C_{1-6} alkyl, hydroxyl, or a halogen atom, and R^{14} represents a hydrogen atom; hydroxyl; a halogen atom; C_{1-6} alkoxy; C_{1-6} alkylcarbonyl; carboxyl; C_{1-6} alkoxy carbonyl; $-(C=O)-NR^{12}R^{13}$, $-NR^{12}R^{13}$ wherein R^{12} or R^{13} which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl optionally substituted by hydroxyl, or alternatively R^{12} and R^{13} may combine with the nitrogen atom attached thereto to form a saturated or unsaturated five- or six-membered heterocyclic group, in which the heterocyclic group is optionally substituted by hydroxyl, an oxygen atom, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkoxy carbonyl, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl groups are optionally substituted by hydroxyl, C_{1-6} alkoxy, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system, amino in which one or two hydrogen atoms on the amino

7


group are optionally substituted by C₁₋₆ alkyl or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system, and the C₁₋₆ alkyl group is optionally substituted by hydroxyl, C₁₋₆ alkoxy, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system; or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system optionally substituted by hydroxyl, an oxygen atom, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl groups are optionally substituted by hydroxyl, C₁₋₆ alkoxy, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system; when the carbocyclic or heterocyclic group is substituted by two C₁₋₆ alkyl groups, the two alkyl groups may combine together to form an alkylene chain; and the carbocyclic or heterocyclic group may be condensed with another saturated or unsaturated five- to seven-membered carbocyclic or heterocyclic group to form a bicyclic group. When n=0, —(CH₂)_n— represents a bond.

More preferably, R¹⁴ may represent a saturated heterocyclic ring attached through its nitrogen atom, wherein R¹⁴ is selected from the following:



More preferably, R¹⁴ may represent an unsaturated heterocyclic ring attached through its CH₂ group, wherein R¹⁴ is selected from the following:

8




R⁴ is preferably hydrogen, C₁₋₆ alkyl or C₁₋₆ alkoxy, wherein the C₁₋₆ alkyl or C₁₋₆ alkoxy group is optionally substituted with one or more halogen atoms. More preferably, R⁴ is hydrogen or trifluoromethyl.

In an especially preferred embodiment, R¹ and R⁴ are hydrogen and R² and R³ are C₁₋₆ alkoxy, particularly methoxy. In a further especially preferred embodiment, R¹, R² and R³ are hydrogen and R⁴ is C₁₋₆ alkyl optionally substituted, particularly trifluoromethyl. In a still further especially preferred embodiment, R¹, R³ and R⁴ are hydrogen and R² is halogen, e.g. fluorine.


R⁵ and R⁶ are preferably selected from hydrogen, C₁₋₆ alkyl or C₁₋₆ alkoxy, optionally substituted, e.g. by halogen and/or NR¹²R¹³ as described above. More preferably, R⁵ and R⁶ are hydrogen.

R⁷, R⁸, R⁹ and R¹⁰, which may be the same or different, preferably represent a hydrogen atom, a halogen atom, nitro or C₁₋₄ alkyl, or C₁₋₄ alkoxy, each optionally halogenated such as methoxy or trifluoromethyl. More preferably, R⁷ and R¹⁰ are hydrogen and at least one of R⁸ and R⁹ is different from hydrogen, e.g. halogen, such as fluorine.

More preferably, the carboxylic ring substituted by R⁷, R⁸, R⁹ and R¹⁰ is selected from the following:




9




In one embodiment, it is preferred that in case R^{11} is C_{1-6} alkyl substituted by a phenyl ring, the phenyl ring is mono- or polysubstituted. R^{11} preferably represents a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system which is optionally substituted, e.g. mono-, di- or trisubstituted by an oxygen atom, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, a halogen atom, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and the C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} alkoxy groups are optionally substituted by a halogen atom or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group. Examples of preferred substituents on the carbocyclic or heterocyclic group are halogen, e.g. F, Cl or Br, C_{1-4} alkyl optionally halogenated, such as methyl, ethyl, or trifluoromethyl, C_{1-4} alkoxy, optionally halogenated such as methoxy, difluoromethoxy or trifluoromethoxy, hydroxyl, cyano, and optionally substituted amino. Still more preferably the carbocyclic or heterocyclic group in R^{11} includes at least one halogen, e.g. fluorine or chlorine, trifluoromethyl or trifluoromethoxy substituent.

More preferably, R^{11} represents an optionally substituted carbocyclic ring selected from the following (connecting atom attached to the sulfonyl group):




10



13

More preferably, R¹¹ represents an optionally substituted nitrogen atom selected from the following (connecting atom labeled by sulfonyl group):



R¹¹ represents

(iii) a nitrogen atom substituted with a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system which is optionally mono- or polysubstituted by an oxygen atom, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, a halogen atom, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and the C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, and C₁₋₆ alkoxy groups are optionally substituted by a halogen atom or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group,

Examples of more preferred compounds include compounds represented by formula:

Reference	
A1	3-Cyano-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide
A2	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-fluoro-benzenesulfonamide
A3	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3,4-difluoro-benzenesulfonamide
A4	Thiophene-2-sulfonic acid 4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A5	3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-hydroxy-benzenesulfonamide
A6	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-fluoro-4-methyl-benzenesulfonamide
A7	N-{5-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]sulfamoyl}-4-methyl-thiophen-2-yl]-acetamide
A8	Quinoline-8-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A9	3-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]sulfamoyl]-thiophene-2-carboxylic acid methyl ester
A10	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide
A11	4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-fluoro-benzenesulfonamide
A12	3-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-4-fluoro-benzenesulfonamide
A13	4-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-fluoro-benzenesulfonamide
A14	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2,6-difluoro-benzenesulfonamide
A15	3-Difluoromethoxy-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide
A16	2-Phenyl-ethanesulfonic acid 4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A17	Naphthalene-1-sulfonic acid 4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A18	2'5-Dichloro-thiophene-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A19	4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-methyl-benzenesulfonamide

14

-continued

Reference	
A20	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2,3,4-trifluoro-benzenesulfonamide
A21	5-Methyl-thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A22	Furan-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A23	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-trifluoromethyl-benzenesulfonamide
A24	3-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide
A25	3-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide
A26	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-methyl-benzenesulfonamide
A27	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-methoxy-benzenesulfonamide
A28	5-Chloro-thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A29	5-Bromo-thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A30	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-phenoxy-benzenesulfonamide
A31	1-Ethyl-1H-pyrazole-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A32	1-Methyl-1H-imidazole-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A33	Cyclopropanesulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A34	Biphenyl-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A35	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-trifluoromethoxy-benzenesulfonamide
A36	5-Phenyl-thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A37	5-Oxazol-5-yl-thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A38	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3,5-difluoro-benzenesulfonamide
A39	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2,4-difluoro-benzenesulfonamide
A40	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2,5-difluoro-benzenesulfonamide
A41	2,6-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide
A42	2,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide
A43	3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide
A44	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-trifluoromethyl-benzenesulfonamide
A45	2-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-4-trifluoromethyl-benzenesulfonamide
A46	2-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-5-trifluoromethyl-benzenesulfonamide
A47	3-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-5-trifluoromethyl-benzenesulfonamide
A48	4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-trifluoromethyl-benzenesulfonamide
A49	3,4-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide
A50	3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-methoxy-benzenesulfonamide
A51	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-methyl-benzenesulfonamide
A52	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-methoxy-benzenesulfonamide
A53	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-trifluoromethoxy-benzenesulfonamide
A54	2-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide
A55	2-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide
A56	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-4-ethyl-benzenesulfonamide
A57	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-4-phenoxy-benzenesulfonamide

Reference	
A58	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-fluoro-2-methyl-benzenesulfonamide
A59	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-fluoro-benzenesulfonamide
A60	4-Bromo-3-chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide
A61	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-4-fluoro-3-methoxy-benzenesulfonamide
A62	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-4-ethoxy-3-methyl-benzenesulfonamide
A63	4-Methoxy-naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A64	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-methoxy-4,5-dimethyl-benzenesulfonamide
A65	N-{2-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylsulfamoyl]-4-methyl-phenyl}-acetamide
A66	N-[4-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylsulfamoyl]-2,6-dimethyl-phenyl]-acetamide
A67	3-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-4-methoxy-benzenesulfonamide
A68	5-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-2-methoxy-benzenesulfonamide
A69	5-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-2-methoxy-4-methyl-benzenesulfonamide
A70	3-tert-Butyl-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-4-methoxy-benzenesulfonamide
A71	Butane-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A72	2-Methyl-propane-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A73	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-phenyl-methanesulfonamide
A74	3-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-4-methoxy-benzenesulfonamide
A75	Biphenyl-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-amide
A76	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-3-phenoxy-benzenesulfonamide
A77	Naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-amide
A78	Isoquinoline-5-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide
A79	3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-2-hydroxy-benzenesulfonamide
A80	2-Methyl-3H-imidazole-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide
A81	Biphenyl-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide
A82	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide
A83	Benzo[b]thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide
A84	Benzo[b]thiophene-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide
A85	1-Methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide
A86	Biphenyl-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide
A87	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-4-(3,5-dimethyl-isoxazol-4-yl)methoxy-benzenesulfonamide
A88	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-fluoro-4-methoxy-benzenesulfonamide
A89	Biphenyl-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-amide
A90	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-3-phenoxy-benzenesulfonamide
A91	Naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-amide
A92	Biphenyl-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-amide
A93	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide
A94	Benzo[b]thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-amide
A95	1-Methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-amide

Reference	
A96	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-2-trifluoromethyl-benzenesulfonamide
A97	Biphenyl-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide
A98	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-3-phenoxy-benzenesulfonamide
A99	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-2,5-difluoro-benzenesulfonamide
A100	Naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide
A101	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide
A102	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide
A103	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-2-trifluoromethyl-benzenesulfonamide
A104	Naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide
A105	3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-4-hydroxy-benzenesulfonamide
A106	3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-2-methoxy-benzenesulfonamide
A107	Biphenyl-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide
A108	Benzo[b]thiophene-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide
A109	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-4-fluoro-3-methoxy-benzenesulfonamide
A110	4-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-2-fluoro-benzenesulfonamide
A111	3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-2-methoxy-benzenesulfonamide
A112	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-2-trifluoromethoxy-benzenesulfonamide
A113	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-2-trifluoromethyl-benzenesulfonamide
A114	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-2-trifluoromethoxy-benzenesulfonamide
A115	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-3-phenoxy-benzenesulfonamide
A116	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-4-fluoro-3-methoxy-benzenesulfonamide
A117	4-Bromo-3-chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-benzenesulfonamide
A118	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-2,5-difluoro-benzenesulfonamide
A119	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-2-trifluoromethoxy-benzenesulfonamide
A120	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-3-phenoxy-benzenesulfonamide
A121	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-4-fluoro-3-methoxy-benzenesulfonamide
A122	4-Bromo-3-chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-benzenesulfonamide
A123	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-2-trifluoromethyl-benzenesulfonamide
A124	04-Bromo-3-chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-benzenesulfonamide
A125	1-Methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide
A126	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-2-trifluoromethoxy-benzenesulfonamide
A127	3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-2-methoxy-benzenesulfonamide
A128	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-2-trifluoromethyl-benzenesulfonamide
A129	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-2-trifluoromethoxy-benzenesulfonamide
A130	4-Methoxy-naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-amide
A131	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-2,5-difluoro-benzenesulfonamide
A132	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide
A133	4-Methoxy-naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide

Reference	
A134	4-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-2-fluoro-benzenesulfonamide
A135	4-Methoxy-naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide
A136	Biphenyl-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A137	1-Methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
A138	Biphenyl-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-amide
A139	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-2,5-difluoro-benzenesulfonamide
A140	Naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-amide
A141	4-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-2-fluoro-benzenesulfonamide
A142	Biphenyl-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-amide
A143	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide
A144	Benzo[b]thiophene-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-amide
A145	1-Methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-amide
A146	4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-2-trifluoromethoxy-benzenesulfonamide
A147	4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-trifluoromethoxy-benzenesulfonamide
A148	4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-2-trifluoromethoxy-benzenesulfonamide
A149	4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-2-trifluoromethoxy-benzenesulfonamide
A150	4-Methoxy-naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-amide
A151	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-2,5-difluoro-benzenesulfonamide
A152	4-Bromo-3-chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-benzenesulfonamide
A153	4-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-2-fluoro-benzenesulfonamide
A154	N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-4-fluoro-3-methoxy-benzenesulfonamide
A155	3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-4-hydroxy-benzenesulfonamide
A156	3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-2-hydroxy-benzenesulfonamide
B1	Thiophene-2-sulfonic acid [2-fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide
B2	3-Cyano-N-[2-fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide
B3	N-[2-Fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-3-methoxy-benzenesulfonamide
B4	Cyclopropanesulfonic acid [2-fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide
B5	3-Chloro-4-fluoro-N-[2-fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide
B6	2,6-Difluoro-N-[2-fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide
B7	5-Methyl-thiophene-2-sulfonic acid [2-fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide
B8	N-[2-Fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-3-trifluoromethyl-benzenesulfonamide
B9	N-[4-(6-Fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide
B10	3,5-Dichloro-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide
B11	3,5-Dichloro-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-2-methoxy-benzenesulfonamide
B12	2,4-Difluoro-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide
B13	3,5-Difluoro-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide
B14	3-Bromo-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide
B15	4-Bromo-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-2-trifluoromethyl-benzenesulfonamide

Reference	
B16	Thiophene-3-sulfonic acid [4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide
B17	3-[4-(6-Fluoro-2-methyl-quinolin-4-yloxy)-phenylsulfamoyl]-thiophene-2-carboxylic acid methyl ester
B18	5-Chloro-thiophene-2-sulfonic acid [4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide
B19	5-Oxazol-5-yl-thiophene-2-sulfonic acid [4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide
B20	Naphthalene-1-sulfonic acid [4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide
B21	1-Ethyl-1H-pyrazole-4-sulfonic acid [4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide
B22	3,5-Dichloro-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-2-hydroxy-benzenesulfonamide
C1	3,5-Dichloro-N-[2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide
C2	Biphenyl-3-sulfonic acid [2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-amide
C3	N-[2-Fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-3-phenoxy-benzenesulfonamide
C4	Naphthalene-1-sulfonic acid [2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-amide
C5	2,5-Dichloro-N-[2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide
C6	2,6-Dichloro-N-[2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide
C7	N-[2-Fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-2-trifluoromethyl-benzenesulfonamide
C8	4-Methoxy-naphthalene-1-sulfonic acid [3-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-amide
C9	3-Fluoro-N-[3-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-4-methoxy-benzenesulfonamide
C10	N-[3-Fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-2-methoxy-4,5-dimethyl-benzenesulfonamide
C11	2,5-Difluoro-N-[2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide
C12	3-Chloro-4-fluoro-N-[2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide
C13	2-Methyl-3H-imidazole-4-sulfonic acid [3-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-amide
C14	4-(3,5-Dimethyl-isoxazol-4-ylmethoxy)-N-[3-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide
C15	Biphenyl-4-sulfonic acid [2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-amide
C16	N-[2-Fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide
C17	Benzo[b]thiophene-2-sulfonic acid [2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-amide
C18	Benzo[b]thiophene-3-sulfonic acid [2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-amide
C19	1-Methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid [2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-amide
D1	Biphenyl-3-sulfonic acid [4-(7-benzyloxy-6-methoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide
D2	Naphthalene-1-sulfonic acid {4-[7-(3-amino-propoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-amide
D3	Biphenyl-3-sulfonic acid {4-[7-(3-amino-propoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-amide
D4	Biphenyl-3-sulfonic acid {3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-amide
D5	N-[3-Fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl]-2-trifluoromethyl-benzenesulfonamide
D6	N-[3-Fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl]-2-trifluoromethoxy-benzenesulfonamide
D7	Biphenyl-3-sulfonic acid {4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-2-methyl-phenyl}-amide
D8	N-[4-[6-Methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-2-methyl-phenyl]-2-trifluoromethoxy-benzenesulfonamide
D9	2,5-Difluoro-N-[4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-2-methyl-phenyl]-benzenesulfonamide
D10	2,5-Difluoro-N-[3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl]-benzenesulfonamide

Reference	
D11	N-{4-[6-Methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-2-methyl-phenyl}-2-trifluoromethyl-benzenesulfonamide
D12	4-Chloro-2-fluoro-N-{3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide
D13	4-Methoxy-naphthalene-1-sulfonic acid {3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-amide
D14	N-{4-[7-(3-Amino-propoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-2-trifluoromethyl-benzenesulfonamide
D15	N-{4-[7-(3-Amino-propoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-2-trifluoromethoxy-benzenesulfonamide
D16	(3-{4-[2-Fluoro-4-(2-trifluoromethoxy-benzenesulfonylamino)-phenoxy]-6-methoxy-quinolin-7-yloxy}-propyl)-carbamic acid tert-butyl ester
D17	N-(3-Fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-2-trifluoromethyl-benzenesulfonamide
D18	2-Bromo-N-(3-fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide
D19	2,4-Difluoro-N-(3-fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide
D20	2,6-Difluoro-N-(3-fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide
D21	Naphthalene-1-sulfonic acid (3-fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-amide
D22	Propane-1-sulfonic acid (3-fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-amide
D23	2-Cyano-N-(3-fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide
D24	4-Chloro-2-fluoro-N-(3-fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide
D25	Butane-1-sulfonic acid (3-fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-amide
D26	2-Bromo-N-{3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide
D27	2-Cyano-N-{3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide
D28	2,4-Difluoro-N-{3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide
D29	Biphenyl-3-sulfonic acid (3-fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-amide
D30	2-Fluoro-N-(3-fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide
D31	2-Cyano-N-(3-fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide
D32	2,6-Difluoro-N-(3-fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide
D33	N-(3-Fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-2-trifluoromethoxy-benzenesulfonamide
D34	2,5-Difluoro-N-(3-fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide
D35	N-(3-Fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}phenyl)-2-trifluoromethyl-benzenesulfonamide
D36	2,5-Difluoro-N-(3-fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide
D37	Biphenyl-3-sulfonic acid (3-fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-amide

Reference	
D38	4-Fluoro-N-(3-fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-3-methoxy-benzenesulfonamide
D39	N-{3-Fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-2-trifluoromethyl-benzenesulfonamide
D40	N-{3-Fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-2-trifluoromethoxy-benzenesulfonamide
D41	2,5-Difluoro-N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide
D42	Biphenyl-3-sulfonic acid {3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-amide
D43	4-Chloro-2-fluoro-N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide
D44	4-Fluoro-N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-3-methoxy-benzenesulfonamide
D45	2-Fluoro-N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide
D46	N-{3-Fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-2-nitro-benzenesulfonamide
D47	2,6-Dichloro-N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide
D48	Naphthalene-1-sulfonic acid {3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-amide
D49	2-Bromo-N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide

Preparation of Starting Materials

The compounds are suitable for use in medicine, particularly in human medicine, but also in veterinary medicine. The compounds may be administered in a pharmaceutically effective amount by any suitable route to subjects in need thereof, e.g. parenterally, topically, rectally, nasally, buccally, vaginally, transdermally, by inhalation, by injection or infusion, by spray or via implanted reservoirs. Preferably, the compounds are administered orally or by injection or infusion, e.g. intravenously. For medical purposes, the compounds are preferably formulated as a pharmaceutical composition, which includes at least one compound as described above, and pharmaceutically acceptable carriers, diluents and/or adjuvants. The pharmaceutical composition may e.g. be a solid dosage form, e.g. a tablet, a capsule etc., or a liquid dosage form, e.g. an injectable or infundible solution.

The dosage of the compounds may be determined by a skilled practitioner according to the type and severity of the disorder to be treated. In general, the dosage of the compound may vary from 0.0001 to 1000 or even more mg/day.

The compounds may be administered as a monotherapy or together with further active agents, particularly chemotherapeutic agents or antitumor antibodies.


The compounds may be produced, for example, according to synthesis routes as depicted in schemes 1 to 3. Starting compounds necessary for the synthesis of the compounds are commercially available or alternatively can be easily produced by conventional methods. In the schemes, R¹ to R¹⁰ are as defined in formula (I).

The 4-chloroquinoline derivatives can be synthesized from substituted anilines by methods described in Org. Synth. Col. Vol. 3, 272 (1955) or from substituted acetophenones by methods described in EP 1153920 (Scheme 1).

21

22


Scheme 1.



A 4-(aminophenoxy)quinoline derivative may be produced by reacting a nitrophenol derivative with the 4-chloroquinoline derivative in a suitable solvent, for example, chlorobenzene, to synthesize a 4-(nitrophenoxy)quinoline derivative or a corresponding quinazoline derivative and then reacting the 4-(nitrophenoxy)quinoline derivative in a suitable solvent, for example, N,N-dimethyl formamide, in the presence of a catalyst, for example, palladium hydroxide-carbon or palladium-carbon, under a hydrogen atmosphere. The nitro group can also be reduced with zinc, iron or the like (Scheme 2).


Alternatively, the 4-(aminophenoxy)quinoline derivative can be produced by reacting an aminophenol derivative with the 4-chloroquinoline derivative in a suitable solvent, for example, dimethyl sulfoxide, in the presence of a base, for example, sodium hydride. Alternatively, the 4-(aminophenoxy)quinazoline derivative can also be produced by dissolving an aminophenol derivative in an aqueous sodium hydroxide solution and subjecting the solution to a two-phase reaction with a solution of the 4-chloroquinazoline derivative in a suitable organic solvent, for example, ethyl methyl ketone, in the presence of a phase transfer catalyst, for example, tetra-n-butylammonium chloride, or in the absence of a catalyst (Scheme 2).

Scheme 2.




23

-continued



A 4-(sulfamoylphenoxy)quinoline derivative may be produced by reacting a 4-(aminophenoxy)quinoline derivative with sulfonyl chloride derivative in a suitable solvent, for example, pyridine (Scheme 3). The reaction may be carried out in room temperature. The solvent can be diluted with hydrochloric acid, when the product precipitated. The crystals can be collected by filtration and the obtained solid material can be dissolved in e.g. 10% sodium acetate solution and extracted e.g. with ethyl acetate. The organic layer can be washed e.g. with sodium chloride solution, dried and the solvent can be evaporated. The resulted solid can be treated with diisopropyl ether. The product can be purified with column chromatography (if necessary).

Scheme 3.



24

EXAMPLES

1) Analytical Methods (HPLC, NMR, TLC and Melting Point)

Analytical HPLC/MS was performed on an Waters HPLC/MS system using reverse phase Waters XTerra MS C18 (5 cm×4.6 mm, 5 μm), gradient 0-95% B (0.00 min 5% B, 0.50 min 5% B, 5.50 min 95% B, 6.00 min 95% B, 6.50 min 5% B, 7.00 min 5% B), Solvent A: Water/0.05% HCOOH, Solvent B: AcCN/0.05% HCOOH over 7.00 min, flow=2.0 ml/min. Separation module was Waters Alliance 2795.

UV spectra were recorded using a Waters 996 DAD UV detector. Mass spectra were obtained using Waters SQD MS detector (Ionization: ES⁺/ES⁻, Source block temp: 120 °C, Desolvation temp: 350 °C., Desolvation Gas: 400 L/h, Cone Gas: 100 L/h, Capillary: 3000 V, Cone: 25 V, Extractor: 3 V, Rf Lens: 0.2 V, Scan: 120 to 1000 m/z in 1 sec., Inter-scan delay: 0.1 s).

¹H NMR spectra were recorded on a Bruker Avance 300 MHz AV spectrometer in deuterated solvents (DMSO-d₆). Chemical shifts are in parts per million (ppm).

Thin-layer chromatography (TLC) analysis was performed with Kieselgel 60 F254 (Merck) plates and visualized using UV light.

Melting point measurement was Büchi melting Point B-54 instrument.

2) Manufacture of Compounds

The following Examples illustrate the preparation of specific compounds, and the AXL Kinase inhibitory properties thereof:

General Procedure for Sulfonamide Compounds (Type A-C):

0.31 mmol appropriately substituted sulfonylchloride and 0.3 mmol 4-(4-amino-phenoxy)quinoline derivative was dissolved 3 ml abs. pyridine and stirred at room temperature while the starting amine disappears (2-3 days). The reaction mixture was poured on ice cold 1M hydrochloric acid, stirred for 1 hour and the precipitated crystalls were filtered out. The obtained solid material was dissolved in 10% sodium acetate solution and extracted with ethyl acetate. The organic layer was washed with sodium chloride solution, dried and the solvent was evaporated. The resulted solid was treated with diisopropyl ether. The product was purified with column chromatography (if it was necessary).

General Procedure for Sulfonamide Compounds (Type D):


0.31 mmol appropriately substituted sulfonylchloride and 0.3 mmol 4-(4-amino-phenoxy)quinoline derivative was dissolved 3 ml abs. pyridine and stirred at room temperature while the starting amine disappears (2-3 days). The reaction mixture was poured into 50 ml of water, extracted with 30 ml of chloroform, and separated the two layers. The organic phase was dried over anhydrous sodium sulfate, evaporated

25

and the residue was purified on TLC plate (eluent chloroform-methanol 95:5, 9:1). The pure product was solidified over diisopropyl ether.

Example A1

3-Cyano-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-enzenesulfonamide



$C_{24}H_{18}FN_3O_5S$ Mw. 479.49


LC/MS purity: 92%, m/z 480 [M+H]⁺ Rt. 2.71 min.

¹H NMR (300 MHz, DMSO-d₆): 10.46 (s, 1H), 8.51 (d, 1H), 8.15 (m, 2H), 8.04 (d, 2H), 7.82 (t, 1H), 7.41 (s, 1H), 7.40 (s, 1H), 7.28 (m, 2H), 7.07 (d, 1H), 6.56 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 223-224° C. Yield: 45%

Example A2

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-fluoro-benzenesulfonamide



$C_{23}H_{18}F_2N_2O_5S$ Mw. 472.47

LC/MS purity: 97%, m/z 471 [M-H]⁻ Rt. 2.80 min.


¹H NMR (300 MHz, DMSO-d₆): 10.37 (s, 1H), 8.51 (d, 1H), 7.76-7.23 (m, 8H), 7.07 (d, 1H), 6.56 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 233-235° C. Yield: 49%

26

Example A3

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3,4-difluoro-benzenesulfonamide



$C_{23}H_{17}F_3N_2O_5S$ Mw. 490.46


LC/MS purity: 94%, m/z 489 [M-H]⁻ Rt. 2.89 min.

¹H NMR (300 MHz, DMSO-d₆): 10.38 (s, 1H), 8.50 (d, 1H), 7.81-7.61 (m, 3H), 7.41 (s, 1H), 7.40 (s, 1H), 7.29 (m, 2H), 7.07 (d, 1H), 6.57 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 217-219° C. Yield: 38%

Example A4

Thiophene-2-sulfonic acid 4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide



$C_{21}H_{17}FN_2O_5S_2$ Mw. 460.51

LC/MS purity: 96%, m/z 459 [M-H]⁻ Rt. 2.66 min.


¹H NMR (300 MHz, DMSO-d₆): 10.35 (s, 1H), 8.52 (d, 1H), 7.96 (d, 1H), 7.52 (d, 1H), 7.43 (s, 1H), 7.41 (s, 1H), 7.32 (m, 1H), 7.17 (t, 1H), 7.09 (d, 1H), 6.67 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 214-216° C. Yield: 37%

27

Example A5

3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-hydroxy-benzenesulfonamide



$C_{23}H_{17}Cl_2FN_2O_6S$ Mw. 539.37


LC/MS purity: 96%, m/z 537 [M-H]⁻ Rt. 3.01 min.

¹H NMR (300 MHz, DMSO-d₆): 8.52 (d, 1H), 7.76 (d, 1H), 7.48 (d, 1H), 7.44 (s, 1H), 7.41 (s, 1H), 7.35 (m, 1H), 7.25 (dd, 1H), 7.04 (d, 1H), 6.57 (d, 1H), 3.95 (s, 3H), 3.91 (s, 3H), 3.6 (bs, 2H)

Melting point: 232-234° C. Yield: 35%

Example A6

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-fluoro-4-methyl-benzenesulfonamide



$C_{24}H_{20}F_2N_2O_5S$ Mw. 486.50

LC/MS purity: 95%, m/z 485 [M-H]⁻ Rt. 2.93 min.


¹H NMR (300 MHz, DMSO-d₆): 10.28 (s, 1H), 8.51 (d, 1H), 7.55-7.23 (m, 7H), 7.07 (dd, 1H), 6.56 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 2.31 (s, 3H)

Melting point: 211-212° C. Yield: 54%

Example A7

N-{5-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenylsulfamoyl]-4-methyl-thiophen-2-yl}-acetamide

28



$C_{24}H_{22}FN_3O_6S_2$ Mw. 531.59


LC/MS purity: 98%, m/z 533 [M+H]⁺ Rt. 2.53 min.

¹H NMR (300 MHz, DMSO-d₆): 12.52 (s, 1H), 10.33 (s, 1H), 8.50 (d, 1H), 7.36 (m, 4H), 7.11 (d, 1H), 6.51 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 2.30 (s, 3H), 2.16 (s, 3H)

Melting point: 133-135° C. Yield: 48%

Example A8

Quinoline-8-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide



$C_{26}H_{20}FN_3O_5S$ Mw. 505.53

LC/MS purity: 97%, m/z 506 [M+H]⁺ Rt. 2.81 min.


¹H NMR (300 MHz, DMSO-d₆): 9.75 (s, 1H), 9.11 (d, 1H), 8.58 (d, 1H), 8.48 (d, 1H), 8.30 (m, 2H), 7.74 (m, 2H), 7.19 (m, 3H), 7.03 (d, 1H), 6.96 (d, 1H), 6.48 (s, 1H), 3.92 (s, 3H), 3.86 (s, 3H)

Melting point: 255-257° C. Yield: 36%

29

Example A9

3-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenylsulfamoyl]-thiophene-2-carboxylic acid methyl ester



$C_{23}H_{19}FN_2O_7S_2$ Mw. 518.54


LC/MS purity: 96%, m/z 519 [M+H]⁺ Rt. 2.84 min.

¹H NMR (300 MHz, DMSO-d₆): 9.80 (s, 1H), 8.51 (d, 1H), 7.97 (d, 1H), 7.39 (m, 4H), 7.26 (d, 1H), 7.05 (d, 1H), 6.55 (d, 1H), 3.94 (s, 3H), 3.89 (s, 3H), 3.88 (s, 3H).

Melting point: 189-190° C. Yield: 45%

Example A10

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide



$C_{23}H_{19}FN_2O_5S$ Mw. 454.48

LC/MS purity: 98%, m/z 453 [M-H]⁻ Rt. 2.70 min.


¹H NMR (300 MHz, DMSO-d₆): 10.22 (s, 1H), 8.50 (d, 1H), 7.75-7.56 (m, 5H), 7.41 (s, 1H), 7.40 (s, 1H), 7.32 (t, 1H), 7.23 (dd, 1H), 7.06 (d, 1H), 6.53 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H).

Melting point: 234-235° C. Yield: 59%

30

Example A11

4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-fluoro-benzenesulfonamide



$C_{23}H_{17}BrF_2N_2O_5S$ Mw. 551.37


LC/MS purity: 97%, m/z 551 [M+H]⁺ Rt. 3.06 min.

¹H NMR (300 MHz, DMSO-d₆): 10.46 (s, 1H), 8.51 (d, 1H), 7.99 (t, 1H), 7.67 (dd, 1H), 7.50 (dd, 1H), 7.41 (s, 1H), 7.40 (s, 1H), 7.30 (m, 2H), 7.07 (d, 1H), 6.58 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H).

Melting point: 209-211° C. Yield: 62%

Example A12

3-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-4-fluoro-benzenesulfonamide



$C_{23}H_{17}ClF_2N_2O_5S$ Mw. 506.92

LC/MS purity: 95%, m/z 505 [M-H]⁻ Rt. 3.00 min.


¹H NMR (300 MHz, DMSO-d₆): 10.39 (s, 1H), 8.51 (d, 1H), 7.89 (dd, 1H), 7.72 (m, 2H), 7.41 (s, 1H), 7.40 (s, 1H), 7.30 (m, 2H), 7.08 (dd, 1H), 6.56 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H).

Melting point: 208-210° C. Yield: 65%

31

Example A13

4-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-fluoro-benzenesulfonamide



$C_{23}H_{17}ClF_2N_2O_5S$ Mw. 506.92


LC/MS purity: 95%, m/z 505 [M-H]⁻ Rt. 2.97 min.

¹H NMR (300 MHz, DMSO-d₆): 10.63 (s, 1H), 8.52 (d, 1H), 7.76 (dd, 1H), 7.70 (t, 1H), 7.48-7.25 (m, 5H), 7.07 (d, 1H), 6.55 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 218-219° C. Yield: 53%

Example A14

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2,6-difluoro-benzenesulfonamide



$C_{23}H_{17}F_3N_2O_5S$ Mw. 490.46

LC/MS purity: 96%, m/z 489 [M-H]⁻ Rt. 2.73 min.


¹H NMR (300 MHz, DMSO-d₆): 10.82 (s, 1H), 8.52 (d, 1H), 7.73 (m, 1H), 7.41 (s, 1H), 7.40 (s, 1H), 7.32 (m, 4H), 7.09 (d, 1H), 6.54 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 223-225° C. Yield: 45%

32

Example A15

3-Difluoromethoxy-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide



$C_{24}H_{19}F_3N_2O_6S$ Mw. 520.49


LC/MS purity: 98%, m/z 519 [M-H]⁻ Rt. 2.93 min.

¹H NMR (300 MHz, DMSO-d₆): 10.36 (s, 1H), 8.50 (d, 1H), 7.62 (m, 2H), 7.49 (m, 2H), 7.41 (s, 1H), 7.40 (s, 1H), 7.35-7.23 (m, 2H), 7.07 (d, 1H), 6.64 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 238-239° C. Yield: 61%

Example A16

2-Phenyl-ethenesulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide



$C_{25}H_{21}FN_2O_5S$ Mw. 480.52


LC/MS purity: 98%, m/z 479 [M-H]⁻ Rt. 2.91 min.

33

¹H NMR (300 MHz, DMSO-d₆): 9.94 (s, 1H), 8.48 (d, 1H), 7.71 (m, 2H), 7.52-7.29 (m, 9H), 7.09 (d, 1H), 6.55 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H) Melting point: 224-225° C. Yield: 26%

Example A17

Naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide



C₂₇H₂₁FN₂O₅S Mw. 504.54


LC/MS purity: 98%, m/z 503 [M-H]⁻ Rt. 3.01 min.

¹H NMR (300 MHz, DMSO-d₆): 10.51 (s, 1H), 8.71 (d, 1H), 8.49 (d, 1H), 8.25 (d, 1H), 8.10 (d, 2H), 7.71 (m, 2H), 7.62 (t, 1H), 7.38 (s, 2H), 7.28 (t, 1H), 7.12 (dd, 1H), 6.99 (d, 1H), 6.44 (d, 1H), 3.93 (s, 3H), 3.87 (s, 3H)

Melting point: 243-245° C. Yield: 41%

Example A18

2,5-Dichloro-thiophene-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide



C₂₁H₁₅Cl₂FN₂O₅S₂ Mw. 529.40

LC/MS purity: 93%, m/z 527 [M-H]⁻ Rt. 3.05 min.


¹H NMR (300 MHz, DMSO-d₆): 10.60 (s, 1H), 8.52 (d, 1H), 7.43-7.26 (m, 5H), 7.09 (d, 1H), 6.57 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 223-225° C. Yield: 35%

34

Example A19

4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-methyl-benzenesulfonamide



C₂₄H₂₀BrFN₂O₅S Mw. 547.40


LC/MS purity: 95%, m/z 545 [M-H]⁻ Rt. 3.10 min.

¹H NMR (300 MHz, DMSO-d₆): 10.28 (s, 1H), 8.51 (d, 1H), 7.82 (d, 1H), 7.71 (s, 1H), 7.46 (d, 1H), 7.41 (s, 1H), 7.40 (s, 1H), 7.30 (m, 1H), 7.06 (d, 1H), 6.55 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 2.41 (s, 3H)

Melting point: 199-201° C. Yield: 56%

Example A20

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2,3,4-trifluoro-benzenesulfonamide



C₂₃H₁₆F₄N₂O₅S Mw. 508.45

LC/MS purity: 95%, m/z 507 [M-H]⁻ Rt. 2.92 min.


¹H NMR (300 MHz, DMSO-d₆): 10.78 (s, 1H), 8.52 (d, 1H), 7.63-7.27 (m, 6H), 7.07 (d, 1H), 6.57 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 188-190° C. Yield: 38%

35

Example A21

5-Methyl-thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide



$C_{22}H_{19}FN_2O_5S_2$ Mw. 474.53


LC/MS purity: 97%, m/z 475 [M+H]⁺ Rt. 2.60 min.

¹H NMR (300 MHz, DMSO-d₆): 10.30 (s, 1H), 8.52 (d, 1H), 7.43-7.26 (m, 5H), 7.09 (d, 1H), 6.88 (d, 1H), 6.57 (d, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 2.50 (s, 3H)

Melting point: 218-220° C. Yield: 68%

Example A22

Furan-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide



$C_{21}H_{17}FN_2O_6S$ Mw. 444.44

LC/MS purity: 96%, m/z 443 [M-H]⁻ Rt. 2.59 min.


¹H NMR (300 MHz, DMSO-d₆): 10.53 (s, 1H), 8.52 (d, 1H), 8.02 (d, 1H), 7.42 (s, 1H), 7.41 (s, 1H), 7.30 (m, 2H), 7.08 (d, 1H), 7.06 (s, 1H), 6.67 (dd, 1H), 6.59 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 210-212° C. Yield: 59%

36

Example A23

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-trifluoromethyl-benzenesulfonamide



$C_{24}H_{18}F_4N_2O_5S$ Mw. 522.48


LC/MS purity: 94%, m/z 521 [M-H]⁻ Rt. 3.03 min.

¹H NMR (300 MHz, DMSO-d₆): 10.46 (s, 1H), 8.50 (d, 1H), 8.05 (m, 3H), 7.85 (t, 1H), 7.40 (s, 2H), 7.33 (t, 1H), 7.22 (dd, 1H), 7.08 (d, 1H), 6.53 (d, 1H), 3.94 (s, 3H), 3.89 (s, 3H)

Melting point: 230-231° C. Yield: 53%

Example A24

3-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide



$C_{23}H_{18}BrFN_2O_5S$ Mw. 533.38

LC/MS purity: 96%, m/z 533 [M+H]⁺ Rt. 2.96 min.


¹H NMR (300 MHz, DMSO-d₆): 11.9 (bs, 1H), 8.45 (d, 1H), 7.81 (s, 1H), 7.70 (d, 1H), 7.64 (d, 1H), 7.42 (m, 3H), 7.23 (t, 1H), 6.98 (dd, 1H), 6.79 (d, 1H), 6.44 (d, 1H), 3.93 (s, 3H), 3.90 (s, 3H)

Melting point: 255-257° C. Yield: 37%

37

Example A25


3-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide

 $C_{23}H_{18}ClFN_2O_5S$ Mw. 488.93LC/MS purity: 96%, m/z 487 [M-H]⁻ Rt. 2.93 min.¹H NMR (300 MHz, DMSO-d₆): 10.38 (s, 1H), 8.49 (d, 1H), 7.65 (m, 4H), 7.42 (s, 1H), 7.39 (s, 1H), 7.30 (t, 1H), 7.18 (d, 1H), 7.00 (d, 1H), 6.52 (d, 1H), 3.93 (s, 3H), 3.90 (s, 3H)

Melting point: 250-251° C. Yield: 62%

Example A26

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-methyl-benzenesulfonamide


 $C_{24}H_{21}FN_2O_5S$ Mw. 468.51LC/MS purity: 98%, m/z 467 [M-H]⁻ Rt. 2.85 min.¹H NMR (300 MHz, DMSO-d₆): 10.16 (s, 1H), 8.50 (d, 1H), 7.56-7.40 (m, 6H), 7.31 (t, 1H), 7.22 (dd, 1H), 7.04 (dd, 1H), 6.52 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 2.37 (s, 3H)

Melting point: 244-245° C. Yield: 49%

38

Example A27


N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-methoxy-benzenesulfonamide

 $C_{24}H_{21}FN_2O_6S$ Mw. 484.51LC/MS purity: 95%, m/z 483 [M-H]⁻ Rt. 2.78 min.¹H NMR (300 MHz, DMSO-d₆): 10.22 (s, 1H), 8.50 (d, 1H), 7.50 (t, 1H), 7.41 (s, 1H), 7.40 (s, 1H), 7.35-7.2 (m, 5H), 7.05 (dd, 1H), 6.53 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 3.80 (s, 3H)

Melting point: 224-225° C. Yield: 68%

Example A28

5-Chloro-thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide


 $C_{21}H_{16}ClFN_2O_5S_2$ Mw. 494.95LC/MS purity: 94%, m/z 493 [M-H]⁻ Rt. 2.94 min.¹H NMR (300 MHz, DMSO-d₆): 10.57 (s, 1H), 8.52 (d, 1H), 7.43-7.25 (m, 7H), 7.1 (d, 1H), 6.60 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 187-189° C. Yield: 54%

39

Example A29

5-Bromo-thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide



$C_{21}H_{16}BrFN_2O_5S_2$ Mw. 539.40


LC/MS purity: 95%, m/z 537 [M-H]⁻ Rt. 2.83 min.

¹H NMR (300 MHz, DMSO-d₆): 10.55 (s, 1H), 8.52 (d, 1H), 7.40 (m, 6H), 7.1 (d, 1H), 6.59 (d, 1H), 3.95 (s, 3H), 3.91 (s, 3H)

Melting point: 207-209° C. Yield: 55%

Example A30

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-phenoxy-benzenesulfonamide



$C_{29}H_{23}FN_2O_6S$ Mw. 546.58

LC/MS purity: 97%, m/z 545 [M-H]⁻ Rt. 3.23 min.


¹H NMR (300 MHz, DMSO-d₆): 10.22 (bs, 1H), 8.49 (d, 1H), 7.61 (t, 1H), 7.44 (m, 5H), 7.27 (m, 5H), 7.04 (m, 3H), 6.54 (d, 1H), 3.95 (s, 3H), 3.90 (s, 3H)

Melting point: 179-180° C. Yield: 75%

40

Example A31

1-Ethyl-1H-pyrazole-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide



$C_{22}H_{21}FN_4O_5S$ Mw. 472.50


LC/MS purity: 98%, m/z 471 [M-H]⁻ Rt. 2.45 min.

¹H NMR (300 MHz, DMSO-d₆): 9.94 (s, 1H), 8.51 (d, 1H), 8.23 (s, 1H), 7.68 (s, 1H), 7.43 (s, 1H), 7.41 (s, 1H), 7.28 (m, 2H), 7.07 (dd, 1H), 6.58 (d, 1H), 4.17 (q, 2H), 3.95 (s, 3H), 3.91 (s, 3H), 1.34 (t, 3H)

Melting point: 211-213° C. Yield: 49%

Example A32

1-Methyl-1H-imidazole-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide



$C_{21}H_{19}FN_4O_5S$ Mw. 458.47

LC/MS purity: 98%, m/z 459 [M+H]⁺ Rt. 2.21 min.


¹H NMR (300 MHz, DMSO-d₆): 9.97 (s, 1H), 8.51 (d, 2H), 7.78 (s, 1H), 7.73 (s, 1H), 7.41 (m, 3H), 7.23 (d, 1H), 7.03 (d, 1H); 6.55 (d, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 3.68 (s, 3H)

Melting point: 215-217° C. Yield: 35%

41

Example A33


Cyclopropanesulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide

 $C_{20}H_{19}FN_2O_5S$ Mw. 418.45LC/MS purity: 98%, m/z 417 [M-H]⁻ Rt. 2.40 min.¹H NMR (300 MHz, DMSO-d₆): 9.64 (bs, 1H), 8.51 (bs, 1H), 7.44 (m, 4H), 7.11 (bs, 1H), 6.62 (bs, 1H), 3.94 (bs, 6H), 2.67 (bs, 1H), 0.97 (bs, 2H), 0.90 (bs, 2H)

Melting point: 179-180° C. Yield: 38%

Example A34

Biphenyl-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide


 $C_{29}H_{23}FN_2O_5S$ Mw. 530.58LC/MS purity: 98%, m/z 529 [M-H]⁻ Rt. 3.20 min.¹H NMR (300 MHz, DMSO-d₆): 10.25 (bs, 1H), 8.44 (d, 1H), 7.96 (m, 2H), 7.70 (m, 4H), 7.54-7.33 (m, 6H), 7.22 (bd, 1H), 7.06 (d, 1H), 6.48 (d, 1H), 3.94 (s, 3H), 3.89 (s, 3H)

Melting point: 193-195° C. Yield: 64%

42

Example A35


N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-trifluoromethoxy-benzenesulfonamide

 $C_{24}H_{18}F_4N_2O_6S$ Mw. 538.48LC/MS purity: 94%, m/z 537 [M-H]⁻ Rt. 3.09 min.¹H NMR (300 MHz, DMSO-d₆): 10.41 (s, 1H), 8.50 (d, 1H), 7.75 (m, 3H), 7.63 (s, 1H), 7.41 (s, 2H), 7.33 (t, 1H), 7.23 (dd, 1H), 7.07 (d, 1H), 6.55 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 221-223° C. Yield: 52%

Example A36

5-Phenyl-thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide

 $C_{27}H_{21}FN_2O_5S_2$ Mw. 536.61LC/MS purity: 93%, m/z 535 [M-H]⁻ Rt. 3.22 min.¹H NMR (300 MHz, DMSO-d₆): 10.45 (s, 1H), 8.47 (d, 1H), 7.72 (m, 2H), 7.58-7.37 (m, 9H), 7.28 (dd, 1H), 7.10 (d, 1H), 6.56 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)


Melting point: 186-188° C. Yield: 52%

Example A37

5-Oxazol-5-yl-thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide

65

43



$C_{24}H_{18}FN_3O_6S_2$ Mw. 527.55


LC/MS purity: 98%, m/z 528 [M+H]⁺ Rt. 2.51 min.

¹H NMR (300 MHz, DMSO-d₆): 10.56 (s, 1H), 8.52 (s, 1H), 8.51 (d, 1H), 7.77 (s, 1H), 7.53 (m, 2H), 7.39 (m, 3H), 7.29 (dd, 1H), 7.10 (d, 1H), 6.58 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 206-208° C. Yield: 36%

Example A38

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3,5-difluoro-benzenesulfonamide



$C_{23}H_{17}F_3N_2O_5S$ Mw. 490.46

LC/MS purity: 96%, m/z 489 [M-H]⁻ Rt. 2.91 min.


¹H NMR (300 MHz, DMSO-d₆): 10.49 (s, 1H), 8.51 (d, 1H), 7.67 (m, 1H), 7.44-7.25 (m, 6H), 7.07 (dd, 1H), 6.59 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 243-245° C. Yield: 47%

44

Example A39

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2,4-difluoro-benzenesulfonamide



$C_{23}H_{17}F_3N_2O_5S$ Mw. 490.46


LC/MS purity: 95%, m/z 489 [M-H]⁻ Rt. 2.81 min.

¹H NMR (300 MHz, DMSO-d₆): 10.56 (s, 1H), 8.51 (d, 1H), 7.78 (dd, 1H), 7.56 (dd, 1H), 7.44-7.23 (m, 5H), 7.06 (dd, 1H), 6.55 (d, 1H), 3.94 (s, 3H), 3.89 (s, 3H)

Melting point: 212-214° C. Yield: 52%

Example A40

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2,5-difluoro-benzenesulfonamide



$C_{23}H_{17}F_3N_2O_5S$ Mw. 490.46

LC/MS purity: 99%, m/z 489 [M-H]⁻ Rt. 2.82 min.


¹H NMR (300 MHz, DMSO-d₆): 10.68 (s, 1H), 8.51 (d, 1H), 7.55 (m, 3H), 7.41 (s, 1H), 7.40 (s, 1H), 7.36 (t, 1H), 7.26 (dd, 1H), 7.06 (dd, 1H), 6.56 (d, 1H), 3.94 (s, 3H), 3.89 (s, 3H)

Melting point: 232-234° C. Yield: 45%

45

Example A41

2,6-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide



$C_{23}H_{17}Cl_2FN_2O_5S$ Mw. 523.37


LC/MS purity: 96%, m/z 523 [M+H]⁺ Rt. 2.92 min.

¹H NMR (300 MHz, DMSO-d₆): 10.61 (s, 1H), 8.51 (d, 1H), 7.57 (m, 3H), 7.41 (s, 2H), 7.34 (t, 1H), 7.25 (dd, 1H), 7.06 (d, 1H), 6.53 (d, 1H), 3.94 (s, 3H), 3.89 (s, 3H)

Melting point: 217-218° C. Yield: 58%

Example A42

2,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide



$C_{23}H_{17}Cl_2FN_2O_5S$ Mw. 523.37

LC/MS purity: 95%, m/z 523 [M-H]⁻ Rt. 3.05 min.


¹H NMR (300 MHz, DMSO-d₆): 10.64 (s, 1H), 8.51 (d, 1H), 7.85 (s, 1H), 7.76 (s, 2H), 7.40 (s, 2H), 7.35 (t, 1H), 7.26 (dd, 1H), 7.06 (d, 1H), 6.56 (d, 1H), 3.94 (s, 3H), 3.89 (s, 3H)

Melting point: 228-230° C. Yield: 63%

46

Example A43

3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide



$C_{23}H_{17}Cl_2FN_2O_5S$ Mw. 523.37


LC/MS purity: 95%, m/z 521 [M-H]⁻ Rt. 3.16 min.

¹H NMR (300 MHz, DMSO-d₆): 10.51 (s, 1H), 8.52 (d, 1H), 8.00 (s, 1H), 7.69 (s, 2H), 7.42 (s, 1H), 7.41 (s, 1H), 7.33 (t, 1H), 7.28 (dd, 1H), 7.09 (d, 1H), 6.57 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 240-242° C.; Yield: 46%

Example A44

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-trifluoromethyl-benzenesulfonamide



$C_{24}H_{18}F_4N_2O_5S$ Mw. 522.48

LC/MS purity: 96%, m/z 521 [M-H]⁻ Rt. 2.95 min.


¹H NMR (300 MHz, DMSO-d₆): 10.37 (s, 1H), 8.51 (d, 1H), 8.03 (m, 2H), 7.87 (m, 2H), 7.40 (s, 2H), 7.34 (t, 1H), 7.24 (dd, 1H), 7.06 (d, 1H), 6.53 (d, 1H), 3.94 (s, 3H), 3.89 (s, 3H)

Melting point: 237-239° C. Yield: 72%

47

Example A45

2-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-4-trifluoromethyl-benzenesulfonamide



$C_{24}H_{17}BrF_4N_2O_5S$ Mw. 601.38


LC/MS purity: 96%, m/z 599 [M-H]⁻ Rt. 3.13 min.

¹H NMR (300 MHz, DMSO-d₆): 10.70 (s, 1H), 8.51 (d, 1H), 8.30 (s, 1H), 8.15 (d, 1H), 7.97 (d, 1H), 7.40 (s, 2H), 7.34 (t, 1H), 7.27 (dd, 1H), 7.05 (dd, 1H), 6.57 (d, 1H), 3.94 (s, 3H), 3.89 (s, 3H)

Melting point: 236-238° C. Yield: 65%

Example A46

2-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-5-trifluoromethyl-benzenesulfonamide



$C_{24}H_{17}BrF_4N_2O_5S$ Mw. 601.38

LC/MS purity: 96%, m/z 599 [M-H]⁻ Rt. 3.17 min.


¹H NMR (300 MHz, DMSO-d₆): 10.72 (s, 1H), 8.50 (d, 1H), 8.16 (d, 1H), 8.14 (s, 1H), 7.95 (dd, 1H), 7.40 (s, 2H), 7.36 (t, 1H), 7.26 (dd, 1H), 7.06 (dd, 1H), 6.53 (d, 1H), 3.94 (s, 3H), 3.89 (s, 3H)

Melting point: 227-230° C. Yield: 42%

48

Example A47

3-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-5-trifluoromethyl-benzenesulfonamide



$C_{24}H_{17}BrF_4N_2O_5S$ Mw. 601.38


LC/MS purity: 95%, m/z 599 [M-H]⁻ Rt. 3.27 min.

¹H NMR (300 MHz, DMSO-d₆): 10.60 (s, 1H), 8.52 (d, 1H), 8.39 (s, 1H), 8.12 (s, 1H), 7.97 (s, 1H), 7.41 (s, 2H), 7.34 (t, 1H), 7.28 (dd, 1H), 7.09 (d, 1H), 6.55 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 214-216° C. Yield: 58%

Example A48

4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-trifluoromethyl-benzenesulfonamide



$C_{24}H_{17}BrF_4N_2O_5S$ Mw. 601.38

LC/MS purity: 96%, m/z 599 [M-H]⁻ Rt. 3.14 min.


¹H NMR (300 MHz, DMSO-d₆): 10.51 (s, 1H), 8.52 (d, 1H), 8.18 (s, 1H), 8.13 (dd, 1H), 7.94 (d, 1H), 7.41 (s, 2H), 7.34 (t, 1H), 7.27 (dd, 1H), 7.07 (dd, 1H), 6.56 (d, 1H), 3.95 (s, 3H), 3.90 (s, 3H)

Melting point: 242-244° C. Yield: 69%

49

Example A49

3,4-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide


 $C_{23}H_{17}Cl_2FN_2O_5S$ Mw. 523.37LC/MS purity: 97%, m/z 521 [M-H]⁻ Rt. 3.12 min.

¹H NMR (300 MHz, DMSO-d₆): 10.45 (s, 1H), 8.50 (d, 1H), 8.31 (s, 1H), 7.86 (m, 2H), 7.68 (d, 2H), 7.42 (s, 1H), 7.40 (s, 1H), 7.31 (t, 1H), 7.23 (dd, 1H), 7.03 (d, 1H), 6.56 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 225-227° C. Yield: 38%

Example A50

3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-methoxy-benzenesulfonamide

 $C_{24}H_{19}Cl_2FN_2O_6S$ Mw. 553.40LC/MS purity: 99%, m/z 551 [M-H]⁻ Rt. 3.23 min.


¹H NMR (300 MHz, DMSO-d₆): 10.37 (s, 1H), 8.51 (d, 1H), 8.03 (d, 1H), 7.63 (d, 1H), 7.42 (s, 1H), 7.40 (s, 1H), 7.33 (t, 1H), 7.25 (dd, 1H), 7.04 (dd, 1H), 6.55 (d, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 3.90 (s, 3H)

Melting point: 193-195° C. Yield: 51%

50

Example A51

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-methyl-benzenesulfonamide


 $C_{24}H_{21}FN_2O_5S$ Mw. 468.51LC/MS purity: 94%, m/z 467 [M-H]⁻ m/z 469 [M-H]⁺ Rt. 2.82 min.

¹H NMR (300 MHz, DMSO-d₆): 10.47 (bs, 1H), 8.49 (d, 1H), 7.92 (d, 1H), 7.68-7.18 (m, 7H), 7.00 (dd, 1H), 6.51 (d, 1H), 3.93 (s, 3H), 3.89 (s, 3H), 2.58 (s, 3H)

Melting point: 218-220° C. Yield: 62%

Example A52

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-methoxy-benzenesulfonamide

 $C_{24}H_{21}FN_2O_6S$ Mw. 484.51LC/MS purity: 98% m/z 483 [M-H]⁻ m/z 485 [M-H]⁺ Rt. 2.71 min.


¹H NMR (300 MHz, DMSO-d₆): 9.82 (bs, 1H), 8.50 (d, 1H), 7.65 (m, 2H), 7.39-7.01 (m, 7H), 6.50 (d, 1H), 3.94 (s, 3H), 3.89 (s, 3H), 2.59 (s, 3H)

Melting point: 213-215° C. Yield: 55%

51

Example A53

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-trifluoromethoxy-benzenesulfonami



$C_{24}H_{18}F_4N_2O_6S$ Mw. 538.48


LC/MS purity: 96% m/z 537 [M-H]⁻, m/z 539 [M-H]⁺ Rt. 3.00 min.

¹H NMR (300 MHz, DMSO-d₆): 10.40 (bs, 1H), 8.52 (d, 1H), 7.90 (d, 1H), 7.80 (m, 1H), 7.70-7.05 (m, 7H), 6.54 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 204-206° C. Yield: 69%

Example A54

2-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamid



$C_{23}H_{18}ClFN_2O_5S$ Mw. 488.93

LC/MS purity: 98% m/z 487 [M-H]⁻, m/z 489 [M-H]⁺ Rt. 2.81 min.


¹H NMR (300 MHz, DMSO-d₆): 10.43 (bs, 1H), 8.50 (d, 1H), 7.69 (d, 1H), 7.64 (m, 2H), 7.51-7.17 (m, 5H), 7.00 (d, 1H), 6.52 (d, 1H), 3.94 (s, 3H), 3.89 (s, 3H)

Melting point: 232-234° C. Yield: 76%

52

Example A55

2-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide



$C_{23}H_{18}BrFN_2O_5S$ Mw. 533.38


LC/MS purity: 98%, m/z 531 [M-H]⁻, m/z 533 [M-H]⁺ Rt. 2.85 min.

¹H NMR (300 MHz, DMSO-d₆): 10.40 (bs, 1H), 8.50 (d, 1H), 7.95 (dd, 1H), 7.88 (dd, 1H), 7.55 (m, 2H), 7.40 (s, 2H), 7.26 (m, 2H), 7.04 (dd, 1H), 6.53 (d, 1H), 3.94 (s, 3H), 3.89 (s, 3H)

Melting point: 225-227° C. Yield: 47%

Example A56

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-4-ethyl-benzenesulfonamide



$C_{25}H_{23}FN_2O_5S$ Mw. 482.53

LC/MS purity: 94%, m/z 481 [M-H]⁻, m/z 483 [M-H]⁺ Rt. 3.01 min.


¹H NMR (300 MHz, DMSO-d₆): 10.14 (bs, 1H), 8.50 (d, 1H), 7.66 (d, 2H), 7.41 (m, 3H), 7.32 (t, 1H), 7.22 (dd, 1H), 7.04 (dd, 1H), 6.54 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 2.68 (q, 2H), 1.20 (t, 3H)

Melting point: 193-195° C. Yield: 66%

53

Example A57

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-4-phenoxy-benzenesulfonamide



$C_{29}H_{23}FN_2O_6S$ Mw. 546.58


LC/MS purity: 95%, m/z 545 [M-H]⁻, m/z 547 [M-H]⁺
Rt. 3.23 min.

¹H NMR (300 MHz, DMSO-d₆): 10.13 (bs, 1H), 8.49 (d, 1H), 7.73 (d, 2H), 7.43 (m, 4H), 7.32-7.22 (m, 4H), 7.10 (m, 4H), 6.55 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 202-204° C. Yield: 76%

Example A58

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-fluoro-2-methyl-benzenesulfonamide



$C_{24}H_{20}F_2N_2O_5S$ Mw. 486.50

LC/MS purity: 94%, m/z 485 [M-H]⁻, m/z 487 [M-H]⁺
Rt. 2.92 min.


¹H NMR (300 MHz, DMSO-d₆): 10.39 (bs, 1H), 8.57 (d, 1H), 7.60-7.31 (m, 6H), 7.23 (dd, 1H), 7.04 (d, 1H), 6.52 (d, 1H), 3.94 (s, 3H), 3.89 (s, 3H)

Melting point: 204-206° C. Yield: 78%

54

Example A59

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-fluoro-benzenesulfonamide



$C_{23}H_{18}F_2N_2O_5S$ Mw. 472.47


LC/MS purity: 98%, m/z 471 [M-H]⁻, m/z 473 [M-H]⁺
Rt. 2.72 min.

¹H NMR (300 MHz, DMSO-d₆): 10.47 (bs, 1H), 8.51 (d, 1H), 7.70 (m, 1H), 7.70 (m, 2H), 7.37 (m, 5H), 7.22 (dd, 1H), 7.03 (dd, 1H), 6.53 (d, 1H), 3.94 (s, 3H), 3.89 (s, 3H)

Melting point: 235-236° C. Yield: 51%

Example A60

4-Bromo-3-chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide



$C_{23}H_{17}BrClFN_2O_5S$ Mw. 567.82

LC/MS purity: 98%, m/z 565 [M-H]⁻, m/z 567 [M-H]⁺
Rt. 3.14 min.


¹H NMR (300 MHz, DMSO-d₆): 10.45 (bs, 1H), 8.51 (d, 1H), 8.02 (d, 1H), 7.87 (s, 1H), 7.58 (dd, 1H), 7.42-7.24 (m, 4H), 7.07 (d, 1H), 6.57 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 231-232° C. Yield: 55%

55

Example A61


N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-4-fluoro-3-methoxy-benzenesulfonamide

 $C_{24}H_{20}F_2N_2O_6S$ Mw. 502.50LC/MS purity: 100%, m/z 501 [M-H]⁻, m/z 503 [M-H]⁺
Rt. 2.69 min.¹H NMR (300 MHz, DMSO-d₆): 10.20 (bs, 1H), 8.50 (d, 1H), 7.49-7.22 (m, 7H), 7.05 (d, 1H), 6.55 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 3.87 (s, 3H)

Melting point: 214-216° C. Yield: 45%

Example A62

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-4-ethoxy-3-methyl-benzenesulfonamide


 $C_{26}H_{25}FN_2O_6S$ Mw. 512.56LC/MS purity: 100%, m/z 521 [M-H]⁻ Rt. 3.09 min.¹H NMR (300 MHz, DMSO-d₆): 9.96 (s, 1H), 8.50 (d, 1H), 7.52 (m, 2H), 7.42 (s, 1H), 7.40 (s, 1H), 7.30 (t, 1H), 7.20 (d, 1H), 7.04 (m, 2H), 6.52 (d, 1H), 4.10 (q, 2H), 3.94 (s, 3H), 3.90 (s, 3H), 1.36 (t, 3H)

Melting point: 158-160° C. Yield: 61%

56

Example A63


4-Methoxy-naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide

 $C_{28}H_{23}FN_2O_6S$ Mw. 534.57LC/MS purity: 97%, m/z 533 [M-H]⁻ Rt. 3.07 min.¹H NMR (300 MHz, DMSO-d₆): 10.31 (s, 1H), 8.68 (d, 1H), 8.48 (d, 2H), 8.29 (d, 1H), 8.07 (d, 1H), 7.70 (m, 2H), 7.38 (s, 1H), 7.37 (s, 1H), 7.28 (t, 1H), 7.07 (m, 3H), 6.45 (d, 1H), 4.05 (s, 3H), 3.93 (s, 3H), 3.88 (s, 3H)

Melting point: 226-227° C. Yield: 62%

Example A64

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-methoxy-4,5-dimethyl-benzenesulfonamide


 $C_{26}H_{25}FN_2O_6S$ Mw. 512.56LC/MS purity: 97%, m/z 511 [M-H]⁻ Rt. 2.97 min.¹H NMR (300 MHz, DMSO-d₆): 9.63 (s, 1H), 8.50 (d, 1H), 7.40 (s, 3H), 7.33 (t, 1H), 7.20 (dd, 1H), 7.02 (m, 2H), 6.51 (d, 1H), 3.94 (s, 3H), 3.88 (s, 3H), 3.84 (s, 3H), 2.27 (s, 3H), 2.15 (s, 3H)

Melting point: 238-240° C. Yield: 53%

57

Example A65

N-{2-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-sulfamoyl]-4-methyl-phenyl}-acetamide



$C_{26}H_{25}N_3O_6S$ Mw. 507.57


LC/MS purity: 99%, m/z 506 [M-H]⁻, m/z 508 [M-H]⁺
Rt. 2.51 min.

¹H NMR (300 MHz, DMSO-d₆): 10.2 (bs, 1H), 10.13 (s, 1H), 8.43 (d, 1H), 8.15 (d, 1H), 7.72 (d, 1H), 7.44 (s, 1H), 7.37 (s, 1H), 7.29 (d, 1H), 7.13 (dd, 4H), 6.35 (d, 1H), 3.93 (s, 3H), 3.89 (s, 3H), 2.54 (s, 3H), 2.03 (s, 3H)

Melting point: 134-136° C. Yield: 49%

Example A66

N-{4-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-sulfamoyl]-2,6-dimethyl-phenyl}-acetamide



$C_{27}H_{27}N_3O_6S$ Mw. 521.60

LC/MS purity: 94%, m/z 520 [M-H]⁻, m/z 522 [M-H]⁺
Rt. 2.49 min.


¹H NMR (300 MHz, DMSO-d₆): 13.5 (bs, 1H), 8.44 (d, 1H), 7.73 (d, 1H), 7.45 (s, 1H), 7.37 (s, 1H), 7.25 (d, 1H), 7.14 (m, 4H), 6.37 (d, 1H), 3.93 (s, 3H), 3.89 (s, 3H), 2.44 (s, 3H), 2.17 (s, 3H), 2.07 (s, 3H)

Melting point: 145-147° C. Yield: 67%

58

Example A67

3-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-4-methoxy-benzenesulfonamide



$C_{24}H_{21}ClN_2O_6S$ Mw. 500.96


LC/MS purity: 99%, m/z 499 [M-H]⁻ m/z 501 [M-H]⁺ Rt. 2.89 min.

¹H NMR (300 MHz, DMSO-d₆): 10.27 (bs, 1H), 8.45 (d, 1H), 7.70 (m, 2H), 7.36 (m, 3H), 7.18 (m, 4H), 6.37 (d, 1H), 3.93 (s, 3H), 3.90 (s, 3H)

Melting point: 226-227° C. Yield: 51%

Example A68

5-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-2-methoxy-benzenesulfonamide



$C_{24}H_{21}ClN_2O_6S$ Mw. 500.96

LC/MS purity: 98%, m/z 499 [M-H]⁻ m/z 501 [M-H]⁺ Rt. 2.90 min.


¹H NMR (300 MHz, DMSO-d₆): 10.24 (s, 1H), 8.44 (d, 1H), 7.66 (m, 2H), 7.44 (s, 1H), 7.37 (s, 1H), 7.27-7.13 (m, 5H), 6.32 (d, 1H), 3.93 (s, 3H), 3.92 (s, 3H), 3.89 (s, 3H)

Melting point: 255-257° C. Yield: 63%

59

Example A69


5-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-2-methoxy-4-methyl-benzenesulfonamide

 $C_{25}H_{23}ClN_2O_6S$ Mw. 514.99LC/MS purity: 98%, m/z 513 [M-H]⁻ Rt. 3.04 min.¹H NMR (300 MHz, DMSO-d₆): 12.0 (bs, 1H), 10.17 (bs, 1H), 8.44 (d, 1H), 7.65 (s, 1H), 7.44 (s, 3H), 7.37 (s, 1H), 7.17 (m, 5H), 6.33 (d, 1H), 3.93 (s, 3H), 3.91 (s, 3H), 3.89 (s, 3H), 2.36 (s, 3H)

Melting point: 236-238° C. Yield: 70%

Example A70

3-tert-Butyl-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-4-methoxy-benzenesulfonamide


 $C_{28}H_{30}N_2O_6S$ Mw. 522.63LC/MS purity: 98%, m/z 521 [M-H]⁻ Rt. 3.24 min.¹H NMR (300 MHz, DMSO-d₆): 10.13 (bs, 1H), 8.43 (d, 1H), 7.62 (d, 1H), 7.56 (s, 1H), 7.44 (s, 1H), 7.38 (s, 5H), 7.16 (m, 5H), 6.33 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 3.87 (s, 3H), 1.29 (s, 9H).

Melting point: 229-231° C. Yield: 56%

60

Example A71


Butane-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide

 $C_{21}H_{23}FN_2O_5S$ Mw. 434.49LC/MS purity: 99%, m/z 433 [M-H]⁻, m/z 435 [M-H]⁺ Rt. 2.67 min.¹H NMR (300 MHz, DMSO-d₆): 9.66 (s, 1H), 8.52 (d, 1H), 7.45 (m, 4H), 7.09 (d, 1H), 6.63 (d, 1H), 3.95 (s, 3H), 3.92 (s, 3H), 3.11 (t, 2H), 1.70 (m, 2H), 1.40 (q, 2H), 0.89 (t, 3H)

Melting point: 164-166° C. Yield: 42%

Example A72

2-Methyl-propane-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide


 $C_{21}H_{23}FN_2O_5S$ Mw. 434.49LC/MS purity: 100%, m/z 433 [M-H]⁻, m/z 435 [M-H]⁺ Rt. 2.48 min.¹H NMR (300 MHz, DMSO-d₆): 9.68 (s, 1H), 8.52 (d, 1H), 7.52-7.41 (m, 3H), 7.43 (dd, 1H), 7.09 (dd, 1H), 3.95 (s, 3H), 3.92 (s, 3H), 3.02 (d, 2H), 2.20 (m, 1H), 1.04 (s, 6H)

Melting point: 175-176° C. Yield: 46%

61

Example A73

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluorophenyl]-C-phenyl-methanesulfonamide



$C_{24}H_{21}FN_2O_5S$ Mw. 468.51


LC/MS purity: 99%, m/z 467 [M-H]⁻, m/z 469 [M-H]⁺
Rt. 2.57 min.

¹H NMR (300 MHz, DMSO-d₆): 9.73 (s, 1H), 8.54 (d, 1H), 7.38 (m, 9H), 7.03 (d, 1H), 6.58 (d, 1H), 3.95 (s, 3H), 3.92 (s, 3H),

Melting point: 204-205° C. Yield: 47%

Example A74

3-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-4-methoxy-benzenesulfonamide



$C_{24}H_{21}BrN_2O_6S$ Mw. 545.41

LC/MS purity: 100%, m/z 543 [M-H]⁻, m/z 545 [M-H]⁺
Rt. 2.78 min.


¹H NMR (300 MHz, DMSO-d₆): 10.25 (bs, 1H), 8.46 (d, 1H), 7.81 (s, 1H), 7.73 (dd, 1H), 7.45 (s, 1H), 7.38 (s, 1H), 7.27 (dd, 1H), 7.17 (m, 4H), 6.35 (s, 1H), 3.93 (s, 3H), 3.92 (s, 3H), 3.90 (s, 3H).

Melting point: 211-212° C. Yield: 74%

62

Example A75

Biphenyl-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-amide



$C_{30}H_{26}N_2O_5S$ Mw. 526.62


LC/MS purity: 99%, m/z 525 [M-H]⁻, m/z 527 [M-H]⁺
Rt. 3.19 min.

¹H NMR (300 MHz, DMSO-d₆): 10.29 (s, 1H), 8.32 (d, 1H), 7.97 (m, 1H), 7.77 (d, 1H), 7.67 (m, 3H), 7.50 (s, 5H), 7.37 (s, 1H), 7.15 (s, 1H), 7.05 (s, 2H), 6.0 (d, 1H), 3.93 (s, 3H), 3.90 (s, 3H), 2.01 (s, 3H)

Melting point: 178-180° C. Yield: 55%

Example A76

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-3-phenoxy-benzenesulfonamide



$C_{30}H_{26}N_2O_6S$ Mw. 542.62

LC/MS purity: 100%, m/z 541 [M-H]⁻, m/z 543 [M-H]⁺
Rt. 3.21 min.


¹H NMR (300 MHz, DMSO-d₆): 10.28 (bs, 1H), 8.40 (d, 1H), 7.63-7.44 (m, 4H), 7.42-7.30 (m, 3H), 7.25-6.97 (m, 7H), 6.28 (d, 1H), 3.94 (s, 3H), 3.89 (s, 3H), 2.08 (s, 3H)

Melting point: 115-117° C. Yield: 65%

63

Example A77

Naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-amide



$C_{28}H_{24}N_2O_5S$ Mw. 500.58


LC/MS purity: 95%, m/z 499 [M-H]⁻, m/z 501 [M-H]⁺
Rt. 2.87 min.

¹H NMR (300 MHz, DMSO-d₆): 10.68 (s, 1H), 8.75 (d, 1H), 8.38 (d, 1H), 8.24 (m, 2H), 8.10 (d, 1H), 7.69 (m, 3H), 7.46 (s, 1H), 7.36 (s, 1H), 7.04 (s, 1H), 6.95 (m, 2H), 6.07 (d, 1H), 3.92 (s, 3H), 3.88 (s, 3H), 1.94 (s, 3H)

Melting point: 118-120° C. Yield: 43%

Example A78

Isoquinoline-5-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide



$C_{26}H_{21}N_3O_5S$ Mw. 487.54

LC/MS purity: 100%, m/z 486 [M-H]⁻, m/z 488 [M-H]⁺
Rt. 2.51 min.

¹H NMR (300 MHz, DMSO-d₆): 10.80 (s, 1H), 9.48 (s, 1H), 8.73 (d, 1H), 8.51 (d, 1H), 8.43 (m, 3H), 7.82 (t, 1H), 7.39 (s, 1H), 7.36 (s, 1H), 7.10 (dd, 4H), 6.26 (d, 1H), 3.92 (s, 3H), 3.87 (s, 3H)

Melting point: 229-231° C. Yield: 74%

64

Example A79


3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-2-hydroxy-benzenesulfonamide

5

10

15

20



$C_{24}H_{20}Cl_2N_2O_6S$ Mw. 535.41

LC/MS purity: 91%, m/z 533 [M-H]⁻, m/z 535 [M-H]⁺
Rt. 2.90 min.

¹H NMR (300 MHz, DMSO-d₆): 10.2 (bs, 1H), 7.87 (d, 1H), 7.73 (s, 1H), 7.68 (d, 1H), 7.62 (s, 1H), 7.14 (m, 5H), 6.59 (d, 1H), 4.01 (s, 6H), 2.05 (s, 3H)

Melting point: 113-117° C. Yield: 25%

Example A80

2-Methyl-3H-imidazole-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide


35

40

45

50

55



$C_{21}H_{20}N_4O_5S$ Mw. 440.48

LC/MS purity: 99%, m/z 439 [M-H]⁻, m/z 441 [M-H]⁺
Rt. 2.02 min.


¹H NMR (300 MHz, DMSO-d₆): 12.4 (s, 1H), 8.58 (dd, 1H), 8.45 (d, 1H), 7.78 (t, 1H), 7.65 (d, 1H), 7.47 (s, 1H), 7.26 (d, 2H), 7.13 (d, 1H), 6.39 (d, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 2.28 (s, 3H)

Melting point: 268-269° C. Yield: 54%

65

Example A81

Biphenyl-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide



$C_{29}H_{24}N_2O_5S$ Mw. 512.59


LC/MS purity: 96%, m/z 511 [M-H]⁻, m/z 513 [M-H]⁺
Rt. 3.12 min.

¹H NMR (300 MHz, DMSO-d₆): 10.42 (bs, 1H), 8.42 (d, 1H), 7.87 (m, 4H), 7.73 (d, 2H), 7.49 (m, 3H), 7.43 (s, 1H), 7.37 (s, 1H), 7.25 (d, 2H), 7.17 (d, 2H), 6.36 (d, 1H), 3.93 (s, 3H), 3.88 (s, 3H)

Melting point: 191-194° C. Yield: 52%

Example A82

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide



$C_{27}H_{22}N_4O_5S$ Mw. 514.56

LC/MS purity: 99%, m/z 513 [M-H]⁻, m/z 515 [M-H]⁺
Rt. 2.67 min.


¹H NMR (300 MHz, DMSO-d₆): 10.2 (bs, 1H), 8.96 (d, 2H), 8.82 (s, 1H), 8.62 (d, 1H), 8.36 (d, 1H), 7.90 (d, 1H), 7.75 (t, 1H), 7.54 (t, 1H), 7.42 (s, 1H), 7.36 (s, 1H), 7.22 (d, 2H), 7.15 (d, 2H), 6.28 (d, 1H), 3.92 (s, 3H), 3.87 (s, 3H)

Melting point: 194-195° C. Yield: 61%

66

Example A83

Benzo[b]thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide



$C_{25}H_{20}N_2O_5S_2$ Mw. 492.58


LC/MS purity: 99%, m/z 491 [M-H]⁻, m/z 493 [M-H]⁺
Rt. 2.90 min.

¹H NMR (300 MHz, DMSO-d₆): 10.72 (s, 1H), 8.44 (d, 1H), 8.08 (d, 1H), 8.02 (d, 1H), 7.51 (m, 3H), 7.44 (s, 1H), 7.37 (s, 1H), 7.29 (d, 2H), 7.19 (d, 2H), 6.36 (d, 1H), 3.93 (s, 3H), 3.88 (s, 3H)

Melting point: 222-225° C. Yield: 64%

Example A84

Benzo[b]thiophene-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide



$C_{25}H_{20}N_2O_5S_2$ Mw. 492.58

LC/MS purity: 100%, m/z 491 [M-H]⁻, m/z 493 [M-H]⁺
Rt. 2.84 min.


¹H NMR (300 MHz, DMSO-d₆): 10.25 (s, 1H), 8.39 (d, 1H), 8.28 (d, 1H), 8.25 (s, 1H), 8.01 (d, 1H), 7.42 (m, 3H), 7.35 (s, 1H), 7.04 (d, 2H), 6.93 (d, 2H), 6.31 (d, 1H), 3.92 (s, 3H), 3.88 (s, 3H)

Melting point: 267-270° C. Yield: 53%

67

Example A85

1-Methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide



$C_{26}H_{23}N_3O_6S$ Mw. 505.55


LC/MS purity: 100%, m/z 504 [M-H]⁻, m/z 506 [M-H]⁺
Rt. 2.37 min.

¹H NMR (300 MHz, DMSO-d₆): 10.1 (bs, 1H), 8.44 (m, 1H), 7.71 (d, 1H), 7.64 (s, 1H), 7.41 (d, 2H), 7.37 (d, 1H), 7.15 (m, 4H), 6.36 (m, 1H), 3.92 (s, 3H), 3.88 (s, 3H), 3.64 (s, 2H), 3.13 (s, 3H)

Melting point: 119-122° C. Yield: 54%

Example A86

Biphenyl-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide



$C_{29}H_{24}N_2O_5S$ Mw. 512.59

LC/MS purity: 97%, m/z 511 [M-H]⁻, m/z 513 [M-H]⁺
Rt. 3.09 min.


¹H NMR (300 MHz, DMSO-d₆): 10.3 (bs, 1H), 8.36 (d, 1H), 7.98 (s, 1H), 7.95 (d, 1H), 7.76 (d, 1H), 7.66 (m, 3H), 7.51 (m, 3H), 7.43 (s, 1H), 7.37 (s, 1H), 7.24 (d, 2H), 7.17 (d, 2H), 6.29 (d, 1H), 3.93 (s, 3H), 3.88 (s, 3H)

Melting point: 197-200° C. Yield: 53%

68

Example A87

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-4-(3,5-dimethyl-isoxazol-4-ylmethoxy)-benzene-sulfonamide



$C_{29}H_{27}N_3O_7S$ Mw. 561.62


LC/MS purity: 97%, m/z 560 [M-H]⁻, m/z 562 [M-H]⁺
Rt. 2.78 min.

¹H NMR (300 MHz, DMSO-d₆): 10.2 (bs, 1H), 8.45 (d, 1H), 7.72 (d, 2H), 7.44 (s, 1H), 7.38 (s, 1H), 7.16 (m, 6H), 6.37 (d, 1H), 4.99 (s, 2H), 3.93 (s, 3H), 3.90 (s, 3H), 2.39 (s, 3H), 2.19 (s, 3H)

Melting point: 188-190° C. Yield: 11%

Example A88

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluorophenyl]-3-fluoro-4-methoxy-benzenesulfonamide



$C_{24}H_{20}F_2N_2O_6S$ Mw. 502.50

LC/MS purity: 100%, m/z 501 [M-H]⁻, m/z 503 [M-H]⁺
Rt. 2.62 min.


¹H NMR (300 MHz, DMSO-d₆): 10.15 (bs, 1H), 8.50 (d, 1H), 7.51 (m, 3H), 7.41-7.21 (m, 4H), 7.04 (dd, 1H), 6.95 (d, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 3.89 (s, 3H)

Melting point: 230-232° C. Yield: 23%

69

Example A89

Biphenyl-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-amide


 $C_{30}H_{26}N_2O_5S$ Mw. 526.62LC/MS purity: 100%, m/z 525 [M-H]⁻, m/z 527 [M-H]⁺
Rt. 3.18 min.¹H NMR (300 MHz, DMSO-d₆): 9.69 (s, 1H), 8.40 (d, 1H), 7.97 (t, 1H), 7.87 (s, 1H), 7.66 (m, 4H), 7.48 (m, 4H), 7.38 (s, 1H), 7.06 (m, 3H), 6.39 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 2.00 (s, 3H)

Melting point: 220-222° C. Yield: 77%

70

Example A91


Naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-amide

 $C_{28}H_{24}N_2O_5S$ Mw. 500.58LC/MS purity: 98%, m/z 499 [M-H]⁻, m/z 451 [M-H]⁺
Rt. 3.01 min.¹H NMR (300 MHz, DMSO-d₆): 9.93 (s, 1H), 8.71 (d, 1H), 8.47 (d, 1H), 8.25 (d, 1H), 8.08 (m, 2H), 7.70 (m, 2H), 7.61 (t, 1H), 7.41 (s, 1H), 7.37 (s, 1H), 7.03 (d, 1H), 6.94 (m, 2H), 6.37 (d, 1H), 3.93 (s, 3H), 3.89 (s, 3H), 1.85 (s, 3H)

Melting point: 233-235° C. Yield: 72%

Example A90


N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-3-phenoxy-benzenesulfonamide

 $C_{30}H_{26}N_2O_6S$ Mw. 542.62LC/MS purity: 100%, m/z 541 [M-H]⁻, m/z 543 [M-H]⁺
Rt. 3.22 min.¹H NMR (300 MHz, DMSO-d₆): 9.71 (s, 1H), 8.46 (d, 1H), 7.61 (t, 1H), 7.43 (m, 5H), 7.18 (t, 1H), 7.08 (m, 7H), 6.44 (d, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 1.98 (s, 3H)

Melting point: 169-170° C. Yield: 70%

Example A92

Biphenyl-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-amide


 $C_{30}H_{26}N_2O_5S$ Mw. 526.62LC/MS purity: 96%, m/z 525 [M-H]⁻, m/z 527 [M-H]⁺
Rt. 3.21 min.¹H NMR (300 MHz, DMSO-d₆): 9.71 (s, 1H), 8.48 (s, 1H), 7.90 (d, 2H), 7.51 (m, 4H), 7.46 (m, 3H), 7.44 (s, 1H), 7.38 (s, 1H), 7.08 (m, 3H), 6.47 (d, 1H), 3.93 (s, 3H), 3.89 (s, 3H), 2.04 (s, 3H)

Melting point: 228-230° C. Yield: 58%

71

Example A93

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide



$C_{28}H_{24}N_4O_5S$ Mw. 528.59


LC/MS purity: 100%, m/z 527 $[M-H]^-$, m/z 529 $[M-H]^+$
Rt. 2.81 min.

1H NMR (300 MHz, DMSO- d_6): 9.79 (bs, 1H), 8.97 (d, 2H), 8.75 (d, 1H), 8.66 (d, 1H), 8.40 (d, 1H), 7.83 (dd, 1H), 7.75 (t, 1H), 7.54 (t, 1H), 7.43 (s, 1H), 7.37 (s, 1H), 7.06 (s, 1H), 7.02 (m, 2H), 6.39 (d, 1H), 3.93 (s, 3H), 3.89 (s, 3H), 2.01 (s, 3H)

Melting point: 103-105° C. Yield: 65%

Example A94

Benzo[b]thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-amide



$C_{26}H_{22}N_2O_5S_2$ Mw. 506.60

LC/MS purity: 98%, m/z 505 $[M-H]^-$, m/z 507 $[M-H]^+$
Rt. 3.05 min.


1H NMR (300 MHz, DMSO- d_6): 10.11 (s, 1H), 8.49 (d, 1H), 8.10 (d, 1H), 8.02 (d, 1H), 7.81 (s, 1H), 7.52 (m, 2H), 7.45 (s, 1H), 7.39 (s, 1H), 7.19 (d, 1H), 7.11 (d, 1H), 7.06 (dd, 1H), 6.48 (d, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 2.07 (s, 3H)

Melting point: 255-257° C. Yield: 34%

72

Example A95

1-Methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-amide



$C_{27}H_{25}N_3O_6S$ Mw. 519.58


LC/MS purity: 100%, m/z 518 $[M-H]^-$, m/z 520 $[M-H]^+$
Rt. 2.36 min.

1H NMR (300 MHz, DMSO- d_6): 9.5 (bs, 1H), 8.61 (m, 3H), 7.44 (s, 1H), 7.38 (s, 1H), 7.02 (m, 4H), 6.45 (d, 1H), 3.91 (s, 3H), 3.87 (s, 3H), 3.64 (s, 2H), 3.14 (s, 3H), 2.50 (s, 3H)

Melting point: 115-116° C. Yield: 71%

Example A96

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-2-trifluoromethyl-benzenesulfonamide



$C_{24}H_{18}F_4N_2O_5S$ Mw. 522.48

LC/MS purity: 99%, m/z 521 $[M-H]^-$, m/z 523 $[M-H]^+$
Rt. 2.99 min.


1H NMR (300 MHz, DMSO- d_6): 11.03 (bs, 1H), 8.45 (d, 1H), 8.16 (d, 1H), 8.04 (d, 1H), 7.90 (m, 3H), 7.47 (s, 1H), 7.40 (s, 1H), 7.38 (t, 1H), 7.16 (d, 1H), 7.03 (d, 1H), 3.94 (s, 3H), 3.91 (s, 3H)

Melting point: 80-83° C. Yield: 51%

73

Example A97


Biphenyl-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide

 $C_{29}H_{23}FN_2O_5S$ Mw. 530.58LC/MS purity: 98%, m/z 529 [M-H]⁻, m/z 531 [M-H]⁺
Rt. 3.27 min.¹H NMR (300 MHz, DMSO-d₆): 10.5 (bs, 1H), 8.37 (d, 1H), 8.04 (s, 1H), 7.98 (d, 1H), 7.80 (d, 1H), 7.69 (m, 3H), 7.55-7.33 (m, 6H), 7.20 (dd, 1H), 7.06 (d, 1H), 6.28 (d, 1H), 3.97 (s, 3H), 3.90 (s, 3H)

Melting point: 109-111° C. Yield: 67%

Example A98

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-3-phenoxy-benzenesulfonamide


 $C_{29}H_{23}FN_2O_6S$ Mw. 546.58LC/MS purity: 99%, m/z 545 [M-H]⁻, m/z 547 [M-H]⁺
Rt. 3.28 min.¹H NMR (300 MHz, DMSO-d₆): 10.62 (bs, 1H), 8.45 (d, 1H), 7.62-7.52 (m, 8H), 7.24 (m, 2H), 7.14-7.00 (m, 4H), 6.36 (d, 1H), 3.95 (s, 3H), 3.93 (s, 3H)

Melting point: 197-199° C. Yield: 65%

74

Example A99


N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-2,5-difluoro-benzenesulfonamide

 $C_{23}H_{17}F_3N_2O_5S$ Mw. 490.46LC/MS purity: 99%, m/z 489 [M-H]⁻, m/z 491 [M-H]⁺
Rt. 2.87 min.¹H NMR (300 MHz, DMSO-d₆): 11.12 (bs, 1H), 8.45 (d, 1H), 7.73-7.55 (m, 3H), 7.48 (s, 1H), 7.41 (s, 1H), 7.39 (t, 1H), 7.19 (dd, 1H), 7.05 (d, 1H), 6.36 (d, 1H), 3.94 (s, 3H), 3.92 (s, 3H)

Melting point: 232-234° C. Yield: 51%

Example A100

Naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide


 $C_{27}H_{21}FN_2O_5S$ Mw. 504.54LC/MS purity: 100%, m/z 503 [M-H]⁻, m/z 505 [M-H]⁺
Rt. 3.04 min.¹H NMR (300 MHz, DMSO-d₆): 11.04 (bs, 1H), 8.73 (d, 1H), 8.41 (d, 1H), 8.28 (m, 2H), 8.12 (d, 1H), 7.71 (m, 3H), 7.42 (s, 1H), 7.37 (s, 1H), 7.26 (t, 1H), 7.08 (dd, 1H), 6.93 (d, 1H), 6.26 (d, 1H), 3.92 (s, 3H), 3.88 (s, 3H)

Melting point: 118-120° C. Yield: 61%

75

Example A101


N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide

C₂₇H₂₁FN₄O₅S Mw. 532.55LC/MS purity: 100%, m/z 531 [M-H]⁻, m/z 533 [M-H]⁺
Rt. 2.86 min.¹H NMR (300 MHz, DMSO-d₆): 10.75 (bs, 1H), 8.97 (d, 2H), 8.85 (s, 1H), 8.65 (d, 1H), 8.37 (d, 1H), 7.96 (d, 1H), 7.78 (t, 1H), 7.55 (t, 1H), 7.45 (s, 1H), 7.37 (s, 1H), 7.34 (d, 1H), 7.19 (dd, 1H), 7.02 (dd, 1H), 6.28 (d, 1H), 3.93 (s, 3H), 3.89 (s, 3H)

Melting point: 105-107° C. Yield: 39%

Example A102

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide


C₂₇H₂₁FN₄O₅S Mw. 532.55LC/MS purity: 100%, m/z 531 [M-H]⁻, m/z 533 [M-H]⁺
Rt. 2.79 min.¹H NMR (300 MHz, DMSO-d₆): 10.33 (bs, 1H), 8.97 (d, 2H), 8.79 (s, 1H), 8.65 (d, 1H), 8.43 (d, 1H), 7.88 (d, 1H), 7.75 (t, 1H), 7.54 (t, 1H), 7.37 (m, 3H), 7.21 (dd, 1H), 7.06 (d, 1H), 6.47 (d, 1H), 3.93 (s, 3H), 3.89 (s, 3H)

Melting point: 137-140° C. Yield: 42%

76

Example A103


N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-2-trifluoromethyl-benzenesulfonamide

C₂₄H₁₉F₃N₂O₅S Mw. 504.49LC/MS purity: 99%, m/z 503 [M-H]⁻, m/z 505 [M-H]⁺
Rt. 2.88 min.¹H NMR (300 MHz, DMSO-d₆): 10.71 (bs, 1H), 8.45 (d, 1H), 8.11 (dd, 1H), 8.02 (dd, 1H), 7.88 (m, 2H), 7.44 (s, 1H), 7.38 (s, 1H), 7.18 (dd, 4H), 6.37 (d, 1H), 3.93 (s, 3H), 3.81 (s, 3H)

Melting point: 224-227° C. Yield: 59%

Example A104

Naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide


C₂₇H₂₂N₂O₅S Mw. 486.55LC/MS purity: 100%, m/z 485 [M-H]⁻, m/z 487 [M-H]⁺
Rt. 2.96 min.¹H NMR (300 MHz, DMSO-d₆): 10.72 (bs, 1H), 8.75 (d, 1H), 8.41 (d, 1H), 8.22 (t, 2H), 8.09 (d, 1H), 7.71 (m, 3H), 7.39 (s, 1H), 7.35 (s, 1H), 7.09 (dd, 4H), 6.27 (d, 1H), 3.92 (s, 3H), 3.86 (s, 3H)

Melting point: 250-253° C. Yield: 61%

Example A105

3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-4-hydroxy-benzenesulfonamide

77



$C_{24}H_{20}Cl_2N_2O_6S$ Mw. 535.41

LC/MS purity: 93%, m/z 533 $[M-H]^-$, m/z 535 $[M-H]^+$
Rt. 2.69 min.

1H NMR (300 MHz, DMSO- d_6): 9.71 (s, 1H), 8.55 (d, 1H), 7.56 (s, 3H), 7.52 (s, 1H), 7.43 (s, 1H), 7.16 (s, 2H), 7.06 (m, 2H), 6.53 (d, 1H), 3.96 (s, 3H), 3.93 (s, 3H), 2.09 (s, 3H)

Melting point: 255-259° C. Yield: 25%


Example A106

3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-2-methoxy-benzenesulfonamide

78

Example A107

Biphenyl-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide



$C_{29}H_{23}FN_2O_5S$ Mw. 530.58


LC/MS purity: 98%, m/z 529 $[M-H]^-$, m/z 531 $[M-H]^+$
Rt. 3.28 min.

1H NMR (300 MHz, DMSO- d_6): 10.72 (bs, 1H), 8.43 (d, 1H), 7.90 (s, 3H), 7.74 (d, 2H), 7.53-7.44 (m, 7H), 7.20 (d, 1H), 7.06 (d, 1H), 6.36 (d, 1H), 3.93 (s, 3H), 3.90 (s, 3H)

Melting point: 167-171° C. Yield: 40%

Example A108

Benzo[b]thiophene-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide




$C_{24}H_{19}Cl_2FN_2O_6S$ Mw. 553.40

LC/MS purity: 98%, m/z 551 $[M-H]^-$, m/z 553 $[M-H]^+$
Rt. 3.31 min.

1H NMR (300 MHz, DMSO- d_6): 10.86 (bs, 1H), 8.46 (d, 1H), 8.06 (d, 1H), 7.81 (d, 1H), 7.48 (s, 1H), 7.38 (m, 2H), 7.17 (dd, 1H), 7.04 (d, 1H), 6.36 (d, 1H), 3.96 (s, 3H), 3.94 (s, 3H), 3.91 (s, 3H)

Melting point: 155-158° C. Yield: 59%



$C_{25}H_{19}FN_2O_5S_2$ Mw. 510.57

LC/MS purity: 99%, m/z 509 $[M-H]^-$, m/z 511 $[M-H]^+$
Rt. 3.03 min.


1H NMR (300 MHz, DMSO- d_6): 10.96 (bs, 1H), 8.72 (s, 1H), 8.43 (d, 1H), 8.23 (d, 1H), 8.14 (d, 1H), 7.55 (m, 2H), 7.45 (s, 1H), 7.38 (s, 1H), 7.31 (t, 1H), 7.16 (dd, 1H), 7.09 (d, 1H), 6.30 (d, 1H), 3.93 (s, 3H), 3.90 (s, 3H)

Melting point: 191-193° C. Yield: 63%

79

Example A109


N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-4-fluoro-3-methoxy-benzenesulfonamide

C₂₄H₂₀F₂N₂O₆S Mw. 502.50LC/MS purity: 97%, m/z 501 [M-H]⁻, m/z 503 [M-H]⁺
Rt. 2.92 min.¹H NMR (300 MHz, DMSO-d₆): 10.60 (bs, 1H), 8.46 (d, 1H), 7.54-7.34 (m, 6H), 7.19 (dd, 1H), 7.03 (d, 1H), 6.35 (d, 1H), 3.94 (s, 3H), 3.92 (s, 3H), 3.90 (s, 3H)

Melting point: 202-204° C. Yield: 61%

Example A110

4-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-2-fluoro-benzenesulfonamide


C₂₃H₁₇ClF₂N₂O₅S Mw. 506.92LC/MS purity: 96%, m/z 505 [M-H]⁻, m/z 507 [M-H]⁺
Rt. 3.01 min.¹H NMR (300 MHz, DMSO-d₆): 11.08 (bs, 1H), 8.45 (d, 1H), 7.92 (m, 2H), 7.77 (dd, 1H), 7.52 (dd, 1H), 7.48 (s, 1H), 7.19 (s, 1H), 7.18 (t, 1H), 7.16 (dd, 1H), 7.03 (dd, 1H), 6.36 (d, 1H), 3.94 (s, 3H), 3.92 (s, 3H)

Melting point: 99-101° C. Yield: 54%

80

Example A111


3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-2-methoxy-benzenesulfonamide

C₂₅H₂₂Cl₂N₂O₆S Mw. 549.43LC/MS purity: 97%, m/z 547 [M-H]⁻, m/z 549 [M-H]⁺
Rt. 3.27 min.¹H NMR (300 MHz, DMSO-d₆): 9.90 (bs, 1H), 8.48 (d, 1H), 8.05 (d, 1H), 7.56 (d, 1H), 7.44 (s, 1H), 7.39 (s, 1H), 7.07 (m, 3H), 6.45 (d, 1H), 3.94 (s, 6H), 3.90 (s, 3H), 2.07 (s, 3H), 2.08 (s, 3H)

Melting point: 159-162° C. Yield: 69%

Example A112

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-2-trifluoromethoxy-benzenesulfonamide


C₂₅H₂₁F₃N₂O₆S Mw. 534.52LC/MS purity: 98%, m/z 533 [M-H]⁻, m/z 535 [M-H]⁺
Rt. 2.91 min.¹H NMR (300 MHz, DMSO-d₆): 9.92 (bs, 1H), 8.48 (d, 1H), 7.86 (d, 1H), 7.79 (t, 1H), 7.69 (d, 1H), 7.53 (d, 1H), 7.44 (s, 1H), 7.39 (s, 1H), 7.09 (d, 1H), 7.07 (s, 1H), 7.01 (dd, 1H), 6.43 (d, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 2.01 (s, 3H), 2.10 (s, 3H)

Melting point: 230-232° C. Yield: 64%

81

Example A113

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-2-trifluoromethyl-benzenesulfonamide



$C_{25}H_{21}F_3N_2O_5S$ Mw. 518.52


LC/MS purity: 96%, m/z 517 [M-H]⁻, m/z 519 [M-H]⁺
Rt. 2.96 min.

¹H NMR (300 MHz, DMSO-d₆): 9.88 (bs, 1H), 8.48 (d, 1H), 8.02 (dd, 1H), 7.95 (dd, 1H), 7.86 (m, 2H), 7.44 (s, 1H), 7.39 (s, 1H), 7.05 (s, 1H), 6.44 (d, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 2.01 (s, 3H), 2.11 (s, 3H)

Melting point: 254-257° C. Yield: 32%

Example A114

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-2-trifluoromethoxy-benzenesulfonamide



$C_{24}H_{19}F_3N_2O_6S$ Mw. 520.49

LC/MS purity: 100%, m/z 519 [M-H]⁻, m/z 521 [M-H]⁺
Rt. 2.96 min.


¹H NMR (300 MHz, DMSO-d₆): 10.61 (bs, 1H), 8.45 (d, 1H), 7.98 (d, 1H), 7.79 (t, 1H), 7.56 (m, 2H), 7.44 (s, 1H), 7.38 (s, 1H), 7.18 (dd, 4H), 6.34 (d, 1H), 3.93 (s, 3H), 3.89 (s, 3H),

Melting point: 222-223° C. Yield: 63%

82

Example A115

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-3-phenoxy-benzenesulfonamide



$C_{29}H_{24}N_2O_6S$ Mw. 528.59


LC/MS purity: 100%, m/z 527 [M-H]⁻, m/z 529 [M-H]⁺
Rt. 3.15 min.

¹H NMR (300 MHz, DMSO-d₆): 10.32 (bs, 1H), 8.44 (d, 1H), 7.60 (t, 1H), 7.45 (m, 6H), 7.30 (d, 1H), 7.18 (m, 5H), 7.01 (d, 2H), 6.36 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 172-174° C. Yield: 57%

Example A116

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-4-fluoro-3-methoxy-benzenesulfonamide



$C_{24}H_{21}FN_2O_6S$ Mw. 484.51

LC/MS purity: 100%, m/z 483 [M-H]⁻, m/z 485 [M-H]⁺
Rt. 2.81 min.


¹H NMR (300 MHz, DMSO-d₆): 10.29 (bs, 1H), 8.45 (d, 1H), 7.38 (m, 5H), 7.19 (m, 4H), 6.36 (d, 1H), 3.93 (s, 3H), 3.89 (s, 3H), 3.87 (s, 3H)

Melting point: 222-224° C. Yield: 69%

83

Example A117


4-Bromo-3-chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-benzenesulfonamide

 $C_{23}H_{18}BrClN_2O_5S$ Mw. 549.83LC/MS purity: 99%, m/z 547 [M-H]⁻, m/z 549 [M-H]⁺
Rt. 3.11 min.¹H NMR (300 MHz, DMSO-d₆): 10.48 (bs, 1H), 8.46 (d, 1H), 8.02 (d, 1H), 7.88 (s, 1H), 7.59 (d, 1H), 7.45 (s, 1H), 7.38 (s, 1H), 7.20 (dd, 4H), 6.38 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 232-234° C. Yield: 73%

Example A118

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-2,5-difluoro-benzenesulfonamide


 $C_{23}H_{18}F_2N_2O_5S$ Mw. 472.47LC/MS purity: 99%, m/z 471 [M-H]⁻, m/z 473 [M-H]⁺
Rt. 2.77 min.¹H NMR (300 MHz, DMSO-d₆): 10.80 (bs, 1H), 8.45 (d, 1H), 7.65-7.50 (m, 3H), 7.44 (s, 1H), 7.38 (s, 1H), 7.21 (dd, 4H), 6.36 (d, 1H), 3.93 (s, 3H), 3.89 (s, 3H)

Melting point: 260-263° C. Yield: 39%

84

Example A119


N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-2-trifluoromethoxy-benzenesulfonamide

 $C_{25}H_{21}F_3N_2O_7S$ Mw. 550.51LC/MS purity: 100%, m/z 549 [M-H]⁻, m/z 551 [M-H]⁺
Rt. 2.96 min.¹H NMR (300 MHz, DMSO-d₆): 10.62 (bs, 1H), 8.39 (d, 1H), 8.03 (dd, 1H), 7.80 (td, 1H), 7.59 (m, 2H), 7.46 (s, 1H), 7.36 (s, 1H), 7.13 (d, 1H), 6.97 (d, 1H), 6.72 (dd, 1H), 6.14 (d, 1H), 3.93 (s, 3H), 3.91 (s, 3H), 3.61 (s, 3H)

Melting point: 211-212° C. Yield: 59%

Example A120

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-3-phenoxy-benzenesulfonamide


 $C_{30}H_{26}N_2O_7S$ Mw. 558.61LC/MS purity: 99%, m/z 557 [M-H]⁻, m/z 559 [M-H]⁺
Rt. 3.19 min.¹H NMR (300 MHz, DMSO-d₆): 10.35 (bs, 1H), 8.38 (d, 1H), 7.59 (t, 1H), 7.47 (dd, 1H), 7.45 (m, 3H), 7.37 (s, 1H), 7.32 (d, 1H), 7.24 (m, 2H), 7.16 (d, 1H), 7.01 (d, 2H), 6.93 (d, 1H), 6.70 (dd, 1H), 6.16 (d, 1H), 3.94 (s, 3H), 3.92 (s, 3H), 3.61 (s, 3H)

Melting point: 106-107° C. Yield: 55%

85

Example A121


N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-4-fluoro-3-methoxy-benzenesulfonamide

 $C_{25}H_{23}FN_2O_7S$ Mw. 514.53LC/MS purity: 99%, m/z 513 [M-H]⁻, m/z 515 [M-H]⁺
Rt. 2.71 min.¹H NMR (300 MHz, DMSO-d₆): 10.3 (bs, 1H), 8.39 (d, 1H), 7.52 (dd, 1H), 7.45 (s, 1H), 7.39 (m, 2H), 7.36 (s, 1H), 7.14 (d, 1H), 6.97 (d, 1H), 6.15 (d, 1H), 3.93 (s, 3H), 3.91 (s, 3H), 3.89 (s, 3H), 3.64 (s, 3H)

Melting point: 109-110° C. Yield: 66%

Example A122

4-Bromo-3-chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-benzenesulfonamide


 $C_{24}H_{20}BrClN_2O_6S$ Mw. 579.86LC/MS purity: 99%, m/z 577 [M-H]⁻, m/z 579 [M-H]⁺
Rt. 3.12 min.¹H NMR (300 MHz, DMSO-d₆): 10.4 (bs, 1H), 8.40 (d, 1H), 8.30 (d, 1H), 7.92 (d, 1H), 7.63 (dd, 1H), 7.47 (s, 1H), 7.36 (s, 1H), 7.17 (d, 1H), 6.96 (d, 1H), 6.74 (d, 1H), 6.17 (d, 1H), 3.93 (s, 3H), 3.91 (s, 3H), 3.64 (s, 3H)

Melting point: 110-113° C. Yield: 75%

86

Example A123


N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-2-trifluoromethyl-benzenesulfonamide

 $C_{25}H_{21}F_3N_2O_6S$ Mw. 534.52LC/MS purity: 100%, m/z 533 [M-H]⁻, m/z 535 [M-H]⁺
Rt. 2.91 min.¹H NMR (300 MHz, DMSO-d₆): 10.74 (bs, 1H), 8.39 (d, 1H), 8.15 (d, 1H), 7.89 (m, 2H), 7.45 (s, 1H), 7.36 (s, 1H), 7.14 (d, 1H), 6.98 (d, 2H), 6.73 (dd, 1H), 6.16 (d, 1H), 3.93 (s, 3H), 3.90 (s, 3H), 3.62 (s, 3H)

Melting point: 198-199° C. Yield: 49%

Example A124

4-Bromo-3-chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-benzenesulfonamide


 $C_{23}H_{17}BrClFN_2O_5S$ Mw. 567.82LC/MS purity: 99%, m/z 565 [M-H]⁻, m/z 567 [M-H]⁺
Rt. 3.22 min.¹H NMR (300 MHz, DMSO-d₆): 11 (bs, 1H), 8.46 (d, 1H), 8.01 (d, 1H), 7.93 (s, 1H), 7.63 (dd, 1H), 7.48 (s, 1H), 7.36 (s, 1H), 7.34 (t, 1H), 7.15 (dd, 1H), 6.98 (d, 1H), 6.37 (d, 1H), 3.94 (s, 3H), 3.92 (s, 3H)

Melting point: 144-147° C. Yield: 43%

87

Example A125

1-Methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluorophenyl]-amide



$C_{26}H_{22}FN_3O_6S$ Mw. 523.54


LC/MS purity: 99%, m/z 533 [M-H]⁻, m/z 535 [M-H]⁺
Rt. 2.60 min.

¹H NMR (300 MHz, DMSO-d₆): 10.7 (bs, 1H), 8.45 (m, 1H), 7.76 (d, 1H), 7.67 (s, 1H), 7.46 (s, 1H), 7.39 (s, 1H), 7.33 (t, 1H), 7.15 (m, 2H), 7.00 (d, 1H), 6.36 (d, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 3.65 (s, 2H), 3.14 (s, 3H)

Melting point: 163-165° C. Yield: 59%

Example A126

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluorophenyl]-2-trifluoromethoxy-benzenesulfonamide



$C_{24}H_{18}F_4N_2O_6S$ Mw. 538.48

LC/MS purity: 100%, m/z 537 [M-H]⁻, m/z 539 [M-H]⁺
Rt. 3.05 min.


¹H NMR (300 MHz, DMSO-d₆): 10.93 (bs, 1H), 8.45 (d, 1H), 8.04 (dd, 1H), 7.79 (dt, 1H), 7.58 (m, 3H), 7.47 (s, 1H), 7.39 (s, 1H), 7.35 (t, 1H), 7.15 (dd, 1H), 6.98 (d, 1H), 3.94 (s, 3H), 3.92 (s, 3H)

Melting point: 203-204° C. Yield: 42%

88

Example A127

3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-2-methoxy-benzene-sulfonamide



$C_{25}H_{22}Cl_2N_2O_6S$ Mw. 549.43


LC/MS purity: 98%, m/z 547 [M-H]⁻, m/z 549 [M-H]⁺
Rt. 3.27 min.

¹H NMR (300 MHz, DMSO-d₆): 10.50 (bs, 1H), 8.41 (d, 1H), 7.74 (d, 1H), 7.51 (s, 1H), 7.44 (s, 1H), 7.38 (s, 1H), 7.07 (m, 3H), 6.17 (d, 1H), 3.96 (s, 3H), 3.94 (s, 3H), 3.91 (s, 3H), 2.03 (s, 3H)

Melting point: 206-208° C. Yield: 78%

Example A128

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-2-trifluoromethyl-benzenesulfonamide



$C_{25}H_{21}F_3N_2O_5S$ Mw. 518.52

LC/MS purity: 100%, m/z 517 [M-H]⁻, m/z 519 [M-H]⁺
Rt. 2.98 min.


¹H NMR (300 MHz, DMSO-d₆): 10.66 (bs, 1H), 8.42 (d, 1H), 8.12 (d, 1H), 8.02 (d, 1H), 7.88 (m, 2H), 7.50 (s, 1H), 7.38 (s, 1H), 7.08 (m, 3H), 6.18 (d, 1H), 3.93 (s, 3H), 3.91 (s, 3H), 2.03 (s, 3H)

Melting point: 209-211° C. Yield: 59%

89

Example A129

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-2-trifluoromethoxy-benzenesulfonamide



$C_{25}H_{21}F_3N_2O_6S$ Mw. 534.52


LC/MS purity: 100%, m/z 533 [M-H]⁻, m/z 535 [M-H]⁺
Rt. 3.04 min.

¹H NMR (300 MHz, DMSO-d₆): 10.55 (s, 1H), 8.41 (d, 1H), 7.99 (d, 1H), 7.79 (t, 1H), 7.55 (m, 2H), 7.51 (s, 1H), 7.38 (s, 1H), 7.12 (d, 1H), 7.08 (d, 1H), 7.01 (d, 1H), 6.15 (d, 1H), 3.94 (s, 3H), 3.92 (s, 3H), 2.02 (s, 3H)

Melting point: 207-209° C. Yield: 71%

Example A130

4-Methoxy-naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-amide



$C_{29}H_{26}N_2O_6S$ Mw. 530.60

LC/MS purity: 96%, m/z 529 [M-H]⁻, m/z 531 [M-H]⁺
Rt. 2.97 min.


¹H NMR (300 MHz, DMSO-d₆): 10.54 (s, 1H), 8.70 (d, 1H), 8.37 (d, 1H), 8.25 (d, 1H), 8.22 (d, 1H), 7.58 (m, 2H), 7.45 (s, 1H), 7.36 (s, 1H), 6.99 (m, 4H), 6.09 (d, 1H), 4.05 (s, 3H), 3.92 (s, 3H), 3.88 (s, 3H), 1.95 (s, 3H)

Melting point: 233-235° C. Yield: 34%

90

Example A131

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-2,5-difluoro-benzenesulfonamide



$C_{24}H_{20}F_2N_2O_5S$ Mw. 486.50


LC/MS purity: 100%, m/z 485 [M-H]⁻, m/z 487 [M-H]⁺
Rt. 2.72 min.

¹H NMR (300 MHz, DMSO-d₆): 10.76 (s, 1H), 8.41 (d, 1H), 7.58 (m, 3H), 7.51 (s, 1H), 7.38 (s, 1H), 7.09 (m, 3H), 6.17 (d, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 2.04 (s, 3H)

Melting point: 239-240° C. Yield: 74%

Example A132

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide



$C_{28}H_{24}N_4O_5S$ Mw. 528.59

LC/MS purity: 99%, m/z 527 [M-H]⁻, m/z 529 [M-H]⁺
Rt. 2.85 min.


¹H NMR (300 MHz, DMSO-d₆): 11.38 (bs, 1H), 8.97 (d, 2H), 8.83 (s, 1H), 8.62 (d, 1H), 8.31 (d, 1H), 7.92 (d, 1H), 7.75 (t, 1H), 7.54 (t, 1H), 7.48 (s, 1H), 7.36 (s, 1H), 7.14 (s, 1H), 7.05 (dd, 2H), 6.10 (d, 1H), 3.93 (s, 3H), 3.90 (s, 3H), 2.00 (s, 3H)

Melting point: 188-190° C. Yield: 16%

91

Example A133


4-Methoxy-naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide

 $C_{28}H_{24}N_2O_6S$ Mw. 516.58LC/MS purity: 96%, m/z 515 [M-H]⁻, m/z 517 [M-H]⁺
Rt. 2.91 min.¹H NMR (300 MHz, DMSO-d₆): 10.60 (bs, 1H), 8.70 (d, 1H), 8.40 (d, 1H), 8.19 (d, 1H), 7.75 (t, 1H), 7.65 (t, 1H), 7.39 (s, 1H), 7.35 (s, 1H), 7.07 (m, 6H), 6.27 (d, 1H), 4.04 (s, 3H), 3.92 (s, 3H), 3.86 (s, 3H)

Melting point: 240-242° C. Yield: 14%

Example A134

4-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-2-fluoro-benzenesulfonamide


 $C_{23}H_{18}ClFN_2O_6S$ Mw. 488.93LC/MS purity: 100%, m/z 487 [M-H]⁻, m/z 489 [M-H]⁺
Rt. 2.92 min.¹H NMR (300 MHz, DMSO-d₆): 10.76 (bs, 1H), 8.45 (d, 1H), 7.83 (t, 1H), 7.75 (d, 1H), 7.49 (d, 1H), 7.44 (s, 1H), 7.38 (s, 1H), 7.18 (dd, 4H), 6.36 (d, 1H), 3.93 (s, 3H), 3.89 (s, 3H)

Melting point: 218-220° C. Yield: 69%

92

Example A135


4-Methoxy-naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide

 $C_{28}H_{23}FN_2O_6S$ Mw. 534.57LC/MS purity: 96%, m/z 533 [M-H]⁻, m/z 535 [M-H]⁺
Rt. 3.14 min.¹H NMR (300 MHz, DMSO-d₆): 10.91 (bs, 1H), 8.69 (d, 1H), 8.40 (d, 1H), 8.27 (m, 2H), 7.77 (t, 1H), 7.65 (t, 1H), 7.42 (s, 1H), 7.37 (s, 1H), 7.25 (m, 1H), 7.08 (m, 2H), 6.91 (dd, 1H), 6.27 (d, 1H), 4.07 (s, 3H), 3.98 (s, 3H), 3.89 (s, 3H)

Melting point: 145-147° C. Yield: 31%

Example A136

Biphenyl-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide


 $C_{29}H_{23}FN_2O_5S$ Mw. 530.58LC/MS purity: 99%, m/z 529 [M-H]⁻, m/z 531 [M-H]⁺
Rt. 3.20 min.¹H NMR (300 MHz, DMSO-d₆): 10.29 (bs, 1H), 8.49 (d, 1H), 7.89 (d, 2H), 7.82 (d, 2H), 7.74 (d, 2H), 7.44 (m, 6H), 7.23 (dd, 1H), 7.04 (d, 1H), 6.55 (d, 1H), 3.93 (s, 3H), 3.89 (s, 3H)

Melting point: 199-201° C. Yield: 38%

93

Example A137

1-Methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluorophenyl]-amide



$C_{26}H_{22}FN_3O_6S$ Mw. 523.54


LC/MS purity: 100%, m/z 522 [M-H]⁻, m/z 524 [M-H]⁺
Rt. 2.53 min.

¹H NMR (300 MHz, DMSO-d₆): 10 (bs, 1H), 8.49 (d, 1H), 7.65 (m, 2H), 7.42-7.28 (m, 4H), 7.20 (dd, 1H), 7.01 (dd, 1H), 6.53 (d, 1H), 3.94 (s, 3H), 3.89 (s, 3H), 3.63 (s, 2H), 3.14 (s, 3H)

Melting point: 195-197° C. Yield: 54%

Example A138

Biphenyl-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-amide



$C_{30}H_{26}N_2O_6S$ Mw. 542.62

LC/MS purity: 99%, m/z 541 [M-H]⁻, m/z 543 [M-H]⁺
Rt. 3.15 min.


¹H NMR (300 MHz, DMSO-d₆): 0.37 (bs, 1H), 8.29 (d, 1H), 8.03 (s, 1H), 7.97 (d, 1H), 7.79 (d, 1H), 7.68 (m, 3H), 7.49 (m, 4H), 7.35 (s, 1H), 7.14 (d, 1H), 6.98 (d, 1H), 6.78 (dd, 1H), 6.08 (d, 1H), 3.92 (s, 3H), 3.89 (s, 3H), 3.60 (s, 3H)

Melting point: 108-110° C. Yield: 47%

94

Example A139

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-2,5-difluoro-benzenesulfonamide



$C_{24}H_{20}F_2N_2O_6S$ Mw. 502.50


LC/MS purity: 99%, m/z 501 [M-H]⁻, m/z 503 [M-H]⁺
Rt. 2.82 min.

¹H NMR (300 MHz, DMSO-d₆): 10.85 (bs, 1H), 8.39 (d, 1H), 7.70-7.54 (m, 3H), 7.46 (s, 1H), 7.36 (s, 1H), 7.16 (d, 1H), 6.98 (d, 1H), 6.77 (dd, 1H), 6.14 (d, 1H), 3.93 (s, 3H), 3.91 (s, 3H), 3.64 (s, 3H)

Melting point: 222-224° C. Yield: 43%

Example A140

Naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-amide



$C_{28}H_{24}N_2O_6S$ Mw. 516.58

LC/MS purity: 98%, m/z 515 [M-H]⁻, m/z 517 [M-H]⁺
Rt. 2.98 min.


¹H NMR (300 MHz, DMSO-d₆): 10.75 (bs, 1H), 8.79 (d, 1H), 8.35 (d, 1H), 8.25 (m, 2H), 8.09 (d, 1H), 7.70 (m, 3H), 7.41 (s, 1H), 7.33 (s, 1H), 6.99 (d, 1H), 6.84 (s, 1H), 6.62 (d, 1H), 6.04 (d, 1H), 3.91 (s, 3H), 3.88 (s, 3H), 3.52 (s, 3H)

Melting point: 136-138° C. Yield: 34%

95

Example A 141


4-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-2-fluoro-benzenesulfonamide

 $C_{24}H_{20}ClFN_2O_6S$ Mw. 518.95LC/MS purity: 100%, m/z 517 [M-H]⁻, m/z 519 [M-H]⁺
Rt. 2.84 min.¹H NMR (300 MHz, DMSO-d₆): 10.80 (bs, 1H), 8.38 (d, 1H), 7.87 (t, 1H), 7.76 (dd, 1H), 7.51 (d, 1H), 7.46 (s, 3H), 7.36 (s, 1H), 7.16 (d, 1H), 6.97 (d, 1H), 6.75 (dd, 1H), 6.15 (d, 1H), 3.93 (s, 3H), 3.91 (s, 3H), 3.66 (s, 3H)

Melting point: 124-126° C. Yield: 43%

Example A142

Biphenyl-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-amide


 $C_{30}H_{26}N_2O_6S$ Mw. 542.62LC/MS purity: 98%, m/z 541 [M-H]⁻, m/z 543 [M-H]⁺
Rt. 3.18 min.¹H NMR (300 MHz, DMSO-d₆): 10.4 (bs, 1H), 8.35 (d, 1H), 7.89 (dd, 4H), 7.73 (d, 1H), 7.50 (m, 4H), 7.44 (s, 1H), 7.35 (s, 1H), 7.15 (d, 1H), 7.00 (d, 1H), 6.78 (dd, 1H), 6.16 (d, 1H), 3.95 (s, 3H), 3.92 (s, 3H), 3.66 (s, 3H)

Melting point: 128-131° C. Yield: 39%

96

Example A143


N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide

 $C_{28}H_{24}N_4O_6S$ Mw. 544.59LC/MS purity: 100%, m/z 543 [M-H]⁻, m/z 545 [M-H]⁺
Rt. 2.80 min.¹H NMR (300 MHz, DMSO-d₆): 10.48 (bs, 1H), 8.97 (d, 2H), 8.86 (s, 1H), 8.64 (d, 1H), 8.27 (d, 1H), 7.95 (d, 1H), 7.77 (t, 1H), 7.54 (t, 1H), 7.43 (d, 1H), 7.34 (s, 1H), 7.12 (d, 1H), 7.08 (d, 1H), 6.74 (dd, 1H), 6.07 (d, 1H), 3.92 (s, 3H), 3.89 (s, 3H), 3.63 (s, 3H)

Melting point: 135-137° C. Yield: 38%

Example A144

Benzo[b]thiophene-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-amide


 $C_{26}H_{22}N_2O_6S_2$ Mw. 522.60LC/MS purity: 100%, m/z 521 [M-H]⁻, m/z 523 [M-H]⁺
Rt. 2.95 min.¹H NMR (300 MHz, DMSO-d₆): 10.68 (s, 1H), 8.67 (s, 1H), 8.37 (d, 1H), 8.24 (d, 1H), 8.13 (d, 1H), 7.54 (m, 2H), 7.43 (s, 1H), 7.35 (s, 1H), 7.18 (d, 1H), 6.93 (d, 1H), 6.70 (dd, 1H), 6.08 (d, 1H), 3.92 (s, 3H), 3.89 (s, 3H), 3.58 (s, 3H)

Melting point: 144-146° C. Yield: 61%

97

Example A145

1-Methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-amide



$C_{27}H_{25}N_3O_7S$ Mw. 535.58


LC/MS purity: 100%, m/z 534 [M-H]⁻, m/z 536 [M-H]⁺
Rt. 2.43 min.

¹H NMR (300 MHz, DMSO-d₆): 10.5 (bs, 1H), 8.38 (d, 1H), 7.76 (d, 1H), 7.67 (s, 1H), 7.45 (s, 1H), 7.35 (s, 1H), 7.10 (t, 2H), 6.96 (d, 1H), 6.72 (d, 1H), 6.18 (d, 1H), 3.93 (s, 3H), 3.90 (s, 3H), 3.64 (s, 2H), 3.63 (s, 3H), 3.13 (s, 3H)

Melting point: 150-152° C. Yield: 18%

Example A146

4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-2-trifluoromethoxy-benzenesulfonamide



$C_{24}H_{17}BrN_4N_2O_6S$ Mw. 617.37

LC/MS purity: 99%, m/z 615 [M-H]⁻, m/z 617 [M-H]⁺
Rt. 3.30 min.


¹H NMR (300 MHz, DMSO-d₆): 11 (bs, 1H), 8.46 (d, 1H), 7.96 (d, 1H), 7.84 (d, 1H), 7.82 (s, 1H), 7.48 (s, 1H), 7.39 (s, 1H), 7.35 (d, 1H), 7.16 (dd, 1H), 6.99 (d, 1H), 6.35 (d, 1H), 3.94 (s, 3H), 3.92 (s, 3H)

Melting point: 226-228° C. Yield: 34%

98

Example A147

4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-trifluoromethoxy-benzenesulfonamide



$C_{24}H_{17}BrN_4N_2O_6S$ Mw. 617.37


LC/MS purity: 100%, m/z 615 [M-H]⁻, m/z 617 [M-H]⁺
Rt. 3.27 min.

¹H NMR (300 MHz, DMSO-d₆): 10.4 (bs, 1H), 8.51 (d, 1H), 7.80 (m, 3H), 7.41 (s, 1H), 7.40 (s, 1H), 7.34 (t, 1H), 7.24 (dd, 1H), 7.04 (d, 1H), 6.53 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H)

Melting point: 227-229° C. Yield: 36%

Example A148

4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-2-trifluoromethoxy-benzenesulfonamide



$C_{25}H_{20}BrF_3N_4N_2O_7S$ Mw. 629.41

LC/MS purity: 99%, m/z 627 [M-H]⁻, m/z 629 [M-H]⁺
Rt. 3.21 min.


¹H NMR (300 MHz, DMSO-d₆): 10.8 (bs, 1H), 8.39 (d, 1H), 7.94 (d, 1H), 7.83 (d, 1H), 7.81 (s, 1H), 7.47 (s, 1H), 7.36 (s, 1H), 7.13 (d, 1H), 6.95 (d, 1H), 6.70 (d, 1H), 6.15 (d, 1H), 3.93 (s, 3H), 3.91 (s, 3H), 3.63 (s, 3H)

Melting point: 176-177° C. Yield: 31%

99

Example A149


4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-2-trifluoromethoxy-benzenesulfonamide

 $C_{24}H_{18}BrF_3N_2O_6S$ Mw. 599.38LC/MS purity: 99%, m/z 597 [M-H]⁻, m/z 599 [M-H]⁺
Rt. 3.20 min.¹H NMR (300 MHz, DMSO-d₆): 10.8 (bs, 1H), 8.45 (d, 1H), 7.89 (d, 1H), 7.82 (d, 1H), 7.80 (s, 1H), 7.45 (s, 1H), 7.38 (s, 1H), 7.17 (dd, 4H), 6.35 (d, 1H), 3.93 (s, 3H), 3.90 (s, 3H)

Melting point: 237-239° C. Yield: 30%

Example A150

4-Methoxy-naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-amide


 $C_{29}H_{26}N_2O_6S$ Mw. 530.60LC/MS purity: 99%, m/z 529 [M-H]⁻, m/z 531 [M-H]⁺
Rt. 3.10 min.¹H NMR (300 MHz, DMSO-d₆): 10 (bs, 1H), 8.71 (d, 1H), 8.46 (d, 1H), 8.28 (d, 1H), 8.01 (d, 1H), 7.67 (m, 2H), 7.41 (s, 1H), 7.37 (s, 1H), 7.05 (d, 2H), 6.92 (s, 1H), 6.91 (d, 1H), 6.36 (d, 1H), 4.07 (s, 3H), 3.93 (s, 3H), 3.88 (s, 3H), 2.09 (s, 3H)

Melting point: 216-217° C. Yield: 34%

100

Example A151


N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-2,5-difluoro-benzenesulfonamide

 $C_{24}H_{20}F_2N_2O_5S$ Mw. 486.50LC/MS purity: 98%, m/z 485 [M-H]⁻, m/z 487 [M-H]⁺
Rt. 2.82 min.¹H NMR (300 MHz, DMSO-d₆): 10.19 (bs, 1H), 8.48 (d, 1H), 7.59 (m, 2H), 7.48 (m, 1H), 7.44 (s, 1H), 7.39 (s, 1H), 7.04 (m, 3H), 6.46 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 2.13 (s, 3H)

Melting point: 259-260° C. Yield: 37%

Example A152

4-Bromo-3-chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-benzenesulfonamide


 $C_{24}H_{20}BrClN_2O_5S$ Mw. 563.86LC/MS purity: 100%, m/z 561 [M-H]⁻, m/z 563 [M-H]⁺
Rt. 3.17 min.¹H NMR (300 MHz, DMSO-d₆): 9.91 (bs, 1H), 8.48 (d, 1H), 8.03 (d, 1H), 7.79 (d, 1H), 7.54 (dd, 1H), 7.45 (s, 1H), 7.39 (s, 1H), 7.12 (s, 1H), 7.03 (dd, 2H), 6.47 (d, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 2.06 (s, 3H)

Melting point: 212-213° C. Yield: 58%

101

Example A153

4-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-2-fluoro-benzenesulfonamide



$C_{24}H_{20}ClFN_2O_5S$ Mw. 502.95


LC/MS purity: 99%, m/z 501 [M-H]⁻, m/z 503 [M-H]⁺
Rt. 2.98 min.

¹H NMR (300 MHz, DMSO-d₆): 10.13 (bs, 1H), 8.48 (d, 1H), 7.73 (m, 2H), 7.46 (d, 1H), 7.44 (s, 1H), 7.39 (s, 1H), 7.03 (m, 2H), 7.01 (dd, 1H), 6.45 (d, 1H), 3.94 (s, 3H), 3.90 (s, 3H), 2.13 (s, 3H)

Melting point: 248-250° C. Yield: 43%

Example A154

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-4-fluoro-3-methoxy-benzenesulfonamide



$C_{25}H_{23}FN_2O_6S$ Mw. 498.53

LC/MS purity: 98%, m/z 497 [M-H]⁻, m/z 499 [M-H]⁺
Rt. 2.87 min.


¹H NMR (300 MHz, DMSO-d₆): 9.67 (bs, 1H), 8.47 (d, 1H), 7.40 (m, 4H), 7.28 (m, 1H), 7.10 (s, 1H), 7.03 (dd, 2H), 6.46 (d, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 3.85 (s, 3H), 2.05 (s, 3H)

Melting point: 228-229° C. Yield: 38%

102

Example A155

3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-4-hydroxy-benzenesulfonamide




$C_{23}H_{18}Cl_2N_2O_6S$ Mw. 521.38

LC/MS purity: 92%, m/z 519 [M-H]⁻, m/z 521 [M-H]⁺
Rt. 2.79 min.

¹H NMR (300 MHz, DMSO-d₆): 9.7 (bs, 1H), 8.42 (d, 1H), 7.49 (s, 1H), 7.37 (s, 1H), 7.27 (s, 2H), 7.10 (m, 4H), 6.35 (d, 1H), 3.94 (s, 3H), 3.91 (s, 3H) Melting point: >260° C. Yield: 45%

Example A156

3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-2-hydroxy-benzenesulfonamide



$C_{24}H_{20}Cl_2N_2O_7S$ Mw. 551.41

LC/MS purity: 99%, m/z 549 [M-H]⁻, m/z 551 [M-H]⁺
Rt. 3.00 min.


¹H NMR (300 MHz, DMSO-d₆): 9.6 (bs, 1H), 8.38 (d, 1H), 7.49 (s, 1H), 7.47 (s, 1H), 7.09 (d, 1H), 6.94 (d, 1H), 6.75 (d, 1H), 3.93 (s, 3H), 3.90 (s, 3H), 3.59 (s, 3H)

Melting point: >240° C. Yield: 26%

103

Example B1

Thiophene-2-sulfonic acid [2-fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide



$C_{20}H_{14}F_2N_2O_3S_2$ Mw. 432.47


LC/MS purity: 96%, m/z 431 [M-H]⁻ Rt. 3.00 min.

¹H NMR (300 MHz, DMSO-d₆): 10.37 (s, 1H), 7.97 (m, 2H), 7.83 (d, 1H), 7.68 (m, 1H), 7.53 (dd, 1H), 7.31 (m, 2H), 7.19 (m, 1H), 7.11 (d, 1H), 6.65 (s, 1H), 2.54 (s, 3H)

Melting point: 166-167° C. Yield: 60%

Example B2

3-Cyano-N-[2-fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide



$C_{23}H_{15}F_2N_3O_3S$ Mw. 451.46

LC/MS purity: 97%, m/z 450 [M-H]⁻ Rt. 3.03 min.


¹H NMR (300 MHz, DMSO-d₆): 10.46 (s, 1H), 8.14 (m, 2H), 8.00 (m, 2H), 7.81 (m, 2H), 7.68 (m, 1H), 7.33 (t, 1H), 7.26 (dd, 1H), 7.08 (d, 1H), 6.65 (s, 1H), 2.54 (s, 3H)

Melting point: 190-191° C. Yield: 37%

104

Example B3

N-[2-Fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-3-methoxy-benzenesulfonamide



$C_{23}H_{18}F_2N_2O_4S$ Mw. 456.47


LC/MS purity: 98%, m/z 455 [M-H]⁻ Rt. 3.16 min.

¹H NMR (300 MHz, DMSO-d₆): 10.22 (s, 1H), 8.00 (m, 1H), 7.82 (m, 1H), 7.67 (m, 1H), 7.49 (t, 1H), 7.37-7.21 (m, 6H), 7.07 (d, 1H), 6.62 (s, 1H), 3.80 (s, 3H), 2.53 (s, 3H)

Melting point: 150-151° C. Yield: 58%

Example B4

Cyclopropanesulfonic acid [2-fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide



$C_{19}H_{16}F_2N_2O_3S$ Mw. 390.41

LC/MS purity: 96%, m/z 391 [M+H]⁺ Rt. 2.54 min.


¹H NMR (300 MHz, DMSO-d₆): 9.67 (s, 1H), 8.01 (m, 1H), 7.85 (m, 1H), 7.70 (m, 1H), 7.52 (t, 1H), 7.37 (dd, 1H), 7.13 (d, 1H), 6.71 (s, 1H), 2.69 (s, 1H), 2.55 (s, 3H), 0.95 (m, 4H)

Melting point: 189-190° C. Yield: 42%

105

Example B5

3-Chloro-4-fluoro-N-[2-fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide



$C_{22}H_{14}ClF_3N_2O_3S$ Mw. 478.88


LC/MS purity: 94%, m/z 477 [M-H]⁻ Rt. 3.45 min.

¹H NMR (300 MHz, DMSO-d₆): 10.38 (s, 1H), 8.00 (m, 1H), 7.91 (m, 1H), 7.84-7.66 (m, 4H), 7.31 (m, 2H), 7.11 (dd, 1H), 6.67 (s, 1H), 2.54 (s, 3H)

Melting point: 205-207° C. Yield: 62%

Example B6

2,6-Difluoro-N-[2-fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide



$C_{22}H_{14}F_4N_2O_3S$ Mw. 462.43

LC/MS purity: 98%, m/z 461 [M-H]⁻ Rt. 3.06 min.


¹H NMR (300 MHz, DMSO-d₆): 10.81 (s, 1H), 8.00 (m, 1H), 7.82 (dd, 1H), 7.68 (m, 2H), 7.38 (t, 1H), 7.27 (m, 3H), 7.08 (d, 1H), 6.62 (s, 1H), 2.54 (s, 3H)

Melting point: 188-190° C. Yield: 53%

106

Example B7

5-Methyl-thiophene-2-sulfonic acid [2-fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide



$C_{21}H_{16}F_2N_2O_3S_2$ Mw. 446.50


LC/MS purity: 97%, m/z 445 [M-H]⁻ Rt. 3.18 min.

¹H NMR (300 MHz, DMSO-d₆): 10.30 (s, 1H), 8.00 (dd, 1H), 7.83 (dd, 1H), 7.69 (m, 1H), 7.32 (m, 3H), 7.10 (d, 1H), 6.87 (dd, 1H), 6.64 (s, 1H), 2.54 (s, 3H)

Melting point: 151-153° C. Yield: 62%

Example B8

N-[2-Fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-3-trifluoromethyl-benzenesulfonamide



$C_{23}H_{15}F_5N_2O_3S$ Mw. 494.44

LC/MS purity: 95%, m/z 493 [M-H]⁻ Rt. 3.51 min.


¹H NMR (300 MHz, DMSO-d₆): 10.45 (s, 1H), 8.00 (m, 4H), 7.83 (m, 2H), 7.68 (m, 1H), 7.34 (t, 1H), 7.26 (d, 1H), 7.09 (d, 1H), 6.63 (s, 1H), 2.53 (s, 3H)

Melting point: 150-152° C. Yield: 47%

107

Example B9

N-[4-(6-Fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide



$C_{22}H_{17}FN_2O_3S$ Mw. 408.45


LC/MS purity: 95%, m/z 407 [M-H]⁻ Rt. 2.90 min.

¹H NMR (300 MHz, DMSO-d₆): 10.37 (s, 1H), 7.97 (m, 1H), 7.81 (m, 3H), 7.70-7.55 (m, 4H), 7.19 (dd, 4H), 6.40 (s, 1H), 2.54 (s, 3H)

Melting point: 207-208° C. Yield: 65%

Example B10

3,5-Dichloro-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide



$C_{22}H_{15}Cl_2FN_2O_3S$ Mw. 477.34

LC/MS purity: 97%, m/z 475 [M-H]⁻ Rt. 3.52 min.


¹H NMR (300 MHz, DMSO-d₆): 10.52 (s, 1H), 7.98 (m, 2H), 7.85 (dd, 1H), 7.66 (m, 3H), 7.23 (dd, 4H), 6.45 (s, 1H), 2.54 (s, 3H)

Melting point: 238-240° C. Yield: 73%

108

Example B11

3,5-Dichloro-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-2-methoxy-benzenesulfonamide



$C_{23}H_{17}Cl_2FN_2O_4S$ Mw. 507.37


LC/MS purity: 96%, m/z 505 [M-H]⁻ Rt. 3.60 min.

¹H NMR (300 MHz, DMSO-d₆): 10.59 (s, 1H), 8.00 (m, 2H), 7.84 (dd, 1H), 7.73 (dd, 1H), 7.67 (m, 1H), 7.21 (dd, 4H), 6.42 (s, 1H), 3.96 (s, 3H), 2.54 (s, 3H)

Melting point: 192-193° C. Yield: 78%

Example B12

2,4-Difluoro-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide



$C_{22}H_{15}F_3N_2O_3S$ Mw. 444.44

LC/MS purity: 95%, m/z 443 [M-H]⁻ Rt. 3.02 min.


¹H NMR (300 MHz, DMSO-d₆): 10.75 (s, 1H), 8.00-7.81 (m, 3H), 7.69 (m, 1H), 7.55 (m, 1H), 7.31-7.17 (m, 5H), 6.40 (s, 1H), 2.54 (s, 3H)

Melting point: 179-180° C. Yield: 62%

109

Example B13

3,5-Difluoro-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamid



$C_{22}H_{15}F_3N_2O_3S$ Mw. 444.44


LC/MS purity: 95%, m/z 443 [M-H]⁻ Rt. 3.17 min.

¹H NMR (300 MHz, DMSO-d₆): 10.54 (s, 1H), 7.99 (m, 1H), 7.85 (m, 1H), 7.67 (m, 2H), 7.44 (m, 2H), 7.23 (dd, 4H), 6.43 (s, 1H), 2.54 (s, 3H)

Melting point: 194-195° C. Yield: 54%

Example B14

3-Bromo-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamid



$C_{22}H_{16}BrFN_2O_3S$ Mw. 487.35

LC/MS purity: 96%, m/z 485 [M-H]⁻ Rt. 3.25 min.


¹H NMR (300 MHz, DMSO-d₆): 10.45 (s, 1H), 7.98 (dd, 1H), 7.85 (m, 3H), 7.76 (d, 1H), 7.67 (m, 1H), 7.55 (t, 1H), 7.21 (dd, 4H), 6.43 (s, 1H), 2.54 (s, 3H)

Melting point: 183-184° C. Yield: 73%

110

Example B15

4-Bromo-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-2-trifluoromethyl-benzenesulfonamide



$C_{23}H_{15}BrF_4N_2O_3S$ Mw. 555.35


LC/MS purity: 96%, m/z 553 [M-H]⁻ Rt. 3.52 min.

¹H NMR (300 MHz, DMSO-d₆): 10.32 (s, 1H), 8.18 (dd, 1H), 8.00 (m, 1H), 7.85 (m, 2H), 7.70 (m, 5H), 6.44 (s, 1H), 2.54 (s, 3H)

Melting point: 191-193° C. Yield: 63%

Example B16

Thiophene-3-sulfonic acid [4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide



$C_{20}H_{15}FN_2O_3S_2$ Mw. 414.48

LC/MS purity: 97%, m/z 413 [M-H]⁻ Rt. 2.81 min.


¹H NMR (300 MHz, DMSO-d₆): 10.31 (s, 1H), 8.18 (dd, 1H), 7.99 (dd, 1H), 7.85 (dd, 1H), 7.73 (m, 1H), 7.67 (m, 1H), 7.30-7.18 (m, 5H), 6.44 (s, 1H), 2.54 (s, 3H)

Melting point: 195-196° C. Yield: 66%

111

Example B17

3-[4-(6-Fluoro-2-methyl-quinolin-4-yloxy)-phenyl-sulfamoyl]-thiophene-2-carboxylic acid methyl ester



$C_{22}H_{17}FN_2O_5S_2$ Mw. 472.52


LC/MS purity: 96%, m/z 471 [M-H]⁻ Rt. 3.02 min.

¹H NMR (300 MHz, DMSO-d₆): 10.20 (s, 1H), 7.99 (m, 2H), 7.84 (dd, 1H), 7.67 (m, 1H), 7.47 (d, 1H), 7.23 (d, 2H), 7.19 (d, 2H), 6.43 (s, 1H), 3.90 (s, 3H), 2.54 (s, 3H)

Melting point: 160-161° C. Yield: 72%

Example B18

5-Chloro-thiophene-2-sulfonic acid [4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide



$C_{20}H_{14}ClFN_2O_3S_2$ Mw. 448.93

LC/MS purity: 97%, m/z 447 [M-H]⁻ Rt. 3.23 min.


¹H NMR (300 MHz, DMSO-d₆): 10.64 (s, 1H), 7.99 (m, 1H), 7.85 (m, 1H), 7.67 (m, 1H), 7.46 (dd, 1H), 7.25 (m, 5H), 6.47 (s, 1H), 2.54 (s, 3H)

Melting point: 170-172° C. Yield: 44%

112

Example B19

5-Oxazol-5-yl-thiophene-2-sulfonic acid [4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide



$C_{23}H_{16}FN_3O_4S_2$ Mw. 481.53


LC/MS purity: 95%, m/z 480 [M-H]⁻ Rt. 3.07 min.

¹H NMR (300 MHz, DMSO-d₆): 10.73 (s, 1H), 8.72 (d, 1H), 7.98 (dd, 1H), 7.85 (dd, 1H), 7.73-7.64 (m, 3H), 7.27 (m, 4H), 7.10 (d, 1H), 6.45 (s, 1H), 2.54 (s, 3H)

Melting point: 164-166° C. Yield: 35%

Example B20

Naphthalene-1-sulfonic acid [4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide



$C_{26}H_{19}FN_2O_3S$ Mw. 458.52

LC/MS purity: 95%, m/z 457 [M-H]⁻ Rt. 3.25 min.


¹H NMR (300 MHz, DMSO-d₆): 10.8 (bs, 1H), 8.78 (d, 1H), 8.22 (d, 2H), 8.08 (d, 1H), 7.95 (dd, 1H), 7.81-7.60 (m, 5H), 7.12 (d, 2H), 7.05 (d, 2H), 6.33 (s, 1H), 2.55 (s, 3H)

Melting point: 223-225° C. Yield: 75%

113

Example B21

1-Ethyl-1H-pyrazole-4-sulfonic acid [4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide



$C_{21}H_{19}FN_4O_3S$ Mw. 426.47


LC/MS purity: 95%, m/z 425 [M-H]⁻ Rt. 2.59 min.

¹H NMR (300 MHz, DMSO-d₆): 10.17 (s, 1H), 8.28 (s, 1H), 7.99 (dd, 1H), 7.86 (dd, 1H), 7.71 (s, 1H), 7.66 (dd, 1H), 7.25 (d, 4H), 6.47 (s, 1H), 4.16 (q, 2H), 2.48 (s, 3H), 1.33 (s, 3H)

Melting point: 165-167° C. Yield: 42%

Example B22

3,5-Dichloro-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-2-hydroxy-benzenesulfonamide



$C_{22}H_{15}Cl_2FN_2O_4S$ Mw. 493.34

LC/MS purity: 94%, m/z 493 [M+H]⁺ Rt. 3.24 min.


¹H NMR (300 MHz, DMSO-d₆): 10.6 (bs, 2H), 7.99 (dd, 1H), 7.86 (m, 2H), 7.66 (m, 2H), 7.25 (d, 2H), 7.19 (d, 2H), 6.44 (s, 1H), 2.52 (s, 3H)

Melting point: 203-205° C. Yield: 56%

114

Example C1

3,5-Dichloro-N-[2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide



$C_{23}H_{14}Cl_2F_4N_2O_3S$ Mw. 545.34


LC/MS purity: 95%, m/z 543 [M-H]⁻, m/z 545 [M-H]⁺ Rt. 5.39 min.

¹H NMR (300 MHz, DMSO-d₆): 10.52 (s, 1H), 8.47 (d, 1H), 8.19 (d, 1H), 8.01 (s, 1H), 7.70 (m, 3H), 7.37 (m, 2H), 7.15 (dd, 1H), 6.76 (s, 1H), 2.59 (s, 3H)

Melting point: 181-183° C. Yield: 44%

Example C2

Biphenyl-3-sulfonic acid [2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-amide



$C_{29}H_{20}F_4N_2O_3S$ Mw. 552.55

LC/MS purity: 98%, m/z 551 [M-H]⁻, m/z 553 [M-H]⁺ Rt. 5.34 min.


¹H NMR (300 MHz, DMSO-d₆): 10.30 (s, 1H), 8.45 (d, 1H), 8.18 (d, 1H), 8.02 (s, 1H), 7.97 (d, 1H), 7.69 (m, 5H), 7.54-7.29 (m, 5H), 7.14 (dd, 1H), 6.70 (s, 1H), 2.53 (s, 3H)

Melting point: 187-188° C. Yield: 57%

115

Example C3

N-[2-Fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-3-phenoxy-benzenesulfonamide



$C_{29}H_{20}F_4N_2O_4S$ Mw. 568.55


LC/MS purity: 94%, m/z 567 [M-H]⁻ Rt. 5.34 min.

¹H NMR (300 MHz, DMSO-d₆): 10.27 (s, 1H), 8.48 (d, 1H), 8.19 (d, 1H), 7.74-7.01 (m, 13H), 6.72 (s, 1H), 2.57 (s, 3H)

Melting point: 167-168° C. Yield: 63%

Example C4

Naphthalene-1-sulfonic acid [2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-amide



$C_{27}H_{18}F_4N_2O_3S$ Mw. 526.51

LC/MS purity: 95%, m/z 525 [M-H]⁻, m/z 527 [M-H]⁺ Rt. 5.15 min.


¹H NMR (300 MHz, DMSO-d₆): 10.53 (s, 1H), 8.72 (d, 1H), 8.43 (d, 1H), 8.26 (d, 1H), 8.14 (m, 3H), 7.67 (m, 4H), 7.31 (t, 1H), 7.19 (dd, 1H), 7.07 (dd, 1H), 6.94 (s, 1H), 2.57 (s, 3H)

Melting point: 232-234° C. Yield: 42%

116

Example C5

2,5-Dichloro-N-[2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide



$C_{23}H_{14}Cl_2F_4N_2O_3S$ Mw. 545.34


LC/MS purity: 95%, m/z 543 [M-H]⁻, m/z 545 [M-H]⁺ Rt. 5.24 min.

¹H NMR (300 MHz, DMSO-d₆): 10.67 (s, 1H), 8.47 (d, 1H), 8.19 (d, 1H), 7.88 (s, 1H), 7.76 (s, 2H), 7.69 (m, 1H), 7.35 (m, 2H), 7.14 (dd, 1H), 6.72 (s, 1H), 2.59 (s, 3H)

Melting point: 207-209° C. Yield: 73%

Example C6

2,6-Dichloro-N-[2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide



$C_{23}H_{14}Cl_2F_4N_2O_3S$ Mw. 545.34

LC/MS purity: 95%, m/z 543 [M-H]⁻, m/z 545 [M-H]⁺ Rt. 5.09 min.


¹H NMR (300 MHz, DMSO-d₆): 10.66 (s, 1H), 8.47 (d, 1H), 8.19 (d, 1H), 7.65 (m, 4H), 7.35 (m, 2H), 7.13 (dd, 1H), 6.68 (s, 1H), 2.57 (s, 3H)

Melting point: 171-173° C. Yield: 54%

117

Example C7

N-[2-Fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-2-trifluoromethyl-benzenesulfonamid



$C_{24}H_{15}F_7N_2O_3S$ Mw. 544.45


LC/MS purity: 95%, m/z 543 [M-H]⁻ Rt. 5.05 min.

¹H NMR (300 MHz, DMSO-d₆): 10.43 (s, 1H), 8.47 (d, 1H), 8.19 (d, 1H), 8.05 (m, 2H), 7.88 (m, 2H), 7.72 (t, 1H), 7.33 (m, 2H), 7.12 (dd, 1H), 6.69 (s, 1H), 2.58 (s, 3H)

Melting point: 183-185° C. Yield: 56%

Example C8

4-Methoxy-naphthalene-1-sulfonic acid [3-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-amide



$C_{28}H_{20}F_4N_2O_4S$ Mw. 556.54

LC/MS purity: 94%, m/z 555 [M-H]⁻, m/z 557 [M-H]⁺ Rt. 5.25 min.


¹H NMR (300 MHz, DMSO-d₆): 10.97 (s, 1H), 8.68 (d, 1H), 8.47 (d, 1H), 8.30 (d, 2H), 8.17 (d, 1H), 7.79 (t, 1H), 7.67 (m, 2H), 7.31 (t, 1H), 7.11 (m, 2H), 6.95 (d, 1H), 6.51 (s, 2H), 4.06 (s, 3H), 2.56 (s, 3H)

Melting point: 242-244° C. Yield: 74%

118

Example C9

3-Fluoro-N-[3-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-4-methoxy-benzenesulfonamide



$C_{24}H_{17}F_5N_2O_4S$ Mw. 524.47


LC/MS purity: 98%, m/z 523 [M-H]⁻ Rt. 4.96 min.

¹H NMR (300 MHz, DMSO-d₆): 10.63 (bs, 1H), 8.53 (d, 1H), 8.20 (d, 1H), 7.65 (m, 3H), 7.40 (m, 2H), 7.19 (dd, 1H), 7.05 (dd, 1H), 6.58 (s, 1H), 3.92 (s, 3H), 2.55 (s, 3H)

Melting point: 128-130° C. Yield: 70%

Example C10

N-[3-Fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-2-methoxy-4,5-dimethyl-benzenesulfonamide



$C_{26}H_{22}F_4N_2O_4S$ Mw. 534.53

LC/MS purity: 95%, m/z 533 [M-H]⁻, m/z 535 [M-H]⁺ Rt. 5.19 min.


¹H NMR (300 MHz, DMSO-d₆): 10.34 (s, 1H), 8.49 (d, 1H), 8.19 (d, 1H), 7.70 (t, 1H), 7.59 (s, 1H), 7.15 (dd, 1H), 7.03 (m, 2H), 6.54 (s, 1H), 3.86 (s, 3H), 2.58 (s, 3H), 2.26 (s, 3H), 2.19 (s, 3H)

Melting point: 230-232° C. Yield: 62%

119

Example C11

2,5-Difluoro-N-[2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide



$C_{23}H_{14}F_6N_2O_3S$ Mw. 512.43


LC/MS purity: 100%, m/z 511 [M-H]⁻ Rt. 4.92 min.

¹H NMR (300 MHz, DMSO-d₆): 10.70 (bs, 1H), 8.47 (d, 2H), 8.18 (d, 1H), 7.69 (t, 1H), 7.53 (m, 3H), 7.37 (t, 1H), 7.27 (d, 1H), 7.07 (d, 1H), 6.71 (s, 1H), 2.58 (s, 3H)

Melting point: 179-181° C. Yield: 52%

Example C12

3-Chloro-4-fluoro-N-[2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide



$C_{23}H_{14}ClF_5N_2O_3S$ Mw. 528.89

LC/MS purity: 98%, m/z 527 [M-H]⁻ Rt. 5.24 min.


¹H NMR (300 MHz, DMSO-d₆): 10.41 (bs, 1H), 8.47 (d, 1H), 8.19 (d, 1H), 7.91 (dd, 1H), 7.71 (m, 3H), 7.33 (m, 2H), 7.12 (d, 1H), 6.75 (s, 1H), 2.58 (s, 3H)

Melting point: 202-203° C. Yield: 57%

120

Example C13

2-Methyl-3H-imidazole-4-sulfonic acid [3-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-amide



$C_{21}H_{16}F_4N_4O_3S$ Mw. 480.44


LC/MS purity: 98%, m/z 479 [M-H]⁻ Rt. 4.07 min.

¹H NMR (300 MHz, DMSO-d₆): 12.5 (s, 1H), 10.6 (bs, 1H), 8.54 (d, 1H), 8.19 (d, 1H), 7.79 (s, 1H), 7.71 (t, 1H), 7.38 (t, 1H), 7.24 (d, 1H), 7.08 (d, 1H), 6.60 (s, 1H), 2.56 (s, 3H), 2.29 (s, 3H)

Melting point: 258-259° C. Yield: 57%

Example C14

4-(3,5-Dimethyl-isoxazol-4-ylmethoxy)-N-[3-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide



$C_{29}H_{23}F_4N_3O_5S$ Mw. 601.58

LC/MS purity: 95%, m/z 600 [M-H]⁻ Rt. 4.96 min.


¹H NMR (300 MHz, DMSO-d₆): 12.20 (bs, 1H), 8.52 (d, 1H), 8.19 (d, 1H), 7.80 (d, 2H), 7.71 (t, 1H), 7.40 (t, 1H), 7.18 (m, 3H), 7.04 (dd, 1H), 6.58 (s, 1H), 5.00 (s, 2H), 2.55 (s, 3H), 2.40 (s, 3H), 2.20 (s, 3H)

Melting point: 193-195° C. Yield: 35%

121

Example C15

Biphenyl-4-sulfonic acid [2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-amide




$C_{29}H_{20}F_4N_2O_3S$ Mw. 552.55

LC/MS purity: 96%, m/z 551 [M-H]⁻, m/z 553 [M-H]⁺
Rt. 5.34 min.

¹H NMR (300 MHz, DMSO-d₆): 10.32 (bs, 1H), 8.46 (d, 1H), 8.18 (d, 1H), 7.87 (dd, 4H), 7.72 (m, 3H), 7.53-7.36 (m, 4H), 7.29 (dd, 1H), 7.10 (d, 1H), 6.73 (s, 1H), 2.56 (s, 3H);
Melting point: 215-217° C.; Yield: 63%

Example C16

N-[2-Fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide



$C_{27}H_{18}F_4N_4O_3S$ Mw. 554.53

LC/MS purity: 97%, m/z 553 [M-H]⁻, m/z 555 [M-H]⁺
Rt. 4.92 min.


¹H NMR (300 MHz, DMSO-d₆): 10.39 (bs, 1H), 8.97 (s, 1H), 8.96 (s, 1H), 8.84 (t, 1H), 8.63 (d, 1H), 8.45 (d, 1H), 8.18 (d, 1H), 7.89 (d, 1H), 7.70 (m, 2H), 7.53 (t, 1H), 7.35 (t, 1H), 7.25 (dd, 1H), 7.07 (d, 1H), 6.68 (s, 1H), 2.58 (s, 3H);

Melting point: 219-220° C.; Yield: 54%

122

Example C17

Benzo[b]thiophene-2-sulfonic acid [2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)-phenyl]-amide



$C_{25}H_{16}F_4N_2O_3S_2$ Mw. 532.54


LC/MS purity: 96%, m/z 531 [M-H]⁻, m/z 533 [M-H]⁺
Rt. 5.16 min.

¹H NMR (300 MHz, DMSO-d₆): 10.65 (s, 1H), 8.47 (d, 1H), 8.19 (d, 1H), 8.10 (d, 1H), 8.03 (d, 1H), 7.95 (s, 1H), 7.69 (t, 1H), 7.50 (m, 3H), 7.33 (dd, 1H), 7.15 (d, 1H), 6.75 (s, 1H), 2.58 (s, 3H)

Melting point: 182-184° C.; Yield: 51%

Example C18

Benzo[b]thiophene-3-sulfonic acid [2-fluoro-4-(2-methyl-8-trifluoromethyl-quinolin-4-yloxy)phenyl]-amide



$C_{25}H_{16}F_4N_2O_3S_2$ Mw. 532.54

LC/MS purity: 96%, m/z 531 [M-H]⁻, m/z 533 [M-H]⁺
Rt. 5.11 min.


¹H NMR (300 MHz, DMSO-d₆): 10.46 (s, 1H), 8.49 (s, 1H), 8.45 (d, 1H), 8.14 (m, 3H), 7.69 (t, 1H), 7.52 (m, 2H), 7.37 (t, 1H), 7.23 (dd, 1H), 7.09 (d, 1H), 6.68 (s, 1H), 2.58 (s, 3H)

Melting point: 242-244° C.; Yield: 75%

123

Example C19

1-Methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid [2-fluoro-4-(2-methyl-8-trifluoro-methyl-quinolin-4-yloxy)-phenyl]-amide



$C_{26}H_{19}F_4N_3O_4S$ Mw. 545.52


LC/MS purity: 90%, m/z 544 [M-H]⁻, m/z 546 [M-H]⁺
Rt. 4.45 min.

¹H NMR (300 MHz, DMSO-d₆): 11.00 (bs, 1H), 8.47 (d, 1H), 8.18 (d, 1H), 7.69 (m, 2H), 7.63 (s, 1H), 7.34 (t, 1H), 7.25 (dd, 1H), 7.11 (d, 1H), 7.05 (d, 1H), 6.71 (s, 1H), 3.64 (s, 2H), 3.14 (s, 3H), 2.57 (s, 3H)

Melting point: 225-226° C.; Yield: 35%

Example D1

Biphenyl-3-sulfonic acid [4-(7-benzyloxy-6-methoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide



$C_{35}H_{27}FN_2O_5S$ Mw. 606.68

LC/MS purity: 100%, m/z 605 [M-H]⁻, m/z 607 [M-H]⁺
Rt. 3.71 min.


¹H NMR (300 MHz, DMSO-d₆): 10.2 (bs, 1H), 8.43 (d, 1H), 7.96 (d, 2H), 7.72 (m, 4H), 7.68-7.25 (m, 11H), 7.18 (d, 1H), 7.23 (dd, 1H), 6.48 (d, 1H), 5.30 (s, 2H), 3.89 (s, 3H)

Melting point: 228-229° C.; Yield: 72%

124

Example D2

Naphthalene-1-sulfonic acid {4-[7-(3-amino-propoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-amide hydrochloride




$C_{29}H_{26}FN_3O_5S.HCl$ Mw (base). 547.61

LC/MS purity: 100%, m/z 546 [M-H]⁻, m/z 548 [M-H]⁺
Rt. 2.41 min.

¹H NMR (300 MHz, DMSO-d₆): 11.28 (s, 1H), 8.72 (m, 2H), 8.30 (t, 2H), 8.12 (m, 3H), 7.77 (m, 5H), 7.38 (m, 1H), 7.16 (dd, 1H), 7.03 (d, 1H), 0.55 (s, 1H), 4.28 (t, 2H), 3.98 (s, 3H), 2.97 (t, 2H), 2.15 (t, 2H) Melting point: ° C. Yield: 85%

Example D3

Biphenyl-3-sulfonic acid {4-[7-(3-amino-propoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-amide hydrochloride



$C_{31}H_{28}FN_3O_5S.HCl$ Mw (base). 573.65

LC/MS purity: 100%, m/z 572 [M-H]⁻, m/z 574 [M-H]⁺
Rt. 2.58 min.


¹H NMR (300 MHz, DMSO-d₆): 10.96 (s, 1H), 8.72 (d, 1H), 8.05 (m, 5H), 7.83 (d, 1H), 7.69 (m, 5H), 7.50 (m, 4H), 7.31 (dd, 1H), 7.18 (dd, 1H), 6.81 (d, 1H), 4.33 (t, 2H), 4.00 (s, 3H), 3.00 (q, 2H), 2.18 (t, 2H)

Melting point: 198-202° C. Yield: 83%

125

Example D4

Biphenyl-3-sulfonic acid {3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-amide



$C_{34}H_{32}FN_3O_6S$ Mw. 629.71


LC/MS purity: 99%, m/z 628 [M-H]⁻, m/z 630 [M-H]⁺
Rt. 2.68 min.

¹H NMR (300 MHz, DMSO-d₆): 10.50 (bs, 1H), 8.37 (d, 1H), 8.03 (s, 1H), 7.96 (d, 1H), 7.79 (d, 1H), 7.66 (m, 3H), 7.48 (m, 5H), 7.34 (t, 1H), 7.02 (d, 1H), 6.28 (d, 1H), 4.26 (t, 2H), 3.90 (s, 3H), 3.39 (m, 4H), 2.78 (t, 2H), 2.60 (m, 4H)

Melting point: 103-104° C. Yield: 36%

Example D5

N-{3-Fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-2-trifluoromethyl-benzenesulfonamide



$C_{29}H_{27}F_4N_3O_6S$ Mw. 621.61

LC/MS purity: 100%, m/z 620 [M-H]⁻, m/z 622 [M-H]⁺
Rt. 2.26 min.


¹H NMR (300 MHz, DMSO-d₆): 11.00 (bs, 1H), 8.45 (d, 1H), 8.16 (d, 1H), 8.02 (d, 1H), 7.90 (m, 2H), 7.47 (s, 1H), 7.42 (s, 1H), 7.38 (t, 1H), 7.16 (t, 1H), 7.02 (d, 1H), 6.36 (d, 1H), 4.27 (t, 2H), 3.91 (s, 3H), 3.59 (t, 4H), 2.79 (t, 2H), 2.53 (m, 4H)

Melting point: 178-180° C. Yield: 43%

126

Example D6

N-{3-Fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-2-trifluoromethoxy-benzenesulfonamide



$C_{29}H_{27}F_4N_3O_7S$ Mw. 637.61


LC/MS purity: 100%, m/z 636 [M-H]⁻, m/z 638 [M-H]⁺
Rt. 2.45 min.

¹H NMR (300 MHz, DMSO-d₆): 11.00 (bs, 1H), 8.45 (d, 1H), 8.04 (dd, 1H), 7.79 (t, 1H), 7.59 (m, 2H), 7.47 (s, 1H), 7.42 (s, 1H), 7.36 (t, 1H), 7.16 (dd, 1H), 7.00 (d, 1H), 6.33 (d, 1H), 4.27 (t, 2H), 3.91 (s, 3H), 3.59 (t, 4H), 2.79 (t, 2H), 2.53 (m, 4H)

Melting point: 185-187° C. Yield: 34%

Example D7

Biphenyl-3-sulfonic acid {4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-2-methyl-phenyl}-amide



$C_{35}H_{35}N_3O_6S$ Mw. 625.75

LC/MS purity: 100%, m/z 624 [M-H]⁻, m/z 626 [M-H]⁺
Rt. 2.59 min.


¹H NMR (300 MHz, DMSO-d₆): 9.82 (s, 1H), 8.40 (s, 1H), 8.01 (s, 1H), 7.86 (s, 1H), 7.67 (m, 4H), 7.48 (m, 3H), 7.46 (s, 1H), 7.44 (s, 1H), 7.07 (m, 3H), 6.37 (d, 1H), 4.26 (t, 2H), 3.90 (s, 3H), 3.59 (t, 4H), 2.78 (t, 2H), 2.53 (m, 4H), 1.99 (s, 3H)

Melting point: 105-107° C. Yield: 66%

127

Example D8

N-{4-[6-Methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-2-methyl-phenyl}-2-trifluoromethoxy-benzenesulfonamide



$C_{30}H_{30}F_3N_3O_7S$ Mw. 633.65


LC/MS purity: 100%, m/z 632 [M-H]⁻, m/z 634 [M-H]⁺
Rt. 2.44 min.

¹H NMR (300 MHz, DMSO-d₆): 9.25 (bs, 1H), 8.47 (d, 1H), 7.86 (d, 1H), 7.76 (t, 1H), 7.53 (m, 2H), 7.44 (s, 1H), 7.42 (s, 1H), 7.09 (d, 1H), 7.07 (s, 1H), 6.98 (d, 1H), 6.42 (d, 1H), 4.26 (t, 2H), 3.90 (s, 3H), 3.59 (t, 4H), 2.79 (t, 2H), 2.54 (t, 4H), 2.07 (m, 3H)

Melting point: 186-188° C. Yield: 46%

Example D9

2,5-Difluoro-N-{4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-2-methyl-phenyl}-benzenesulfonamide



$C_{29}H_{29}F_2N_3O_6S$ Mw. 585.63

LC/MS purity: 100%, m/z 584 [M-H]⁻, m/z 586 [M-H]⁺
Rt. 2.09 min.


¹H NMR (300 MHz, DMSO-d₆): 10.18 (bs, 1H), 8.48 (d, 1H), 7.58 (m, 2H), 7.45 (m, 3H), 7.06 (m, 3H), 6.45 (d, 1H), 4.27 (t, 2H), 3.90 (s, 3H), 3.59 (t, 4H), 2.78 (t, 2H), 2.54 (t, 4H), 2.07 (m, 3H)

Melting point: 195-196° C. Yield: 41%

128

Example D10

2,5-Difluoro-N-{3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide



$C_{28}H_{26}F_3N_3O_6S$ Mw. 589.60


LC/MS purity: 100%, m/z 588 [M-H]⁻, m/z 590 [M-H]⁺
Rt. 2.31 min.

¹H NMR (300 MHz, DMSO-d₆): 10.6 (bs, 1H), 8.46 (s, 1H), 7.61 (m, 1H), 7.43 (m, 4H), 7.21 (t, 1H), 7.04 (d, 1H), 6.89 (d, 1H), 6.35 (d, 1H), 4.26 (t, 2H), 3.92 (s, 3H), 3.60 (t, 4H), 2.78 (t, 2H), 2.53 (m, 4H)

Melting point: 169-173° C. Yield: 26%

Example D11

N-{4-[6-Methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-2-methyl-phenyl}-2-trifluoromethyl-benzenesulfonamide



$C_{30}H_{30}F_3N_3O_6S$ Mw. 617.65

LC/MS purity: 100%, m/z 616 [M-H]⁻, m/z 618 [M-H]⁺
Rt. 2.41 min.


¹H NMR (300 MHz, DMSO-d₆): 9.89 (bs, 1H), 8.48 (d, 1H), 8.01 (m, 1H), 7.95 (m, 1H), 7.86 (m, 2H), 7.42 (d, 2H), 7.03 (m, 3H), 6.43 (d, 1H), 4.27 (t, 2H), 3.90 (s, 3H), 3.59 (t, 4H), 2.78 (t, 2H), 2.53 (m, 4H), 2.10 (s, 3H)

Melting point: 127-130° C. Yield: 31%

129

Example D12

4-Chloro-2-fluoro-N-{3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide



$C_{28}H_{26}ClF_2N_3O_6S$ Mw. 606.05


LC/MS purity: 100%, m/z 604 [M-H]⁻, m/z 606 [M-H]⁺
Rt. 2.42 min.

¹H NMR (300 MHz, DMSO-d₆): 11.2 (bs, 1H), 8.45 (d, 1H), 7.90 (t, 1H), 7.75 (d, 1H), 7.52-7.33 (m, 4H), 7.15 (d, 1H), 7.02 (d, 1H), 6.35 (d, 1H), 4.27 (t, 2H), 3.91 (s, 3H), 3.59 (t, 4H), 2.78 (t, 2H), 2.53 (m, 4H)

Melting point: 212-214° C. Yield: 42%

Example D13

4-Methoxy-naphthalene-1-sulfonic acid {3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-amide



$C_{33}H_{32}FN_3O_7S$ Mw. 633.70

LC/MS purity: 100%, m/z 632 [M-H]⁻, m/z 634 [M-H]⁺
Rt. 2.53 min.


¹H NMR (300 MHz, DMSO-d₆): 11 (bs, 1H), 8.70 (d, 1H), 8.40 (d, 1H), 8.27 (t, 3H), 7.76 (t, 1H), 7.65 (t, 1H), 7.42 (s, 1H), 7.40 (s, 1H), 7.23 (t, 1H), 7.11 (d, 1H), 7.04 (d, 1H), 6.90 (d, 1H), 6.27 (d, 1H), 4.25 (t, 2H), 4.06 (s, 3H), 3.58 (t, 4H), 2.77 (t, 2H), 2.54 (m, 4H)

Melting point: 189-190° C. Yield: 35%

130

Example D14

N-{4-[7-(3-Amino-propoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-2-trifluoromethyl-benzenesulfonamide hydrochloride



$C_{26}H_{23}F_4N_3O_5S.HCl$ Mw (base). 565.55


LC/MS purity: 100%, m/z 564 [M-H]⁻, m/z 566 [M-H]⁺
Rt. 2.39 min.

¹H NMR (300 MHz, DMSO-d₆): 11.28 (s, 1H), 8.75 (d, 1H), 8.20 (d, 1H), 8.04 (m, 4H), 7.90 (m, 2H), 7.70 (s, 1H), 7.68 (s, 1H), 7.51 (t, 1H), 7.25 (dd, 1H), 7.12 (d, 1H), 6.82 (d, 1H), 4.32 (t, 2H), 4.00 (s, 3H), 3.00 (m, 2H), 2.17 (t, 2H)

Melting point: 197-199° C. Yield: 86%

Example D15

N-{4-[7-(3-Amino-propoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-2-trifluoromethoxy-benzenesulfonamide hydrochloride



$C_{26}H_{23}F_4N_3O_6S$ Mw. 581.55

LC/MS purity: 100%, m/z 580 [M-H]⁻, m/z 582 [M-H]⁺
Rt. 2.44 min.


¹H NMR (300 MHz, DMSO-d₆): 11.16 (s, 1H), 8.76 (d, 1H), 8.07 (m, 6H), 7.82 (t, 1H), 7.69 (s, 2H), 7.50 (t, 1H), 7.23 (dd, 1H), 7.07 (d, 1H), 6.80 (d, 1H), 4.32 (t, 2H), 4.00 (s, 3H), 2.96 (m, 2H), 2.17 (t, 2H)

Melting point: 95-97° C. Yield: 90%

131

Example D16

(3-{4-[2-Fluoro-4-(2-trifluoromethoxy-benzene-sulfonylamino)-phenoxy]-6-methoxy-quinolin-7-yloxy}-propyl)-carbamic acid tert-butyl ester



$C_{31}H_{31}F_4N_3O_8S$ Mw. 681.67


LC/MS purity: 100%, m/z 680 [M-H]⁻, m/z 682 [M-H]⁺
Rt. 3.48 min.

¹H NMR (300 MHz, DMSO-d₆): 10.94 (bs, 1H), 8.43 (d, 1H), 8.03 (d, 1H), 7.80 (t, 1H), 7.58 (m, 2H), 7.46 (s, 1H), 7.36 (dd, 2H), 7.14 (dd, 1H), 6.99 (d, 1H), 6.90 (t, 1H), 6.31 (d, 1H), 4.14 (t, 2H), 3.91 (s, 3H), 3.12 (m, 2H), 1.91 (t, 2H), 1.03 (s, 9H)

Melting point: 181-183° C. Yield: 76%

Example D17

N-(3-Fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-2-trifluoromethyl-benzenesulfonamide



$C_{32}H_{33}F_4N_3O_5S$ Mw. 647.69

LC/MS purity: 98%, m/z 646 [M-H]⁻, m/z 648 [M-H]⁺
Rt. 2.78 min.


¹H NMR (300 MHz, DMSO-d₆): 12 (bs, 1H), 8.40 (d, 1H), 8.08 (d, 1H), 7.76 (d, 1H), 7.64 (t, 1H), 7.55 (t, 1H), 7.46 (s, 1H), 7.33 (s, 1H), 6.96 (t, 1H), 6.75 (d, 1H), 6.63 (d, 1H), 6.32 (d, 1H), 4.15 (t, 2H), 3.90 (s, 3H), 2.84 (m, 2H), 2.55 (m, 2H), 2.42 (m, 1H), 1.92 (m, 2H), 1.56 (m, 2H), 1.29 (m, 2H), 1.14 (m, 2H), 0.87 (d, 3H)

Melting point: 110-112° C. Yield: 45%

132

Example D18

2-Bromo-N-(3-fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide



$C_{31}H_{33}BrFN_3O_5S$ Mw. 658.59

LC/MS purity: 99%, m/z 656 [M-H]⁻, m/z 658 [M-H]⁺
Rt. 2.76 min.


¹H NMR (300 MHz, DMSO-d₆): 11.5 (bs, 1H), 8.39 (d, 1H), 7.97 (d, 1H), 7.58 (d, 1H), 7.46 (s, 1H), 7.35 (m, 2H), 7.23 (t, 1H), 6.91 (t, 1H), 6.73 (d, 1H), 6.61 (d, 1H), 6.33 (d, 1H), 4.15 (t, 2H), 3.90 (s, 3H), 2.82 (m, 2H), 2.40 (m, 1H), 1.90 (m, 4H), 1.55 (m, 2H), 1.30 (m, 2H), 1.10 (m, 2H), 0.87 (d, 3H)

Melting point: 184-186° C. Yield: 52%

Example D19

2,4-Difluoro-N-(3-fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide

133



$C_{31}H_{32}F_3N_3O_5S$ Mw. 615.68


LC/MS purity: 100%, m/z 614 [M-H]⁻, m/z 616 [M-H]⁺
Rt. 2.73 min.

¹H NMR (300 MHz, DMSO-d₆): 10.5 (bs, 1H), 8.42 (d, 1H), 7.87 (d, 1H), 7.47 (s, 1H), 7.35 (bs, 2H), 7.15 (bs, 2H), 6.96 (d, 1H), 6.80 (bs, 1H), 6.33 (d, 1H), 4.16 (t, 2H), 3.90 (s, 3H), 2.91 (m, 2H), 2.53 (m, 1H), 1.98 (m, 4H), 1.59 (m, 2H), 1.34 (m, 2H), 1.17 (m, 2H), 0.87 (d, 3H)

Melting point: 135-137° C. Yield: 46%

Example D20

2,6-Difluoro-N-(3-fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide



$C_{31}H_{32}F_3N_3O_5S$ Mw. 615.68

LC/MS purity: 94%, m/z 614 [M-H]⁻, m/z 616 [M-H]⁺
Rt. 2.67 min.


¹H NMR (300 MHz, DMSO-d₆): 10.5 (bs, 1H), 7.47 (bs, 2H), 7.35 (s, 1H), 7.08 (m, 3H), 6.94 (d, 1H), 6.76 (d, 1H), 6.33 (d, 1H), 4.16 (t, 2H), 3.90 (s, 3H), 2.92 (m, 2H), 2.54 (m, 1H), 1.98 (m, 5H), 1.59 (m, 2H), 1.35 (m, 2H), 1.18 (m, 2H), 0.88 (d, 3H)

Melting point: 200-203° C.; Yield: 37%

134

Example D21

Naphthalene-1-sulfonic acid (3-fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-amide



$C_{35}H_{36}FN_3O_5S$ Mw. 629.76


LC/MS purity: 95%, m/z 628 [M-H]⁻, m/z 630 [M-H]⁺
Rt. 2.89 min.

¹H NMR (300 MHz, DMSO-d₆): 10.7 (bs, 1H), 8.78 (d, 1H), 8.38 (d, 1H), 8.22 (m, 2H), 8.06 (d, 1H), 7.66 (m, 3H), 7.41 (s, 1H), 7.31 (s, 1H), 7.15 (t, 1H), 7.00 (d, 1H), 6.86 (d, 1H), 6.24 (d, 1H), 4.15 (t, 2H), 3.87 (s, 3H), 2.92 (m, 2H), 2.54 (m, 1H), 1.99 (m, 4H), 1.59 (m, 2H), 1.21 (m, 2H), 1.17 (m, 2H), 0.87 (d, 3H)

Melting point: 140-143° C. Yield: 35%

Example D22

Propane-1-sulfonic acid (3-fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-amide



$C_{28}H_{36}FN_3O_5S$ Mw. 545.68

LC/MS purity: 99%, m/z 544 [M-H]⁻, m/z 546 [M-H]⁺
Rt. 2.50 min.


¹H NMR (300 MHz, DMSO-d₆): 10.2 (bs, 1H), 8.45 (d, 1H), 7.49 (s, 1H), 7.36 (s, 1H), 7.34 (d, 1H), 7.16 (d, 1H), 7.03 (d, 1H), 6.44 (d, 1H), 4.26 (t, 1H), 3.93 (s, 3H), 3.07 (bs, 2H), 2.71 (m, 2H), 2.62 (m, 2H), 2.44 (m, 1H), 1.92 (m, 3H), 1.69 (m, 2H), 1.57 (m, 2H), 1.21 (m, 2H), 1.13 (m, 2H), 0.95 (t, 3H), 0.87 (d, 3H)

Melting point: 160-162° C.; Yield: 16%

135

Example D23

2-Cyano-N-(3-fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide



$C_{32}H_{33}FN_4O_5S$ Mw. 604.71


LC/MS purity: 99%, m/z 603 [M-H]⁻, m/z 605 [M-H]⁺
Rt. 2.52 min.

¹H NMR (300 MHz, DMSO-d₆): 10.5 (bs, 1H), 8.44 (d, 1H), 7.99 (d, 1H), 7.77 (t, 1H), 7.63 (t, 2H), 7.49 (s, 1H), 7.38 (s, 1H), 7.09 (t, 1H), 6.94 (d, 1H), 6.77 (d, 1H), 6.37 (d, 1H), 4.20 (t, 2H), 3.92 (s, 3H), 3.14 (m, 2H), 2.77 (m, 2H), 2.33 (m, 1H), 2.07 (m, 2H), 2.07 (m, 2H), 1.69 (m, 2H), 1.45 (m, 2H), 1.24 (m, 2H), 0.90 (d, 3H)

Melting point: 139-142° C.; Yield: 19%

Example D24

4-Chloro-2-fluoro-N-(3-fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide



$C_{31}H_{32}ClF_2N_3O_5S$ Mw. 632.13

LC/MS purity: 99%, m/z 630 [M-H]⁻, m/z 632 [M-H]⁺
Rt. 2.58 min.


¹H NMR (300 MHz, DMSO-d₆): 10.8 (bs, 1H), 8.44 (d, 1H), 7.86 (t, 1H), 7.62 (d, 1H), 7.49 (s, 1H), 7.45 (d, 1H), 7.39 (s, 1H), 7.26 (m, 2H), 7.06 (d, 1H), 6.92 (d, 1H), 6.36 (d, 1H), 4.21 (t, 1H), 3.92 (s, 3H), 3.05 (m, 2H), 2.75 (m, 2H), 2.51 (m, 1H), 2.00 (m, 4H), 1.61 (m, 4H), 0.87 (d, 3H)

Melting point: 136-138° C. Yield: 24%

136

Example D25

Butane-1-sulfonic acid (3-fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-amide



$C_{29}H_{38}FN_3O_5S$ Mw. 559.71


LC/MS purity: 96%, m/z 558 [M-H]⁻, m/z 560 [M-H]⁺
Rt. 2.68 min.

¹H NMR (300 MHz, DMSO-d₆): 10.24 (bs, 1H), 8.47 (d, 1H), 7.51 (s, 1H), 7.43 (s, 1H), 7.41 (s, 1H), 7.26 (d, 1H), 7.14 (d, 1H), 6.46 (d, 1H), 4.21 (t, 2H), 3.94 (s, 3H), 3.18 (m, 6H), 3.00 (m, 2H), 2.51 (t, 1H), 3.94 (s, 3H), 3.18 (m, 6H), 3.00 (m, 2H), 2.51 (m, 1H), 2.16 (m, 2H), 1.65 (m, 6H), 1.37 (m, 2H), 0.85 (m, 6H)

Melting point: 104-106° C. Yield: 23%

Example D26

2-Bromo-N-{3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide



$C_{28}H_{27}BrFN_3O_6S$ Mw. 632.51

LC/MS purity: 99%, m/z 630 [M-H]⁻, m/z 632 [M-H]⁺
Rt. 2.53 min.


¹H NMR (300 MHz, DMSO-d₆): 11 (bs, 1H), 8.44 (d, 1H), 8.13 (d, 1H), 7.85 (d, 1H), 7.56 (m, 2H), 7.46 (s, 1H), 7.42 (s, 1H), 7.32 (t, 1H), 7.10 (dd, 1H), 6.99 (d, 1H), 6.34 (d, 1H), 4.26 (t, 2H), 3.93 (s, 3H), 3.59 (t, 4H), 2.78 (t, 2H), 2.53 (m, 4H)

Melting point: 175-177° C. Yield: 18%

137

Example D27

2-Cyano-N-{3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide



$C_{29}H_{27}FN_4O_6S$ Mw. 578.62

LC/MS purity: 99%, m/z 577 [M-H]⁻, m/z 579 [M-H]⁺
Rt. 2.29 min.


¹H NMR (300 MHz, DMSO-d₆): 11 (bs, 1H), 8.45 (d, 1H), 8.09 (m, 2H), 7.92 (t, 1H), 7.83 (t, 1H), 7.48 (s, 1H), 7.43 (s, 1H), 7.33 (t, 1H), 7.15 (d, 1H), 6.96 (d, 1H), 6.40 (d, 1H), 4.27 (t, 2H), 3.92 (s, 3H), 3.60 (m, 4H), 2.80 (t, 2H), 2.53 (m, 4H)

Melting point: 193-196° C. Yield: 23%

138

Example D28

2,4-Difluoro-N-{3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide



$C_{28}H_{26}F_3N_3O_6S$ Mw. 589.60


LC/MS purity: 99%, m/z 588 [M-H]⁻, m/z 590 [M-H]⁺
Rt. 2.42 min.

¹H NMR (300 MHz, DMSO-d₆): 11 (bs, 1H), 8.45 (d, 1H), 7.97 (q, 1H), 7.59-7.27 (m, 5H), 7.15 (dd, 1H), 7.02 (d, 1H), 6.35 (t, 1H), 3.91 (s, 3H), 3.59 (m, 4H), 2.78 (m, 4H), 2.53 (m, 4H)

Melting point: 189-191° C. Yield: 19%

Example D29

Biphenyl-3-sulfonic acid (3-fluoro-4-[6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy]-phenyl)-amide



$C_{37}H_{38}FN_3O_5S$ Mw. 655.79

LC/MS purity: 100%, m/z 654 [M-H]⁻, m/z 656 [M-H]⁺
Rt. 2.93 min.


¹H NMR (300 MHz, DMSO-d₆): 11 (bs, 1H), 8.36 (d, 1H), 8.02 (s, 1H), 7.94 (d, 1H), 7.79 (d, 1H), 7.70 (m, 3H), 7.52 (m, 4H), 7.36 (s, 1H), 7.30 (t, 1H), 7.14 (d, 1H), 7.00 (d, 1H), 6.28 (d, 1H), 4.17 (t, 2H), 3.90 (s, 3H), 2.88 (m, 2H), 2.50 (m, 1H), 1.98 (m, 4H), 1.58 (m, 2H), 1.34 (m, 2H), 1.15 (m, 2H), 0.88 (d, 3H)

Melting point: 196-198° C. Yield: 16%

139

Example D30

2-Fluoro-N-(3-fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide



$C_{31}H_{33}F_2N_3O_5S$ Mw. 597.69

LC/MS purity: 99%, m/z 596 [M-H]⁻, m/z 598 [M-H]⁺
Rt. 2.55 min.


¹H NMR (300 MHz, DMSO-d₆): 10.5 (bs, 1H), 8.43 (d, 1H), 7.87 (t, 1H), 7.66 (q, 1H), 7.47 (s, 1H), 7.35 (m, 3H), 7.26 (t, 1H), 7.08 (dd, 1H), 6.94 (d, 1H), 6.33 (d, 1H), 4.18 (t, 2H), 3.92 (s, 3H), 2.86 (m, 2H), 2.54 (m, 3H), 1.99 (m, 3H), 1.60 (m, 5H), 0.84 (d, 3H)

Melting point: 102-106° C. Yield: 25%

140

Example D32

2,6-Difluoro-N-(3-fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide



$C_{31}H_{32}F_3N_3O_5S$ Mw. 615.68


LC/MS purity: 100%, m/z 614 [M-H]⁻, m/z 616 [M-H]⁺
Rt. 2.71 min.

¹H NMR (300 MHz, DMSO-d₆): 12.5 (bs, 1H), 8.44 (d, 1H), 7.59 (t, 1H), 7.49 (s, 1H), 7.33 (s, 1H), 7.20 (m, 3H), 7.04 (d, 1H), 6.88 (d, 1H), 6.35 (d, 1H), 4.20 (t, 2H), 3.92 (s, 3H), 2.98 (s, 2H), 2.67 (m, 2H), 2.04 (m, 3H), 1.86 (m, 1H), 1.60 (m, 5H), 0.86 (d, 3H)

Melting point: 117-119° C. Yield: 29%

Example D31

2-Cyano-N-(3-fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide



$C_{32}H_{33}FN_4O_5S$ Mw. 604.71


LC/MS purity: 99%, m/z 603 [M-H]⁻, m/z 605 [M-H]⁺
Rt. 2.50 min.

¹H NMR (300 MHz, DMSO-d₆): 10.8 (bs, 1H), 8.42 (d, 1H), 8.38 (d, 1H), 7.88 (d, 1H), 7.74 (t, 1H), 7.60 (t, 1H), 7.49 (s, 1H), 7.37 (s, 1H), 7.06 (t, 1H), 6.90 (dd, 1H), 6.74 (d, 1H), 6.37 (d, 1H), 4.19 (t, 2H), 3.92 (s, 3H), 3.07 (m, 2H), 2.63 (m, 2H), 2.50 (m, 1H), 2.03 (m, 3H), 1.66 (m, 5H), 0.87 (d, 3H)

Melting point: 131-132° C. Yield: 34%

Example D33

N-(3-Fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-2-trifluoromethoxy-benzenesulfonamide



$C_{32}H_{33}F_4N_3O_6S$ Mw. 663.69

LC/MS purity: 99%, m/z 662 [M-H]⁻, m/z 664 [M-H]⁺
Rt. 2.75 min.


¹H NMR (300 MHz, DMSO-d₆): 11.5 (bs, 1H), 8.41 (d, 1H), 7.89 (d, 1H), 7.48 (s, 1H), 7.45 (d, 1H), 7.34 (m, 3H), 6.93 (t, 1H), 6.80 (d, 1H), 6.61 (d, 1H), 6.33 (d, 1H), 4.16 (t, 2H), 3.92 (s, 3H), 2.85 (m, 2H), 2.43 (m, 1H), 1.90 (m, 4H), 1.57 (m, 2H), 1.31 (m, 2H), 1.14 (m, 2H), 0.88 (d, 3H)

Melting point: 206-208° C. Yield: 32%

141

Example D34

2,5-Difluoro-N-(3-fluoro-4-{6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide



$C_{31}H_{32}F_3N_3O_5S$ Mw. 615.68


LC/MS purity: 100%, m/z 614 [M-H]⁻, m/z 616 [M-H]⁺
Rt. 2.61 min.

¹H NMR (300 MHz, DMSO-d₆): 10.2 (bs, 1H), 7.59 (m, 1H), 7.49 (s, 1H), 7.42 (s, 2H), 7.38 (s, 1H), 7.18 (t, 1H), 7.02 (dd, 1H), 6.86 (d, 1H), 6.36 (d, 1H), 4.20 (t, 1H), 3.93 (s, 3H), 3.08 (m, 2H), 2.73 (m, 2H), 2.63 (m, 1H), 2.27 (m, 2H), 2.04 (m, 2H), 1.66 (m, 2H), 1.44 (m, 1H), 1.21 (m, 2H), 0.90 (d, 3H)

Melting point: 223-225° C. Yield: 42%

Example D35

N-(3-Fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}phenyl)-2-trifluoromethyl-benzenesulfonamide



142

$C_{32}H_{33}F_4N_3O_5S$ Mw. 647.69


LC/MS purity: 94%, m/z 646 [M-H]⁻, m/z 648 [M-H]⁺
Rt. 2.86 min.

¹H NMR (300 MHz, DMSO-d₆): 10.6 (bs, 1H), 8.44 (d, 1H), 8.15 (d, 1H), 7.97 (d, 1H), 7.84 (m, 2H), 7.48 (s, 1H), 7.39 (s, 1H), 7.28 (t, 1H), 7.07 (d, 1H), 6.94 (d, 1H), 6.36 (d, 1H), 4.21 (t, 2H), 3.92 (m, 3H), 2.89 (m, 2H), 2.76 (m, 2H), 2.26 (m, 1H), 1.99 (m, 3H), 1.68 (m, 4H), 1.02 (m, 1H), 0.86 (d, 3H)

Melting point: 118-121° C. Yield: 38%

Example D36

2,5-Difluoro-N-(3-fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-benzenesulfonamide



$C_{31}H_{32}F_3N_3O_5S$ Mw. 615.68


LC/MS purity: 95%, m/z 614 [M-H]⁻, m/z 616 [M-H]⁺
Rt. 2.83 min.

¹H NMR (300 MHz, DMSO-d₆): 10.3 (bs, 1H), 8.44 (d, 1H), 7.61 (bs, 1H), 7.44 (m, 4H), 7.22 (t, 1H), 7.05 (d, 1H), 6.90 (d, 1H), 6.36 (d, 1H), 4.21 (m, 2H), 3.93 (s, 3H), 3.07 (bs, 2H), 2.63 (bs, 2H), 2.39 (m, 1H), 2.25 (m, 3H), 1.69 (m, 5H), 0.87 (d, 3H)

Melting point: 103-107° C. Yield: 45%

Example D37

Biphenyl-3-sulfonic acid (3-fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-amide




143

C₃₇H₃₈FN₃O₅S Mw. 655.79LC/MS purity: 97%, m/z 654 [M-H]⁻, m/z 656 [M-H]⁺
Rt. 3.06 min.¹H NMR (300 MHz, DMSO-d₆): 10.5 (bs, 1H), 8.36 (d, 1H), 8.02 (s, 1H), 7.94 (d, 1H), 7.79 (d, 1H), 7.67 (m, 3H), 7.49 (m, 4H), 7.36 (s, 1H), 7.29 (t, 1H), 7.14 (d, 1H), 6.99 (d, 1H), 6.28 (d, 1H), 4.16 (t, 2H), 3.90 (s, 3H), 2.81 (m, 2H), 2.46 (m, 3H), 1.95 (m, 3H), 1.60 (m, 5H), 0.83 (d, 3H)

Melting point: 190-192° C. Yield: 39%

Example D38


4-Fluoro-N-(3-fluoro-4-[6-methoxy-7-[3-(3-methylpiperidin-1-yl)propoxy]-quinolin-4-yloxy]-phenyl)-3-methoxy-benzenesulfonamide

C₃₂H₃₅F₂N₃O₆S Mw. 627.71LC/MS purity: 97%, m/z 626 [M-H]⁻, m/z 628 [M-H]⁺
Rt. 2.88 min.¹H NMR (300 MHz, DMSO-d₆): 10.4 (bs, 1H), 8.45 (d, 1H), 7.55-7.31 (m, 6H), 7.17 (dd, 1H), 7.01 (d, 1H), 6.35 (d, 1H), 4.19 (t, 2H), 3.92 (s, 3H), 3.89 (s, 3H), 2.90 (m, 2H), 2.60 (m, 3H), 2.02 (m, 3H), 1.65 (m, 5H), 0.85 (d, 3H)

Melting point: 98-101° C. Yield: 34%

Example D39

N-{3-Fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)-quinolin-4-yloxy]-phenyl}-2-trifluoromethyl-benzenesulfonamide




144

C₃₀H₂₉F₄N₃O₆S Mw. 635.64LC/MS purity: 99%, m/z 634 [M-H]⁻, m/z 636 [M-H]⁺
Rt. 2.71 min.¹H NMR (300 MHz, DMSO-d₆): 11 (bs, 1H), 8.45 (d, 1H), 8.16 (d, 1H), 8.02 (d, 1H), 7.88 (m, 2H), 7.47 (s, 1H), 7.38 (s, 1H), 7.35 (t, 1H), 7.14 (d, 1H), 7.01 (d, 1H), 6.36 (d, 1H), 4.19 (t, 2H), 3.91 (s, 3H), 3.60 (t, 4H), 2.51 (m, 2H), 2.41 (m, 4H), 1.98 (t, 2H)

Melting point: 180-181° C. Yield: 29%

Example D40

N-{3-Fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)-quinolin-4-yloxy]-phenyl}-2-trifluoromethoxy-benzenesulfonamide


C₃₀H₂₉F₄N₃O₇S Mw. 651.64LC/MS purity: 98%, m/z 650 [M-H]⁻, m/z 652 [M-H]⁺
Rt. 2.79 min.¹H NMR (300 MHz, DMSO-d₆): 10.9 (bs, 1H), 8.44 (d, 1H), 8.03 (d, 1H), 7.77 (m, 1H), 7.57 (m, 2H), 7.47 (s, 1H), 7.38 (s, 1H), 7.33 (t, 1H), 7.14 (d, 1H), 6.98 (d, 1H), 4.19 (t, 2H), 3.92 (s, 3H), 3.58 (bs, 4H), 2.51 (m, 2H), 2.40 (m, 6H), 1.98 (t, 1H)

Melting point: 183-184° C. Yield: 40%

145

Example D41

2,5-Difluoro-N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide




$C_{29}H_{28}F_3N_3O_6S$ Mw. 603.62

LC/MS purity: 97%, m/z 602 [M-H]⁻, m/z 604 [M-H]⁺
Rt. 2.59 min.

¹H NMR (300 MHz, DMSO-d₆): 11 (bs, 1H), 8.44 (d, 1H), 7.70 (bs, 1H), 7.56 (m, 2H), 7.48 (s, 1H), 7.39 (s, 1H), 7.33 (d, 1H), 7.16 (dd, 1H), 7.04 (d, 1H), 6.35 (d, 1H), 4.19 (t, 2H), 3.92 (s, 3H), 3.60 (bs, 4H), 2.43 (m, 6H), 1.98 (t, 2H)

Melting point: 192-195° C. Yield: 43%

Example D42 Biphenyl-3-sulfonic acid {3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-amide



$C_{35}H_{34}FN_3O_6S$ Mw. 643.74

LC/MS purity: 97%, m/z 642 [M-H]⁻, m/z 644 [M-H]⁺
Rt. 2.97 min.


¹H NMR (300 MHz, DMSO-d₆): 10.7 (bs, 1H), 8.37 (d, 1H), 8.03 (s, 1H), 7.97 (d, 1H), 7.80 (d, 1H), 7.69 (m, 3H), 7.52 (m, 4H), 7.45 (s, 1H), 7.32 (s, 1H), 7.18 (d, 1H), 7.05 (d, 1H), 6.28 (d, 1H), 4.18 (t, 2H), 3.90 (s, 3H), 3.58 (m, 4H), 2.46 (t, 2H), 2.38 (m, 4H), 1.96 (t, 2H)

Melting point: 210-212° C. Yield: 39%

146

Example D43

4-Chloro-2-fluoro-N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide



$C_{29}H_{28}ClF_2N_3O_6S$ Mw. 620.08


LC/MS purity: 95%, m/z 618 [M-H]⁻, m/z 620 [M-H]⁺
Rt. 2.73 min.

¹H NMR (300 MHz, DMSO-d₆): 11 (bs, 1H), 8.45 (d, 1H), 7.89 (t, 1H), 7.74 (d, 1H), 7.49 (d, 1H), 7.47 (s, 1H), 7.38 (s, 1H), 7.33 (d, 1H), 7.14 (d, 1H), 7.00 (d, 1H), 6.35 (d, 1H), 4.19 (t, 2H), 3.92 (s, 3H), 3.59 (bs, 4H), 2.48 (bs, 2H), 2.42 (bs, 4H), 1.98 (t, 2H)

Melting point: 200-203° C. Yield: 35%

Example D44

4-Fluoro-N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-3-methoxy-benzenesulfonamide



65

147


$C_{30}H_{31}F_2N_3O_7S$ Mw. 615.66
LC/MS purity: 96%, m/z 614 [M-H]⁻, m/z 616 [M-H]⁺
Rt. 2.63 min.

¹H NMR (300 MHz, DMSO-d₆): 10.8 (bs, 1H), 8.44 (d, 1H), 7.54-7.32 (m, 6H), 7.17 (dd, 1H), 7.02 (d, 1H), 6.34 (d, 1H), 4.19 (t, 2H), 3.92 (s, 3H), 3.89 (s, 3H), 3.31 (m, 4H), 2.44 (t, 2H), 2.39 (m, 4H), 1.98 (t, 2H)

Melting point: 90-93° C. Yield: 58%

Example D45

2-Fluoro-N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide




$C_{29}H_{29}F_2N_3O_6S$ Mw. 585.63
LC/MS purity: 99%, m/z 584 [M-H]⁻, m/z 586 [M-H]⁺
Rt. 2.49 min.

¹H NMR (300 MHz, DMSO-d₆): 11 (bs, 1H), 8.44 (d, 1H), 7.90 (t, 1H), 7.73 (m, 1H), 7.46 (s, 1H), 7.40 (m, 3H), 7.38 (s, 1H), 7.15 (dd, 1H), 7.02 (d, 1H), 6.33 (d, 1H), 4.19 (t, 2H), 3.91 (s, 3H), 3.59 (m, 4H), 2.47 (t, 2H), 2.40 (m, 4H), 1.98 (t, 2H)

Melting point: 179-181° C. Yield: 59%

Example D46

N-{3-Fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-2-nitro-benzenesulfonamide



$C_{29}H_{29}FN_4O_8S$ Mw. 612.64
LC/MS purity: 99%, m/z 611 [M-H]⁻, m/z 613 [M-H]⁺
Rt. 2.58 min.


¹H NMR (300 MHz, DMSO-d₆): 11 (bs, 1H), 8.45 (d, 1H), 8.03 (m, 1H), 7.94 (m, 1H), 7.84 (m, 2H), 7.48 (s, 1H), 7.39 (s, 1H), 7.34 (t, 1H), 7.13 (d, 1H), 6.98 (d, 1H), 6.37 (d, 1H), 4.20 (t, 2H), 3.92 (s, 3H), 3.61 (bs, 4H), 2.56 (bs, 6H), 2.00 (m, 2H)

Melting point: 166-168° C. Yield: 29%

148

Example D47

2,6-Dichloro-N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide



$C_{29}H_{28}Cl_2FN_3O_6S$ Mw. 636.53


LC/MS purity: 99%, m/z 634 [M-H]⁻, m/z 636 [M-H]⁺
Rt. 2.71 min.

¹H NMR (300 MHz, DMSO-d₆): 11.1 (bs, 1H), 8.44 (d, 1H), 7.60 (m, 2H), 7.47 (s, 1H), 7.38 (s, 1H), 7.34 (m, 2H), 7.13 (d, 1H), 6.99 (d, 1H), 6.33 (d, 1H), 4.19 (bs, 2H), 3.91 (s, 3H), 3.59 (bs, 4H), 3.17 (bs, 2H), 2.43 (m, 4H), 1.99 (bs, 2H)

Melting point: 194-196° C.; Yield: 16%

Example D48

Naphthalene-1-sulfonic acid {3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-amide



$C_{33}H_{32}FN_3O_6S$ Mw. 617.70

LC/MS purity: 96%, m/z 616 [M-H]⁻, m/z 618 [M-H]⁺
Rt. 2.62 min.


¹H NMR (300 MHz, DMSO-d₆): 11.1 (bs, 1H), 8.75 (d, 1H), 8.40 (d, 1H), 8.28 (m, 2H), 8.11 (d, 1H), 7.71 (m, 3H), 7.42 (s, 1H), 7.36 (s, 1H), 7.24 (t, 1H), 7.05 (d, 1H), 6.91 (d, 1H), 6.31 (dd, 1H), 4.18 (t, 2H), 3.89 (s, 3H), 3.57 (bs, 4H), 2.46 (m, 2H), 2.38 (bs, 4H), 1.96 (m, 2H)

Melting point: 108-111° C. Yield: 26%

149

Example D49

2-Bromo-N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-benzenesulfonamide



$C_{29}H_{29}BrFN_3O_6S$ Mw. 646.54

LC/MS purity: 98%, m/z 644 [M-H]⁻, m/z 646 [M-H]⁺
Rt. 2.63 min.

¹H NMR (300 MHz, DMSO-d₆): 11 (bs, 1H), 8.43 (d, 1H), 8.13 (d, 1H), 7.86 (d, 1H), 7.58 (m, 2H), 7.46 (s, 1H), 7.38 (s, 1H), 7.33 (t, 1H), 7.12 (dd, 1H), 7.00 (dd, 1H), 6.33 (d, 1H), 4.19 (t, 2H), 3.91 (s, 3H), 3.58 (bs, 4H), 2.45 (t, 2H), 2.39 (m, 4H), 1.97 (t, 2H)

Melting point: 185-188° C.; Yield: 35%

3) Inhibitory Activity of Compounds on Axl Phosphorylation in NIH-3T3-AXL Cellular Tyrosine Kinase Assay

Establishment of Wild Type AXL (wtAXL) Receptor Tyrosine Kinase-Overexpressing Stable Cell Line NIH-3T3-AXL (Clone 22) WtAXL cDNA was cloned into vector pLX-SN(ESK) and transfected into Phoenix E packaging cells. The viral supernatant was collected and used to infect target cells NIH3T3 N7. Monoclonal NIH3T3-AXL cell lines stably expressing wtAXL were generated by selecting retrovirally infected cells in medium containing puromycin (2 µg/ml) and subsequent clonal separation. NIH-3T3-AXL (clone 22) cells were used for further experiment because AXL was highly expressed and constitutively phosphorylated in these cells. In addition, these cells demonstrated aggressive behaviors on matrigel matrix (Matrigel™ Matrix, BD Biosciences, Bedford, Mass., USA). Moreover, the inhibitory effects of compounds on AXL phosphorylation discovered by using NIH-3T3 AXL (clone 22) system have been confirmed in human breast cancer cells endogenously expressing AXL in our previous study (Zhang Y X, et al. AXL is a potential target for therapeutic intervention in breast cancer progression. *Cancer Res.* 2008; 68:1905-15).

Determination of the morphology of cells grown on matrigel was carried out as described previously, with some modifications (Thompson E W, et al. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. *J Cell Physiol* 1992; 150:534-44). Briefly, in a 96-well flat-bottomed plate, 10000 cells/100 µl cell suspension was plated on the surface of precoated matrigel (3 mg/ml). Colony outgrowth was visualized with a Zeiss Axiovert S100 microscope (Carl Zeiss UK, Welwyn Garden City, UK).

150

NIH-3T3-AXL Cellular Kinase Assay

NIH-3T3-AXL (Clone 22) cells were seeded onto 6-well plates (1.5×10^5 cells/well) in 1.5 ml culture medium and cultured overnight, followed by serum depletion in 0.1% heat inactivated FCS/DMEM for 24 h. Serial dilutions of compounds were added, and the cells were further incubated or 2 h. Cells were washed with PBS, and lysed on ice in 500 µl lysis buffer (50 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM EGTA, 10% Glycerol, 1% Triton X-100, 100 mM NaF, 10 mM $Na_4P_2O_7 \cdot 10H_2O$, 1 mM Na_3VO_4 , 1 mM phenylmethylsulfonyl fluoride, and 10 mg/ml aprotinin) for 15 min. The clarified cell lysate (10 min at 13000 rpm at 4° C.) were used for immunoprecipitation. Equal amounts of protein were mixed with 2 µg anti-AXL polyclonal antibody (homemade) and 20 µl Protein A sepharose beads, and rotated for 6 hr at 4° C. After immunoprecipitation, the beads were washed three times with 1xHNTG (50 mM HEPES (pH 7.5), 150 mM NaCl, 10% Glycerol, 0.2% Triton X-100). The final pellet was suspended in 20 µl 2x Laemmli buffer, and boiled for 5 min at 100° C. The immunoprecipitates were separated by 7.5% SDS-PAGE gel electrophoresis, and the proteins were transferred to nitrocellulose membrane. Unspecific binding was blocked by incubating the membrane for 1 hr in 0.25% gelatin in 1xNET buffer (50 mM Tris.HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 0.1% Triton X-100). The membrane was then incubated with anti-phosphotyrosine antibody (4G10) overnight at 4° C. followed by washing with 1xTBST buffer three times. After incubating membrane with HRP-conjugated anti-mouse secondary antibody for 1 hour at room temperature followed by washing with 1xTBST buffer three times, the proteins were visualized by ECL. Afterwards, the membrane was stripped and reprobed with anti-AXL antibody (SC-1096, Santa Cruz Biotechnology, Santa Cruz, Calif.).

The results of the assay are described in Table 2.

Cellular IC50 [µM]	
A1-50	
A1	4.5
A2	3.01
A3	3.4
A4	6
A5	0.5
A6	4.3
A7	>10
A8	10
A9	3.7
A10	2.6
A11	2.26
A12	1.26
A13	2.9
A14	1.4
A15	2.265
A16	1.805
A17	0.89
A18	2.1
A19	4.5
A20	5.05
A21	4.7
A22	9.6
A23	6
A24	2.4
A25	2.38
A26	4.73
A27	2.54
A28	3.9
A29	2.3
A30	0.63
A31	>10
A32	>10

US 9,206,130 B2

151

-continued

Cellular IC50 [μM]	
A33	>10
A34	0.43
A35	3
A36	2.8
A37	>10
A38	>10
A39	6.4
A40	<1
A41	<1
A42	<1
A43	<1
A44	<1
A45	>10
A46	>10
A47	10
A48	1.5
A49	3,00
A50	<1
A51	<3
A52	>3
A53	3
A54	>1
A55	>1
A56	>1
A57	>3
A58	>1
A59	>1
A60	0.8
A61	0.7
A62	0.47
A63	>1
A64	>1
A65	>10
A66	>10
A67	>10
A68	>10
A69	>10
A70	>10
A71	>3
A72	0.58
A73	>3
A74	>1
A75	>3
A76	>10
A77	>10
A78	>3
A79	0.48
A80	>10
A81	>10
A82	>1
A83	>3
A84	>3
A85	>3
A86	>1
A87	3
A88	>1
A89	0.45
A90	>10
A91	>10
A92	>10
A93	>3
A94	>10
A95	>10
A96	0.077
A97	0.54
A98	0.74
A99	0.18
A100	0.74
A101	>1
A102	>1
A103	0.35
A104	3
A105	10
A106	0.75
A107	>10
A108	>1
A109	>1

152

-continued

Cellular IC50 [μM]	
A110	1.18
A111	>3
A112	>3
A113	>3
A114	0.47
A115	1.26
A116	>3
A117	>10
A118	0.54
A119	>3
A120	>10
A121	>10
A122	>10
A123	1.96
A124	>3
A125	10
A126	0.13
A127	>3
A128	2.25
A129	>3
A130	>10
A131	1.68
A132	>10
A133	>10
A134	>1
A135	0.82
A136	>10
A137	>10
A138	>10
A139	2.2
A140	>10
A141	>10
A142	>10
A143	>10
A144	>10
A145	>10
A146	0.89
A147	>3
A148	>10
A149	>3
A150	>10
A151	>10
A152	>10
A153	>10
A154	>10
A155	>3
A156	>1
<hr/>	
B1	>10
B2	>10
B3	8,00
B4	>10
B5	>10
B6	>10
B7	>10
B8	>10
B9	>10
B10	>10
B11	<1
B12	>10
B13	<1
B14	<1
B15	>10
B16	>10
B17	>10
B18	>10
B19	8,00
B20	>10
B21	>10
B22	7,00

-continued

Cellular IC50 [μM]	
C01	>10
C02	>10
C03	>10
C04	>10
C05	>10
C06	>10
C07	>10
C08	>10
C09	>10
C10	>10
C11	>10
C12	>10
C13	>1
C14	>10
C15	>10
C16	>10
C17	>10
C18	>10
C19	>10
D01	>10
D02	0.695
D03	0.837
D04	0.32
D05	0.049
D06	0.069
D07	0.35
D08	2.5
D09	2.46
D10	0.052
D11	>3
D12	0.3
D13	0.057
D14	0.238
D15	0.364
D16	0.271
D17	0.046
D18	0.151
D19	0.128
D20	0.029
D21	0.347
D22	0.477
D23	0.211
D24	0.181
D25	0.378
D26	0.15
D27	0.783
D28	>1
D29	0.178
D30	0.082
D31	0.323
D32	0.042
D33	0.068
D34	0.016

LIST OF REFERENCES


- Weigelt B, Peterse J L, van 't Veer L J. Breast cancer metastasis: markers and models. *Nat Rev Cancer* 2005; 5:591-602.
- Shawver L K, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. *Cancer Cell* 2002; 1:117-123.
- Sebolt-Leopold J S, English J M. Mechanisms of drug inhibition of signalling molecules. *Nature* 2006; 441:457-462.
- Hanahan D, Weinberg R A. The hallmarks of cancer. *Cell* 2000; 100:57-70.
- Blume-Jensen P, Hunter T. Oncogenic kinase signalling. *Nature* 2001; 411:355-365.

- Slamon D J, Clark G M, Wong S G, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987; 235:177-182.
- Slamon D J, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 2001; 344:783-792.
- Cobleigh M A, Vogel C L, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. *J Clin Oncol* 1999; 17:2639-2648.
- Varnum B C, Young C, Elliott G, et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. *Nature* 1995; 373:623-626.
- Stitt T N, Conn G, Gore M, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. *Cell* 1995; 80:661-670.
- Nagata K, Ohashi K, Nakano T, et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. *J Biol Chem* 1996; 271:30022-30027.
- Hafizi S, Dahlback B. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. *Cytokine Growth Factor Rev* 2006; 17:295-304.
- Janssen J W, Schulz A S, Steenvoorden A C, et al. A novel putative tyrosine kinase receptor with oncogenic potential. *Oncogene* 1991; 6:2113-2120.
- O'Bryan J P, Frye R A, Cogswell P C, et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. *Mol Cell Biol* 1991; 11:5016-5031.
- Berclaz G, Altermatt H J, Rohrbach V, et al. Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast. *Ann Oncol* 2001; 12:819-824.
- Craven R J, Xu L H, WeinerTM, et al. Receptor tyrosine kinases expressed in metastatic colon cancer. *Int J Cancer* 1995; 60:791-797.
- Shieh Y S, Lai C Y, Kao Y R, et al. Expression of axl in lung adenocarcinoma and correlation with tumor progression. *Neoplasia* 2005; 7:1058-1064.
- Sun W, Fujimoto J, Tamaya T. Coexpression of Gas6/Axl in human ovarian cancers. *Oncology* 2004; 66:450-457.
- Green J, Ikram M, Vyas J, et al. Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours. *Br J Cancer* 2006; 94:1446-1451.
- Ito T, Ito M, Naito S, et al. Expression of the Axl receptor tyrosine kinase in human thyroid carcinoma. *Thyroid* 1999; 9:563-567.
- Holland S J, Powell M J, Franci C, et al. Multiple roles for the receptor tyrosine kinase axl in tumor formation. *Cancer Res* 2005; 65:9294-9303.
- Vajkoczy P, Knyazev P, Kunkel A, et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. *Proc Natl Acad Sci USA* 2006; 103:5799-5804.

155

The invention claimed is:

1. Compounds of the formula (I):



wherein

R¹ is hydrogen;R² is fluorine, or methoxy;R³ is hydrogen, benzyloxy, methoxy, 3-amino-propoxy, 2-morpholin-4-yl-ethoxy, 3-(4-methyl-piperidin-1-yl)-propoxy, 3-(3-methyl-piperidin-1-yl)-propoxy, or 3-morpholin-4-yl-propoxy;R⁴ is hydrogen, or —CF₃;R⁵ is hydrogen, or —CH₃;R⁶ is hydrogen;R⁷, R⁸, R⁹ and R¹⁰, which may be the same or different, represent a hydrogen atom, halogen, C₁₋₆ alkyl, and/or C₁₋₆ alkoxy,R¹¹ represents

a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system which is optionally substituted,

R¹⁵ represents hydrogen; or

pharmaceutically acceptable salts thereof.

2. The compounds of claim 1, wherein R⁷ and R¹⁰ are hydrogen.3. The compounds of claim 1, wherein at least one of R⁸ and R⁹ is different from hydrogen and halogen.4. The compounds of claim 1 wherein the substituents of the carbocyclic or heterocyclic ring system in R¹¹ are selected from halogen, C₁₋₄ alkyl optionally halogenated, C₁₋₄ alkoxy optionally halogenated, hydroxyl, cyano, and optionally substituted amino.5. The compounds of claim 4, wherein the carbocyclic or heterocyclic group in R¹¹ is optionally mono- or polysubstituted by at least one halogen, trifluoromethyl or a trifluoromethoxy substituent.

6. The compounds of claim 1 selected from

3-Cyano-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide,

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-fluoro-benzenesulfonamide,

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3,4-difluoro-benzenesulfonamide,

Thiophene-2-sulfonic acid 4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide,

3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-hydroxy-benzenesulfonamide,

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-fluoro-4-methyl-benzenesulfonamide,

N-{5-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenylsulfamoyl]-4-methyl-thiophen-2-yl}-acetamide,

156

Quinoline-8-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]amide,

3-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl-sulfamoyl]-thiophene-2-carboxylic acid methyl ester,

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide,

4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-fluoro-benzenesulfonamide,

3-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-4-fluoro-benzenesulfonamide,

4-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-fluoro-benzenesulfonamide,

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2,6-difluoro-benzenesulfonamide,

3-Difluoromethoxy-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide,

Naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide,

2,5-Dichloro-thiophene-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide,

4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-methyl-benzenesulfonamide,

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2,3,4-trifluoro-benzenesulfonamide,

5-Methyl-thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide,

Furan-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide,

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-trifluoromethyl-benzenesulfonamide,

3-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide,

3-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide,

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-methoxy-benzenesulfonamide,

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-phenoxy-benzenesulfonamide,

5-Chloro-thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide,

5-Bromo-thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide,

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-phenoxy-benzenesulfonamide,

1-Ethyl-1H-pyrazole-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide,

1-Methyl-1H-imidazole-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide,

Cyclopropanesulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide,

Biphenyl-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide,

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-trifluoromethoxy-benzenesulfonamide,

5-Phenyl-thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide,

5-Oxazol-5-yl-thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide,

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3,5-difluoro-benzenesulfonamide,

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2,4-difluoro-benzenesulfonamide,

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2,5-difluoro-benzenesulfonamide,

2,6-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide,

2,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide,
 3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-trifluoromethyl-benzenesulfonamide,
 2-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-4-trifluoromethyl-benzenesulfonamide,
 2-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-5-trifluoromethyl-benzenesulfonamide,
 3-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-5-trifluoromethyl-benzenesulfonamide,
 4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-trifluoromethyl-benzenesulfonamide,
 3,4-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide,
 3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-methoxy-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-methyl-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-methoxy-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-trifluoromethoxy-benzenesulfonamide,
 2-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide,
 2-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-4-ethyl-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-4-phenoxy-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-fluoro-2-methyl-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-fluoro-benzenesulfonamide,
 4-Bromo-3-chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-4-fluoro-3-methoxy-benzenesulfonamide,
 N-{2-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylsulfamoyl]-4-methyl-phenyl}-acetamide,
 N-{4-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylsulfamoyl]-2,6-dimethyl-phenyl}-acetamide,
 3-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-4-methoxy-benzenesulfonamide,
 5-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-2-methoxy-benzenesulfonamide,
 5-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-2-methoxy-4-methyl-benzenesulfonamide,
 3-tert-Butyl-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-4-methoxy-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-4-ethoxy-3-methyl-benzenesulfonamide,
 4-Methoxy-naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-methoxy-4,5-dimethyl-benzenesulfonamide,
 3-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-4-methoxy-benzenesulfonamide,
 Biphenyl-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-amide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-3-phenoxy-benzenesulfonamide,
 Naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-amide,

Isoquinoline-5-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide,
 3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-2-hydroxy-benzenesulfonamide,
 2-Methyl-3H-imidazole-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide,
 Biphenyl-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide,
 Benzo[b]thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide,
 Benzo[b]thiophene-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide,
 1-Methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide,
 Biphenyl-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-4-(3,5-dimethyl-isoxazol-4-ylmethoxy)-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-fluoro-4-methoxy-benzenesulfonamide,
 Biphenyl-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-amide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-3-phenoxy-benzenesulfonamide,
 Naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-amide,
 Biphenyl-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-amide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide,
 Benzo[b]thiophene-2-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-amide,
 1-Methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-amide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-2-trifluoromethyl-benzenesulfonamide,
 Biphenyl-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-3-phenoxy-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-2,5-difluoro-benzenesulfonamide,
 Naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-trifluoromethyl-benzenesulfonamide,
 Naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide,
 3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-4-hydroxy-benzenesulfonamide,
 3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-2-methoxy-benzenesulfonamide,
 Biphenyl-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide,
 Benzo[b]thiophene-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-4-fluoro-3-methoxy-benzenesulfonamide,
 4-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-2-fluoro-benzenesulfonamide,

3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-2-methoxy-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-2-trifluoromethoxy-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-2-trifluoromethyl-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-2-trifluoromethoxy-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-3-phenoxy-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-4-fluoro-3-methoxy-benzenesulfonamide,
 4-Bromo-3-chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-2,5-difluoro-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-2-trifluoromethoxy-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-3-phenoxy-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-4-fluoro-3-methoxy-benzenesulfonamide,
 4-Bromo-3-chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-2-trifluoromethyl-benzenesulfonamide,
 4-Bromo-3-chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-3-fluoro-phenyl-benzenesulfonamide,
 1-Methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-2-trifluoromethoxy-benzenesulfonamide,
 3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-2-methoxy-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-2-trifluoromethyl-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-2-trifluoromethoxy-benzenesulfonamide,
 4-Methoxy-naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-amide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-2,5-difluoro-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methyl-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide,
 4-Methoxy-naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide,
 4-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-2-fluoro-benzenesulfonamide,
 4-Methoxy-naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide,
 Biphenyl-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide,
 1-Methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide,
 Biphenyl-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-amide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-2,5-difluoro-benzenesulfonamide,
 Naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-amide,
 4-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-2-fluoro-benzenesulfonamide,
 Biphenyl-4-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-amide,

N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-3-pyrimidin-2-yl-benzenesulfonamide,
 Benzo[b]thiophene-3-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-amide,
 1-Methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-amide,
 4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-2-trifluoromethoxy-benzenesulfonamide,
 4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-2-trifluoromethoxy-benzenesulfonamide,
 4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-2-trifluoromethoxy-benzenesulfonamide,
 4-Bromo-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-2-trifluoromethoxy-benzenesulfonamide,
 4-Methoxy-naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-amide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-2,5-difluoro-benzenesulfonamide,
 4-Bromo-3-chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-benzenesulfonamide,
 4-Chloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-2-fluoro-benzenesulfonamide,
 N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-2-methyl-phenyl]-4-fluoro-3-methoxy-benzenesulfonamide,
 3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-4-hydroxy-benzenesulfonamide,
 3,5-Dichloro-N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-methoxy-phenyl]-2-hydroxy-benzenesulfonamide,
 Thiophene-2-sulfonic acid [2-fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide,
 3-Cyano-N-[2-fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide,
 N-[2-Fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-3-methoxy-benzenesulfonamide,
 Cyclopropanesulfonic acid [2-fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide,
 3-Chloro-4-fluoro-N-[2-fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide,
 2,6-Difluoro-N-[2-fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide,
 5-Methyl-thiophene-2-sulfonic acid [2-fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide,
 N-[2-Fluoro-4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-3-trifluoromethyl-benzenesulfonamide,
 N-[4-(6-Fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide,
 3,5-Dichloro-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide,
 3,5-Dichloro-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-2-methoxy-benzenesulfonamide,
 2,4-Difluoro-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide,
 3,5-Difluoro-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide,
 3-Bromo-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-benzenesulfonamide,
 4-Bromo-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-2-trifluoromethyl-benzenesulfonamide,
 Thiophene-3-sulfonic acid [4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide,
 3-[4-(6-Fluoro-2-methyl-quinolin-4-yloxy)-phenylsulfamoyl]-thiophene-2-carboxylic acid methyl ester,

161

5-Chloro-thiophene-2-sulfonic acid [4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide,
 5-Oxazol-5-yl-thiophene-2-sulfonic acid [4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide,
 Naphthalene-1-sulfonic acid [4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide, 5
 1-Ethyl-1H-pyrazole-4-sulfonic acid [4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-amide,
 3,5-Dichloro-N-[4-(6-fluoro-2-methyl-quinolin-4-yloxy)-phenyl]-2-hydroxy-benzenesulfonamide, 10
 Biphenyl-3-sulfonic acid [4-(7-benzyloxy-6-methoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-amide,
 Naphthalene-1-sulfonic acid {4-[7-(3-amino-propoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-amide,
 Biphenyl-3-sulfonic acid {4-[7-(3-amino-propoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-amide, 15
 Biphenyl-3-sulfonic acid {3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-amide,
 N-{3-Fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-2-trifluoromethyl-benzenesulfonamide, 20
 N-{3-Fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-2-trifluoromethoxy-benzenesulfonamide, 25
 Biphenyl-3-sulfonic acid {4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-2-methyl-phenyl}-amide,
 N-{4-[6-Methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-2-methyl-phenyl}-2-trifluoromethoxy-benzenesulfonamide, 30
 2,5-Difluoro-N-{4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-2-methyl-phenyl}-benzene sulfonamide,
 2,5-Difluoro-N-{3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-benzene sulfonamide, 35
 N-{4-[6-Methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-2-methyl-phenyl}-2-trifluoromethyl-benzenesulfonamide, 40
 4-Chloro-2-fluoro-N-{3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-benzene sulfonamide,
 4-Methoxy-naphthalene-1-sulfonic acid {3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-amide, 45
 N-{4-[7-(3-Amino-propoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-2-trifluoromethyl-benzenesulfonamide,
 N-{4-[7-(3-Amino-propoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-2-trifluoromethoxy-benzenesulfonamide, 50
 N-(3-Fluoro-4-[6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy]-phenyl)-2-trifluoromethyl-benzenesulfonamide, 55
 2-Bromo-N-(3-fluoro-4-[6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy]-phenyl)-benzene sulfonamide,
 2,4-Difluoro-N-(3-fluoro-4-[6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy]-phenyl)-benzenesulfonamide, 60
 2,6-Difluoro-N-(3-fluoro-4-[6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy]-phenyl)-benzenesulfonamide,
 Naphthalene-1-sulfonic acid (3-fluoro-4-[6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy]-phenyl)-amide, 65

162

2-Cyano-N-(3-fluoro-4-[6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy]-phenyl)-benzenesulfonamide,
 4-Chloro-2-fluoro-N-(3-fluoro-4-[6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy]-phenyl)-benzenesulfonamide,
 2-Bromo-N-{3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-benzene sulfonamide,
 2-Cyano-N-{3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-benzene sulfonamide,
 2,4-Difluoro-N-{3-fluoro-4-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-benzene sulfonamide,
 Biphenyl-3-sulfonic acid (3-fluoro-4-[6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy]-phenyl)-amide,
 2-Fluoro-N-(3-fluoro-4-[6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy]-phenyl)-benzene sulfonamide,
 2-Cyano-N-(3-fluoro-4-[6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy]-phenyl)-benzene sulfonamide,
 2,6-Difluoro-N-(3-fluoro-4-[6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy]-phenyl)-benzenesulfonamide,
 N-(3-Fluoro-4-[6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy]-phenyl)-2-trifluoromethoxy-benzenesulfonamide,
 2,5-Difluoro-N-(3-fluoro-4-[6-methoxy-7-[3-(4-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy]-phenyl)-benzenesulfonamide,
 N-(3-Fluoro-4-[6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy]-phenyl)-2-trifluoromethyl-benzenesulfonamide,
 2,5-Difluoro-N-(3-fluoro-4-[6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy]-phenyl)-benzenesulfonamide,
 Biphenyl-3-sulfonic acid (3-fluoro-4-[6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy]-phenyl)-amide,
 4-Fluoro-N-(3-fluoro-4-[6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy]-phenyl)-3-methoxy-benzenesulfonamide,
 N-{3-Fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-2-trifluoromethyl-benzenesulfonamide,
 N-{3-Fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-2-trifluoromethoxy-benzenesulfonamide,
 2,5-Difluoro-N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-benzene sulfonamide,
 Biphenyl-3-sulfonic acid {3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-amide,
 4-Chloro-2-fluoro-N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-benzene sulfonamide,
 4-Fluoro-N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-3-methoxy-benzenesulfonamide,
 2-Fluoro-N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-benzene sulfonamide,

N-{3-Fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-2-nitro-benzene-sulfonamide,
2,6-Dichloro-N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-benzene sulfonamide, 5
Naphthalene-1-sulfonic acid {3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-amide, and
2-Bromo-N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-benzene sulfonamide. 10

7. A pharmaceutical composition comprising at least one compound according to claim 1.

8. The pharmaceutical composition according to claim 7, 15 further comprising pharmaceutically acceptable carriers, diluents and/or adjuvants.

9. The pharmaceutical composition of claim 7, wherein the composition is administrable parenterally, topically, rectally, nasally, buccally, vaginally, transdermally, by inhalation, by 20 injection or infusion, by spray or via implanted reservoir.

* * * * *